Impaired repression at a vasopressin promoter polymorphism in a rat model of trait anxiety and depression by Murgatroyd, Christopher A.
   
 
 
 
 
 
Impaired repression at a vasopressin promoter polymorphism  
in a rat model of trait anxiety and depression 
 
 
 
Dissertation 
der Fakultät für Biologie der 
Ludwig-Maximilians-Universität zu München 
 
 
 
 
 
Christopher A. Murgatroyd 
 
 
 
 
28.09.2004 
   
 
 
Mit Genehmigung der der Fakultät für Biologie der 
Ludwig-Maximilians-Universität zu München 
 
 
 
 
 
Berichterstatter:   Prof. Dr. R. Landgraf 
 
 
 
Mitberichterstatter:  
Prüfungskommission:  Prof. Dr. E. H. Weiss 
 
     Prof. Dr. C. N. David 
     Prof. Dr. B. Grothe 
Weitere Mitglieder:   Prof. Dr. M. Götz 
     Prof. Dr. R. Klein 
 
 
 
Mitbetreuung durch den   
promovierten Mitarbeiter:  Dr. Dietmar Spengler 
 
 
 
Dekan:    Prof. Dr. Peter Dittrich 
 
 
 
Tag der mündlichen Prüfung:  07.02.2005 
 
 
 
 
 
   
Impaired repression at a vasopressin promoter polymorphism  
in a rat model of trait anxiety and depression 
 
 
CHRISTOPHER A. MURGATROYD 
 
 
 
 
 
 
 
Max-Planck-Institut für Psychiatrie 
Kraepelinstr. 2-10  
80804 München 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2004 
 
 
   
 
 
With thanks to my parents  
and grandparents for  
all their support 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
CONTENTS 
1 INTRODUCTION............................................................................................................ 1 
1.1 HAB and LAB rats....................................................................................................... 1 
1.1.2 Behaviour ............................................................................................................... 2 
1.1.3 Neuroendocrinology............................................................................................... 3 
1.1.4 AVP status.............................................................................................................. 4 
1.2 HAB and LAB mice...................................................................................................... 7 
1.2.1 Behaviour ............................................................................................................... 7 
1.2.2 Neuroendocrinology............................................................................................... 7 
1.2.3 AVP status.............................................................................................................. 8 
1.3 Human affective disorders........................................................................................... 9 
1.3.1 Neuroendocrinology............................................................................................. 10 
1.3.2 AVP status............................................................................................................ 10
 
2 MATERIALS AND METHODS................................................................................... 12 
2.1 Materials ..................................................................................................................... 12 
2.1.1 Chemicals ............................................................................................................. 12 
2.1.2 Radiation .............................................................................................................. 13 
2.1.3 Restriction endonucleases .................................................................................... 13 
2.1.4 Modifying enzymes.............................................................................................. 14 
2.1.5 Antibodies ............................................................................................................ 14 
2.1.6 Vectors ................................................................................................................. 14 
2.1.7 Plastics.................................................................................................................. 15 
2.1.8 Molecular biology kits ......................................................................................... 15 
2.1.9 Cell lines............................................................................................................... 15 
2.1.10 Primer sequences.................................................................................................. 15 
2.1.11 Sequences and accession numbers ....................................................................... 17 
2.2 Methods ....................................................................................................................... 18 
2.2.1 DNA Analysis ...................................................................................................... 18 
2.2.2 RNA analysis........................................................................................................ 23 
2.2.3 Plasmids ............................................................................................................... 28 
2.2.4 Cell culture and transfection experiments............................................................ 34 
2.2.5 Protein preparation ............................................................................................... 36 
2.2.6 Statistical analysis and computer software........................................................... 41 
 
3 RESULTS........................................................................................................................ 42 
3.1 Candidate gene approach .......................................................................................... 43 
3.1.1 CRH...................................................................................................................... 44 
3.2 AVP.............................................................................................................................. 44 
3.2.1 AVP levels in the PVN correlate with anxiety-related behaviour ....................... 45 
3.2.2 Sequence analysis................................................................................................. 46 
   
3.2.3 Sequence and genotyping of the adjacent oxytocin gene..................................... 50 
3.2.4 Association of AVP gene and anxiety in EPM test.............................................. 51 
3.2.5 Genotyping HAB AVP allele in an outbred population....................................... 54 
3.2.6 In vivo tanscription analysis ................................................................................. 55 
3.2.7 Transcription factor element analysis .................................................................. 58 
3.2.8 C(-592)T and cAMP responsive element............................................................. 59 
3.2.9 A(-1276)G and YY1............................................................................................. 59 
3.2.10 A(-1276)G and CArG box binding factor A (CBF-A)......................................... 65 
3.2.11 Reporter assays..................................................................................................... 73 
3.2.12 CBF-A expression in the PVN ............................................................................. 77 
3.2.13 Model for the polymorphic CArG element leading to differential AVP 
 expression............................................................................................................. 81 
3.3 Genetic analysis of HAB and LAB mice lines.......................................................... 82 
3.3.1 Marker analysis of mouse chromosome 2............................................................ 82 
3.3.2 AVP...................................................................................................................... 83 
3.4 Human AVP gene as a candidate gene for anxiety ................................................. 89 
3.4.1 Sequence analysis................................................................................................. 89 
3.4.2 C(-229)T promoter SNP....................................................................................... 90 
3.4.3 G(-558)T downstream SNP.................................................................................. 91 
 
4 DISCUSSION ................................................................................................................. 93 
4.1 HAB rat ....................................................................................................................... 93 
4.2 HAB mouse ................................................................................................................. 98 
4.3 LAB mouse.................................................................................................................. 98 
 
5 SUMMARY................................................................................................................... 100 
 
6 ABBREVIATIONS ...................................................................................................... 102 
6.1 Standard.................................................................................................................... 102 
6.2 Buffers and substances............................................................................................. 102 
6.3 Non standard ............................................................................................................ 102 
 
7 REFERENCE LIST ..................................................................................................... 104 
8 ACKNOWLEDGMENTS ........................................................................................... 121 
9 CURRICULUM VITAE.............................................................................................. 122 
Introduction 
1 Introduction 
Anxiety disorders and major depression represent two of the most common and debilitating 
psychiatric disorders. Epidemiological studies show that anxiety disorders – including panic 
disorder, phobic disorders and generalised anxiety - can run in families (Hettema et al., 2001). 
Moreover, twin studies suggest that a genetic predisposition accounts for, at least, part of the 
familial nature of the disorders, with heritibilities of 30-40% (Kendler, 2001). However, 
despite decades of intensive research, the underlying genetic cause(s) of these remain elusive 
(Nestler et al., 2002). Functional studies have yet to identify a focal brain region or particular 
neurotransmitter system as the primary site of the abnormality and, furthermore, genetic 
studies have failed to provide evidence for specific culpability genes (Segurado et al., 2003) 
and allelic variations showing replicable associations in the general population (Lohmueller et 
al., 2003).  
Current research lines in this field include identification of candidate genes in 
selectively bred animal models. The concept implies that, in these animal models, specific 
loci associating with a phenotype provide compelling candidate genes for complex human 
disorders. Indeed, recent animal studies have investigated the concordance of disease 
associating genes across species. For instance, in the case of hypertension, a remarkable 
degree of concordance of quantitative trait loci (QTL) regions in comparison of mouse with 
rat and human is beginning to emerge (DiPetrillo et al., 2004). 
To gain insight into the molecular mechanisms underlying affective disorders, animal 
models were generated by selectively breeding Wistar rat lines for either high (HAB) or low 
(LAB) anxiety-related behaviour. This approach was followed up in mice also bred for either 
high or low anxiety-related behaviour. This concept of selectional inbreeding is postulated to 
concentrate loci playing major roles in the selected phenotype. In turn, the results from these 
two animal studies then provide a basis for extrapolating these findings to association studies 
in humans.  
1.1 HAB and LAB rats 
Criteria for animal models of depression have been intensively discussed in the last two 
decades, however, the criterion proposed by McKinney and Bunney (McKinney and Bunney, 
1969) has been the most widely accepted. These authors propose that the validity of an animal 
model can be determined by the extent that (a) it is ‘reasonably analogous’ to the human 
disorder in its manifestations or symptomatology, (b) there is a behavioural change that can 
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be objectively monitored, (c) the behavioural changes observed should be reversed by the 
same treatment modalities that are effective in humans, and (d) the system should be 
reproducible between investigators. Taking these guidelines into consideration, it is proposed 
that the HAB rat represents a robust and unique model for human anxiety. 
1.1.2 Behaviour 
Ten-week old Wistar rats were selected for inbreeding using behavioural results from the 
elevated plus-maze (EPM) test. The EPM test is the most widely used apparatus for 
measuring anxiety in rodents (Pellow et al., 1985). The test is performed by placing a naive 
rat in the centre of an elevated plus-maze with two open and two enclosed arms, and allowing 
it to freely explore. It is accepted that the reluctance of rats to explore the open arms of the 
maze is caused by fear of open spaces. Furthermore, anxiolytic compounds increase, whereas 
anxiogenic compounds decrease, the percentage of time spent on open the arms (Pellow et al., 
1985). The results from the EPM test were used to select mating pairs to establish the HAB 
and LAB lines. To date, HAB rats of both sexes spend less time in the open arms of the maze 
and enter this area less frequently. Specifically, HAB animals spend around 5% of the total 
time on the EPM test in the open arms compared to 50% in LAB animals. 
The high anxiety phenotype in the HAB rats is not only detectable in the EPM test, but 
also in the open field, the modified hole board and in other tests of unconditioned anxiety 
such as the black and white box and the social interaction test (for a review see Henniger et al., 
2000;Wigger et al., 2001). Furthermore, in a social defeat paradigm, HAB and LAB rats 
differed significantly in their coping behaviour - HAB rats emitting more ultrasound 
vocalisation calls and spending more time freezing in contrast to the LAB rats which showed 
increased locomotor activity and signs of aggressive behaviour towards a resident animal 
indicative of active stress coping (Koolhaas et al., 1999). Measuring ultrasound vocalisation 
in the rat pups revealed that the HAB rats vocalized significantly more than LAB animals 
(Wigger et al., 2001). This confirms, not only the early expression of the trait in the HAB rats 
development, but also of anxiety-related behaviour independent of locomotor activity 
(Tornatzky and Miczek, 1994). 
While there were no differences in fighting, threatening, social grooming, self-
grooming, sniffing, burying, and feeding or drinking, HAB rats displayed markedly less 
rearing, indicative of exploratory curiosity, but spent more time sleeping than LAB animals 
(Henniger et al., 2000). Again, all the tests performed confirmed that the difference in 
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anxiety-related behaviour is independent of gender. It is of further importance to note that 
basal blood pressure and heart rate failed to differ between HAB and LAB rats.  
In addition to the innate anxiety, HAB rats also present with a depression-like 
behaviour showing remarkably passive stress coping in the forced swim (FS) test (Keck et al., 
2001). The FS test (Porsolt et al., 1977), which is considered to have predictive value for the 
efficacy of antidepressant treatments (Lucki, 1997), revealed that HAB rats floated much 
more and struggled far less than LAB animals. This preference of passive coping, in addition 
to the behavioural despair, is interesting when considering that anxiety and depression share 
many overlapping symptoms, often co-existing, in the clinic (for review see Gorwood, 2004).  
The possibility of a genetic contribution or determinant underlying the anxiety-like 
behaviour was tested in the HAB line by examining the influence of postnatal factors in the 
divergent emotionality of HAB and LAB rats. In a cross-fostering experiment animals were 
reared, from the first postnatal day until weaning, by mothers of the opposite rat line and 
behaviourally characterized as adults. From this study it emerged that none of the anxiety 
parameters revealed variances between fostered controls and cross-fostered animals within 
either line (Wigger et al., 2001). Additionally, HAB mothers showed no deficits in their 
maternal behaviour making it highly unlikely that environmental factors (Meaney, 2001), or 
epigenetic programming stemming from maternal behaviour (Weaver et al., 2004) may 
contribute to the line-specific divergences detectable in the adults. Moreover, cross-breeding 
of HAB and LAB rats resulted in F1 offspring displaying intermediate anxiety-related 
behaviour on the EPM test, perhaps again supporting a role of genetic factors in the 
behavioural differences between HAB and LAB rats (Wigger et al., 2001).  
1.1.3 Neuroendocrinology 
Hyperactivity of the hypothalamic–pituitary–adrenal (HPA) axis is one of the key findings 
described in major depressive and affective disorders (Holsboer, 2000). Corticotropin-
releasing hormone (CRH) and vasopressin (AVP) are the main regulators of this stress system 
acting synergistically in stimulating adrenocorticotropin (ACTH) release from the anterior 
pituitary which subsequently causes the release of cortisol (humans) or corticosterone 
(rodents) from the adrenal gland, which, in turn, regulates CRH and AVP production via 
negative feedback (figure 1A). HPA axis function can be examined by conducting a 
neuroendocrine challenge test that attenuates or enhances cortisol/corticosterone (CORT), 
ACTH or CRH release. This test entails administration of the synthetic corticosteroid, 
dexamethasone (DEX), to the subject and measuring CORT levels 12h later. If CORT levels 
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are not decreased then the subject is said to suffer from DEX non-suppression. A further 
improvement on this test is the combined DEX/CRH challenge test in which the HPA axis is 
both stimulated by the administration of CRH and inhibited with DEX (Holsboer et al., 1987), 
resulting in a far greater sensitivity (for review see Heuser et al., 1994). When the DEX/CRH 
test was performed in the two rat lines it became evident that HAB rats were DEX non-
suppressers (Keck et al., 2002). It was further speculated by the authors that this phenomenon 
pointed towards an enhanced activity and critical involvement of the neuropeptide AVP, 
which was supported by the observation of increased basal synthesis and release of AVP 
within the paraventricular nucleus (PVN) of the hypothalamus in the HAB rats, as described 
in more detail below. 
Anxiolytic and antidepressive drugs generally yield contradictory results when 
administered to normal rats indicating that - in parallel to the situation in humans - the 
efficacy of an anxiolytic may depend on the animal's basal level of anxiety (Liebsch et al., 
1998;Will et al., 2003). Indeed, HAB rats responded to diazepam with a 20-fold increase in 
the percentage of time spent on the open arms of the EPM test, in contrast to a 2.5-fold 
increase in LAB rats (Liebsch et al., 1998). Of further note, diazepam functions in the rat by 
stimulating basal HPA axis activity (Vargas et al., 2001). As previously stated, the behaviour 
of the HAB rats is indicative, not only of anxiety-related, but also depression-like symptoms 
and accordingly responded to, the classical antidepressive selective serotonin re-uptake 
inhibitor (SSRI), paroxetine, with a more active stress-coping strategy in the FS test, in 
contrast to the LAB rats which failed to respond (Keck et al., 2003). Similarly to diazepam, 
paroxetine again attenuates HPA axis overactivity (Nickel et al., 2003). 
As previously described, the HAB rats are DEX non-suppressors, however, periferal 
administration of the AVP V1-receptor antagonist d(CH2)5Tyr(Me)AVP in HABs, resulted in 
a reduced level of anxiety/ depression-related behaviour (Keck et al., 2002). This indicates 
that AVP has major effects in both the neuroendocrine system and in the anxiety-related 
behaviour. 
1.1.4 AVP status 
CRH and AVP are the main regulators of the HPA stress system; being released from the 
hypothalamic parvocellular neurons of the PVN. In situ-hybridisation analysis of the 
hypothalamic PVN in HAB and LAB rats revealed that CRH mRNA expression was similar 
between the lines under both basal and stress conditions. The most striking molecular finding, 
however, and the focus of the present study, relates to AVP mRNA expression, which was 
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found to be significantly higher in the parvocellular and magnocellular neurons of the PVN of 
HAB rats under both basal and stress conditions (figure 1B) (Wigger et al., 2004). 
Furthermore, the HAB rats presented with a significantly higher AVP release from the PVN 
in microdialysate experiments (figure 1C) (Wigger et al., 2004). 
 
 
A B C
Brain
CRH AVP
Cortisol
ACTH
-ve 
-ve 
-ve 
 
Figure 1. Scheme of HPA axis and differential AVP expression between HAB and LAB animals.  
(A) Schematic diagram of the HPA axis. (B) in situ-hybridisation experiments using a radiolabelled AVP 
mRNA-specific oligonucleotide in the PVN (Wigger et al., 2004) reveal an increase in expression of AVP 
mRNA in the HAB rat line. (C) Microdialysate measurement of AVP peptide in the PVN reveal a 
significant increase in AVP peptide release from the PVN in the HAB line rats. *, Significantly different 
(p<0.05). 
 
Measurements of oxytocin - the structurally and functionally related neuropeptide - 
failed to reveal differences between the HAB and LAB rats in either mRNA or protein 
content in the PVN or release in the dialysate. When comparing the levels of AVP between 
the various AVP-containing hypothalamic nuclei strict tissue-specificity emerged whereby 
AVP overexpression occurred only in the parvocellular and magnocellular neurons of the 
PVN, whereas no elevations were present in other AVP expressing nuclei in the 
hypothalamus, namely the supraoptic nucleus (SON) and the suprachiasmatic nucleus (SCN).  
Taking together the aforementioned evidence; (a) higher AVP mRNA expression, and 
release in the parvocellular and magnocellular neurons of the PVN in HAB rats, (b) an AVP 
V1a receptor antagonist results in reduced anxiety/depression related behaviour, and  
(c) hyper-reactive HPA axis and Dex/CRH results in the HAB animals are driven by AVP 
overexpression which paroxetine treatment normalized, it was hypothesized that AVP plays a 
major role in the anxiety/depression related behaviour and neuroendocrine features of the 
HAB. Therefore, to pursue further this issue, and to gain insight into the molecular 
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mechanism underlying the anxiety in our rat lines, we decided to investigate the AVP locus as 
a candidate gene for anxiety and depression. 
The structures of AVP and oxytocin were determined by du Vigneaud in 1954, and 
earned him the nobel prize in 1955 (du Vigneaud, 1954). AVP is a cyclic nonapeptide that is 
synthesised centrally in the hypothalamus. The peptide is released in response to a variety of 
stimuli including increasing plasma osmolarity, hypovolaemia, hypotension and 
hypoglycaemia (Dunn et al., 1973;Laszlo et al., 1991) and has powerful antidiuretic and 
vasoconstrictor effects (Hofbauer et al., 1984). AVP has also been implicated in learning and 
memory (Engelmann et al., 1996), however, it is the role of AVP in the regulation of the HPA 
axis that forms the main focus of this study (for review see Scott and Dinan, 2002;Gazdar et 
al., 1980;Landgraf, 2001). Although the cell-specific expression and physiological regulation 
of the AVP gene has been described in some detail (for review see Burbach, 2002), much less 
is known about the regulatory elements and transcription factors bound within the promoter 
that control these processes. The AVP promoter is positively regulated by the cAMP 
signalling pathway (Verbeeck et al., 1990), and two cAMP responsive elements (CRE) have 
been identified at -227 to -220bp and -123 to -116bp in the rat promoter (Iwasaki et al., 1997). 
Furthermore, an AP1 site has also been identified in the rat promoter (Grace et al., 1999), 
although its functional role in AVP expression remains to be established (Coulson et al., 
1999b). A number of E-box motifs localise to the region -157 to -23bp, which are predicted to 
be bound by members of the basic helix-loop-helix (bHLH) transcription factor family. 
Among these Clock, Bmal1, Sim1 and Arnt2 behave as transactivators, involved in 
controlling either circadian rhythm or neuronal development (for review see Burbach, 2002). 
Expression of the AVP gene is suppressed by adrenal glucocorticoids through a putative 
glucocorticoid response element (GRE) which maps to -622 to -608bp in the rat promoter 
(Iwasaki et al., 1997). Both GR-DNA dependent and independent mechanisms for repression 
have been assigned to this element (Kim et al., 2001). In addition, AVP gene expression also 
appears to be regulated by other members of the nuclear hormone receptor family, notably by 
androgen (Adan and Burbach, 1992) and oestrogen receptors (Shapiro et al., 2000).  
In addition to the upstream AVP promoter, regulatory regions located downstream to 
the gene are also suggested to control the cell-specific expression of AVP. Specifically, a 
178bp sequence immediately downstream of exon 3, has been demonstrated to contribute to 
tissue-specific expression of green fluorescent protein reporter constructs in hypothalamic 
slice-explant cultures (Fields et al., 2003).  
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In this study we sought to examine the molecular mechanisms underlying the 
differential expression and release of AVP in the PVN of HAB and LAB lines. We show that 
the promoter of the AVP gene in the HAB animal, containing a number of SNPs, works in cis 
to produce higher levels of AVP. In this promoter region we discovered that the disruption of 
a CArG element in the HAB rat, located 1276bp upstream from the AVP start codon, plays a 
major role in this promoter overexpression by disrupting the binding of CBF-A which, in turn, 
acts as a repressor for AVP expression. We, therefore, conclude that constitutive 
overexpression of AVP in the PVN of HAB rats is critically dependent on the HAB allele. 
The relevance of AVP to the anxiety-related behaviour was further investigated in an 
association study involving the F2 offspring from a HAB/LAB and HAB/outbred cross, 
which supported a possible involvement of the AVP gene in controlling behaviour on the 
EPM and FS tests. Therefore, we speculate that this allele might contribute to the behavioural 
and endocrine correlates of trait anxiety and depression in this rat line. 
1.2 HAB and LAB mice 
Above findings prompted us to examine, in addition, the relevance of AVP as a candidate 
gene for anxiety in other mammals. Therefore, to address this topic, mice have recently been 
subjected to selective bi-directional inbreeding on the EPM test for either high (HAB) or low 
(LAB) anxiety-related behaviour. In this protocol ‘outbred’ CD1 mice were employed on the 
basis that a population of outbred animals should display a higher degree of variance in 
behaviour, which might facilitate the bi-directional selective inbreeding strategy (Kroemer et 
al., submitted). 
1.2.1 Behaviour 
Within a few rounds of selective inbreeding, HAB and LAB mice lines - in a similar fashion 
to the rats - differed markedly and consistently in their anxiety-like behaviour on the EPM test. 
In addition to this deficit in emotionality, the HAB mice were also impaired in their stress 
coping, depression-like, behaviour in the FS test, resembling again the aforementioned HAB 
rat line. Results of the tail suspension (TS) test which, similarly to the EPM test, also 
measures behavioural despair (Chermat et al., 1986), again support the presence of a passive 
stress coping behaviour in the HAB mice. 
1.2.2 Neuroendocrinology 
The smaller blood volume of mice compared to rats prevents application of the DEX/CRH 
test in the HAB and LAB mice lines in the same manner as it was performed in the rat lines. 
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Therefore, HPA axis functioning in these animals has yet to be characterised. The behavioural 
responses to antidepressant and anxiolytic drugs in the HAB mice appeared to differ from the 
HAB rat line because HAB mice revealed no responses to paroxetine, and, furthermore, 
administration of the benzodiazepine diazepam resulted in no anxiolytic effects (Landgraf R, 
unpublished data). The HAB mice did, however, react mildly to imipramine (Landgraf R, 
unpublished data), which is a tricyclic antidepressant whose mechanism of action, in contrary 
to paroxetine and diazepam, is thought to involve the transmitter-uptake mechanism of 
monoaminergic neurons (Mongeau et al., 1997). 
1.2.3 AVP status 
The most striking feature of the mice lines, in the context of this study, was the finding that 
AVP mRNA expression, as well as release of the neuropeptide, are higher in the PVN of 
HAB mice when compared to LAB mice (figure 2) (Landgraf R, unpublished data).  
 
 
Figure 2. In situ-hybridisation experiments for AVP mRNA in the PVN of HAB and LAB mice reveal a  
3 to 4-fold increase in expression in the HAB line mice (Landgraf R, unpublished data). 
 
The finding that selective inbreeding in two separate species of rodents on the same 
behavioural paradigm resulted in a similar behavioural endophenotype, accompanied in 
parallel at the molecular level by a dramatic overexpression of AVP, represents a remarkable 
outcome. In addition to the AVP overexpression in the HAB mice, it should be noted that the 
LAB mice contained a stark reduction in AVP expression in the PVN when compared to 
HAB and normal anxiety-related behaviour (NAB) mice, in contrast to the LAB rats (see 
below). It was, therefore, speculated that AVP might play a role in the behavioural and 
neuroendocrine features typical of trait anxiety and depression in the two mice lines providing 
an impetus for us to investigate the mouse AVP gene as a vulnerability candidate. Indeed, 
sequencing of the AVP gene and promoter led to the finding of line-specific differences 
which we speculate underlie the expression differences seen in the PVN between the LAB 
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and HAB mice in a similar way to that seen in the anxious rat line. Furthermore, it is possible 
that the conserved amino acid change in the signal peptide might play a role in AVP post-
translational regulation by altering the processing and release of AVP. In this respect it was of 
further interest to note that subsequent metabolic studies in the LAB mice revealed a defect in 
their osmotic regulation, being acutely prone to a hyperosmotic challenge (Landgraf R, 
unpublished data). This supports the theory that this altered signal peptide leads to the 
observed reduction in AVP, resulting in a diabetes insipidus (DI) -related phenotype.  
1.3 Human affective disorders 
The impact of depression and anxiety disorders worldwide is overwhelming (figure 3). The 
World Bank report on the global burden of disease ranked major depression fourth among all 
medical illnesses in terms of its disabling impact on the world population (Murray and Lopez, 
1996) It was further estimated that, by the year 2020, depression would be second only to 
ischemic heart disease with anxiety disorders ranking close behind (for review see Hirschfeld, 
2001). Indeed, between 10% and 20% of adults in any given 12-month period will visit their 
primary care physician during an episode of mental illness (Kirmayer et al., 1993).  
 
 
Figure 3. Prevalence of major depression and anxiety disorders in the community. Adopted from (Kessler 
et al., 1994;Kessler et al., 1995). Values based on 12-month comorbid prevalence data. GAD= generalized 
anxiety disorder, PTSD= posttraumatic stress disorder.  
 
The debilitating nature of the disease, as well as representing a burden to the 
individual concerned, results in an increasingly higher strain on the state. In fact, 24% of high 
medical utilizers, the top 10%, have been found to suffer from major depression and 22%, 
from an anxiety disorder (Katon et al., 1990), representing, respectively, a cost of 82 and 53 
billion dollars a year in the US (Uhl and Grow, 2004).  
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1.3.1 Neuroendocrinology 
Disturbances in HPA axis regulation seem to play a profound role in the development, course 
and remission of major depression and affective disorder. Patient studies consistently 
evidence a close correlation between a stable remission of the clinical symptoms and a 
normalization of HPA regulation (for review see Holsboer, 2003). Furthermore, the finding 
that healthy probands, with a family history of mood disorder, show abnormalities on the 
Dex/CRH test (Holsboer et al., 1995), supports the theory that culpability genes can 
contribute to the development of mood disorders via HPA axis function. 
1.3.2 AVP status 
The overall aim in this research, as to almost any animal research, was to extrapolate findings 
from the rat and mouse models to the human, thereby aiding in the development of diagnostic 
markers and therapeutic tools. Therefore, this study progressed towards the direction of 
analysing the AVP gene in humans to determine to what extent, if any, AVP might act as a 
marker for human affective disorders. It is well known that AVP has an important role in the 
regulation of the HPA axis in patients. It is, therefore, of interest in this regard to note the 
previous literature linking increased numbers of CRH neurons co-expressing AVP mRNA in 
the PVN of depressed patients (Purba et al., 1996) and aged subjects (Raadsheer et al., 1993) 
reflecting a hyperactivity of these neurons and subsequent HPA axis. Furthermore, numerous 
studies reported higher levels of AVP in the plasma of depressed patients (Inder et al., 
2001;van Londen et al., 1997;van Londen et al., 1998), and in the cerebral spinal fluid (CSF) 
of patients presenting with a range of affective disorders such as depression (Frank et al., 
2000;Gold et al., 1981;Pitts et al., 1995;Sorensen et al., 1985), psychotic depression (Gold 
PW, unpublished data 1986), obsessive compulsive disorder (Altemus et al., 1992;Altemus et 
al., 1994), anorexia nervosa (Gold et al., 1983), bulimia nervosa (Frank et al., 2000;Demitrack 
et al., 1992), aggression (Coccaro et al., 1998) and chronic pain disorder (Wahlbeck et al., 
1996). Moreover, reductions in CSF concentrations of AVP have been reported in patients 
with major depression upon treatment with antidepressants such as fluoxitine (De Bellis et al., 
1993), clomipramine hydrochloride (Altemus et al., 1994), and clonidine (Peskind et al., 
1987). A recent study using a non-peptide AVP 1b receptor (AVPR1b) antagonist has pointed 
to a role for AVP in the modulation of emotional processes via the V1b receptor (Griebel et 
al., 2002). Following on, a further study revealed that a haplotype, involving a number of 
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genetic variations in the AVPR1b gene, associated in patients with affective disorders (van 
West et al., 2004). 
We, therefore, concluded this study by providing a framework to address the question 
of the relevance of the AVP gene to affective disorders in the human by elucidating and 
characterising SNPs in the promoter 5’ of the AVP gene and downstream 3’ to the gene. 
These markers, together, provide a useful basis for a prospective case/control association 
study. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
Consumable Supplier Consumable Supplier 
1kb ladder Fermentas 3MM-Papier Wattman 
Agar GibcoBRL Agarose (low-melting point) Gibco 
Agarose (peqGOLDuniversal) Peqlab (Erlangen) Ammoniumperoxodisuphate Sigma 
Ampicillin Roth Antibiotic/antimycotic Gibco 
Boric acid  Biomol Bovine serum Invitrogen 
Bradford assay Biorad Bromophenol blue Biorad 
BSA Sigma Chloroform Roth 
Chloroform (RNase free)  Merck Coomasie blue Biorad 
Developing emulsion (slides) Kodak Developing solution (film) Kodak 
Developing solution (slides) Kodak DMSO  Sigma 
DNA marker (1kb)  NEB DNA marker λ/ HindIII GibcoBRL 
dNTPs (set of 4)  Fermentas DTT Sigma 
DMEM (-Na.pyruvate) Gibco EDTA Sigma 
Ethanol  Merck  Ethidiumbromide Biomol 
Ficoll 400 Sigma Fixing solution (films) Kodak 
Fixing solution (slides) Kodak Foetal bovine serum Gibco 
Formaldehyde Merck Formamide Sigma 
L-Glutathione reduced Sigma Glutathionine Sepharose Amersham 
Glycerine Sigma Glycerol Biomol 
Glycine  Biomol  Glycogen Fermentas 
Guanidine thiocyanate  Merck IGEPAL Sigma 
IPTG Fermentas Isoamylalkohol Merck 
β-mercaptoethanol Merck Methanol Merck 
Milk powder Regilait (France) MOPS Sigma 
Nitrocellulose film BA-S85 Schleicher&Schuell  N-lauroyl-sacosine Sigma 
Oligonucleotides  MWG /Invitrogen Optimem1 medium Gibco 
Paraformaldehyde Sigma PBS Gibco 
Phenol Appligene  Phenol pH 7.5 Appligene  
Ponceau  Sigma 2-propanol Merck 
2-propanol (RNase free) Merck Protein marker NEB 
Poly(d(I-C)) Roche Polaroid instant film Polaroid 
Polyacrylamide–rotiphorese 30 Roth Polyacrylamide –rotiphorese 40 Roth 
Potassium chloride Sigma Roti-Histokit II Roth 
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RPMI 1640 (+L-glutamine) Gibco Salmon testes DNA Sigma 
Sarcosyl Sigma SDS Biomol 
Siliconising fluid Sigma Sodium acetate Merck 
Sodium chloride  Merck Streptavidin Agarose  Novagen 
Taurine USB (USA) TEMED Sigma 
Toluidine blue Sigma Transfer Ribonucleic acid Sigma 
Tris Riedel-deHaen Triton X-100 Roth 
Trypsin  Gibco Tryptone Roth 
Urea  Roth Ultima Gold Packard 
X-Gal Sigma X-ray film (Biomax) Kodak 
Xylencyanol Chroma-gesellschaft Yeast extract GibcoBRL 
 
2.1.2 Radiation 
Nucleotide Activity Supplier 
35S-thio-rUTP 12.5 mCi/mM NEN 
(35S)UTP-αS 10mCi/ml Hartmann Analytica 
32P αdCTP 1x9,25 MBq Amersham 
α-33P dATP  1x9,25 MBq / 1x250µCi Amersham 
(33P)ddNTPs) Redivue (set of 4) 10mCi/ml Amersham 
γ32P-ATP 1x9,25 MBq Amersham 
 
2.1.3 Restriction endonucleases 
Enzyme Supplier Enzyme Supplier Enzyme Supplier 
AciI NEB BbvI NEB BsmAI NEB  
DraIII NEB BamHI Fermentas EcoRI  Fermentas  
EcoRV  Fermentas EamI1041(Ksp6321) Fermentas  HindIll Fermentas  
KpnI Fermentas HaeIII NEB HincII NEB 
NlaIII NEB  Pvul Fermentas MaeIII NEB  
MseI NEB Sacl Fermentas SfaNI NEB 
SmaI Fermentas Sphl Fermentas Tth1III NEB 
Xbal Fermentas  XhoI Fermentas   
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2.1.4 Modifying enzymes  
Enzyme Supplier Enzyme Supplier 
T3-RNA polymerase Roche T4-DNA-Ligase Roche 
T4 DNA polymerase Fermentas T4 polynucleotide kinase Fermentas 
T7-RNA polymerase Fermentas CIAP  Fermentas 
DNA pol. I, klenow fagment NEB DNA polymerase (Taq.) Fermentas 
DNA polymerase(Pfu) Fermentas DNaseI Fermentas 
Proteinase K Boehringer Manheim Proteinase K (RNase free) Sigma 
Ribonuclease A Sigma RNase Sigma 
RNase inhibitor Fermentas S1 Nuclease Amersham 
Streptokinase Sigma   
 
2.1.5 Antibodies 
2.1.5.1 Primary antibodies 
Antibody Epitope Host Supplier  
YY1 (H-10)X full length human YY1(monoclonal) Mouse  Santa Cruz 
α-N-CBF-A 1st 75aa mouse CBF-A (polyclonal) Rabbit gift Leanderson et al. 
Anti-GST Shistosomal GST (polyclonal) Goat Pharmacia 
Anti-Flag  M2 (monoclonal) Mouse Sigma 
Anti-His His6 (monoclonal) Mouse Roche 
 
2.1.5.2 Secondary antibodies 
Antibody Epitope Host Supplier  
Anti-rabbit rabbit IgG Goat Perbio 
Anti-goat goat IgG Donkey Santa Cruz 
Anti-mouse mouse IgG Goat Santa Cruz 
    
2.1.6 Vectors 
Vector  Supplier  
pBSKII Stratagene  
pGL2basic  Promega  
pGEX-2TK  Pharmacia  
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2.1.7 Plastics 
Consumable Supplier Consumable Supplier Consumable Supplier
Filtertips Sarstedt PCR plates/caps (96) ABgene Cell culture plates Greiner 
Pipette tips  Sarstedt Scalpels  Merck   Micro test plates Greiner 
Cuvette 1mm   Biorad X-ray cassette Kodak Gel chambers Biorad 
 
2.1.8 Molecular biology kits 
 
Consumable  Supplier  Consumable Supplier 
Chemagenic DNA tissue Chemagen Chemagenic stand 2x12 Chemagen 
NucleoSpin Tissue  Macherey Nagel NucleoSpin plasmid quickprep Macherey Nagel
DNAeasy extraction kit Qiagen RNeasy Qiagen 
Thermosequ. Radio. Term. 
cycle sequencing 
USB 
 
Thermosequ. (33P) Term. cycle 
sequencing 
Amersham 
ExoSAP-IT USB Lumi-light Western blotting substrate Roche 
LipofectamineTM Invitrogen OneStep RT-PCR Qiagen 
Picogreen DNA 
quantification reagent 
Molecular probes GeneRacer superscriptII and zero 
blunt TOPO cloning 
Invitrogen 
Bio-spin 6 columns Biorad silver stain kit SIGMA 
2.1.9 Cell lines 
 
Name  Derived tissue  Morphology Supplier  Reference  
Saos-2 prim. Osteosarcoma epithelial DSMZ  (Fogh et al., 1977) 
Neuro2a  murine neuroblastoma neuronal  ATCC  (Klebe RJ, 1969) 
Lu-165 small cell lung can. SSLC Terasaki. T (Terasaki et al., 1994) 
HeLa cerv.epith.adenocarcin. epithelial ATCC  (Scherer, 1954) 
3T3 murine embryo  fibroblast ATCC (Todaro, 1963) 
 
2.1.10 Primer sequences 
2.1.10.1 SSCP primer pairs 
Rat CRF  1f, tca gta tgt ttt cca cac ttg gat; 1r, cga ccc tct tca gaa agc ac; 2f, tat tag gca aat gct gcg tg;  
2r, agc tca ggc agc aca aag tt; 3f, cca agg gag gag aag gta gg; 3r, gcg ggt atg gga cac aat aa; 4f, tca atc caa tct 
gcc act ca; 4r, aaa gct cat atg gtg cga gc; 5f, cgg cga ata gct taa acc tg; 5r, aag gtg ggg gag aga ggt aa; 6f, agg 
aag tcc cgc tac acc tt; 6r, atc aga atc ggc tga ggt tg; 7f, ccg ttg aat ttc ttg caa cc; 7r, tga gat cca gag aga tgg gc;  
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8f, gga gag gga gag gcg gtc; 8r, ttg tgc atg cta att aag ggg; 9f, gaa gat gta cag gga gag agc c; 9r, cca aat tga cca 
agg atc aga; 10f, agg ggt ggc tag gac aaa at; 10r, gga caa att gca ggg cta gt. 
Rat AVP 1f, tca atg cca gct ttc tgc ta; 1r, agt cct agg tga gcc cac ag; 2f, ata gta cca gcc tca ggg ca;  
2r, gcc aca gtc atg gag tca ag; 3f, gca tgt gtc aca act gtc ctt t; 3r, tga gca ttt cag cag ctc tc; 4f, gca gac ctg cta gtc 
ctt gg; 4r, gct gtc agc agt gat tca gg; 5f, gat tgc aca gca cca atc ac; 5r, agc atc atg gcg agc ata g. 
Rat Oxytocin  1f, ctc ctt gag gag aag gct ga; 1r, ggt tgg tcc act ttg gta cg; 2f, aag ggg tgg gca act aga 
ac; 2r, ttg acc tgg gac tgt ctg tg; 3f, gtg agt tca agc cca gcc ta; 3r, cat ctc agg gct gga gaa ct; 4f, gca aga gca act 
caa cca c; 4r, tgg tct aca gac cta gtt c; 5f, gtc ttc ctg cca tgg ttt gt; 5r, tgc tgg gaa caa aat tca ga; 6f, ggg gag atg 
gct taa tgg tt; 6r, tgc atg gga aga atg cta ca; 7f, cac aca cta ggc agg cag tc; 7r, gct ggc ctt gaa ctc aca gt; 8f, agc 
tga tgg cct gtg ttt tc; 8r, ggc tca gtg gtt agg agc ac; 9f, agg gcc ttt ggt aga gca gt; 9r, atg agg ttg gat agc gca ag. 
 
2.1.10.2 Sequencing primers 
Rat AVP 1f, cgg gcg ctc tag agg atc; 1r, aag gta gtg gtg cac tat cag; 2f,gac tgg agt cct cac acc; 2r, atg tac 
aga tat aca tgc aaa c; 3f, tgc cac cat cat cag gct g; 3r, tga gtc cat tcc ttt gtc tc; 4f, gta atc cca gca gac atg tg;  
4r, ggc agc ttc cac cag att g; 5f, gga gtt aaa cta tgt taa atc ag; 5r, atc aca tcc act aga gct ttg; 6f, gca cac agg cag 
cat ggc; 6r, ttc taa ggc agt cgt tta gtc; 7f, cta tgt agt aag gtc aag gtc; 7r, cca ccg cca cag tga ttg; 8f, ctc acc tcc ctg 
att gca c; 8r, tga taa gta tct ctc att ttc tg; 9f, gcc aca taa agg aca gtg tc; 9r, tca gag act tac ctc tcc g; 10f, gga cat 
gcc act caa ggg; 10r, tac agg cgt gca tca ccg; 11f, aat act cta gga aga aga caa; 11r, gaa aca gct tcc ttg gtc a; 
12f, gac aca gtg tgc ctc tat g, 12r, gct ctc ctg gac ctt ctg; 13f, gtt agc agc cac gtt gtc; 13r, aca tac aat aca gat ctg; 
14f, cca tgc cca agt gga gc; 14r, gct gga acg agg cca ag; 15f, cca gca acg caa agc agc; 15r, aat aga gac aga cac 
cag g. 
Rat Oxytocin 1f, aac gga tct gtg att cag gg; 1r, cct agg ttt gat tcc cag ca; 2f, cac tgg aac tgg gat aag t; 2r, ccc 
cag gag ctg tca tta aa; 3f, aat caa gga gct ggg gag at; 3r, gat gcc ctc ttc tgg tgt gt; 4f, tga tgg cct gtg ttt tct ca; 
4r, gag ctc aaa agg gac aca gc; 5f, tag aag aag ggc tga gct gc; 5r, agg gga tgc tct ctg aag gt; 6f, ctt ggc cta ctg gct 
ctg ac; 6r, atc atc aca aag cag ggc tc. 
Mouse AVP 1f, cta gaa gcc gtg ggc tag gt; 1r, ggg gag agc ttg gga ata gtg;  2f, cat tgc cac cat agc ttt cc; 
2r, gtt agc agc cac gtt gtc; 3f, caa gag aag gga cac cat ag; 3r, ttc cttt ggt cag aag aaa cct; 4f, att tct gct cga cct cag 
ag; 4r, act ctg tgc tct cct gga c; 5f, atc gcc aga gca cca gca ac; 5r, cac ccc aga aat aga gac ag.  
Human AVP 1f 5’, tgg cct gag tat agg agg c; 1r 5’, aag gga cac aga at gaga g; 2f 5’, gtg tca tgt ctt gca 
ctt tc; 2r5’, cag ttc tgg aag tag cac g; 3f 3’; cca gtc atc cgc agc ccg a, 3r 3’; ttt gtg ttt cag tct cct g, 4f 3’; cac tta 
gtc tgt aac gtg a, 4r 3’; gag gcg aga gca gag tg. 
Mouse chromosome 2 markers 1f, ccc aag gtt cat aat gaa ttc c; 1r, agc agg tct caa tgc cag g; 2f, aat 
gga aag cta agc acc tac; 2r, gag ggc ttc act gca tgt g; 3f, ctc ctc cac ttg cat gca ac; 3r, cct ggg aga aac atg agg ag; 
4f, tga gga gct gtc aca tta gg; 4r, ctc aac att taa tca ctt ctc c; 5f, ctg tcc tgc att agc tgt ctg; 5r, act gat gtg gcc aca 
gtc c; 6f, ggc ttt aat gtc agt caa acc; 6r, gaa gaa ctt gtg tgg aaa gag; 7f, acc aac att caa agt cct tgg; 7r, gac atg gtg 
gat gga taa cag; 8f, aac caa cag aaa gag aag agc; 8r, taa agg ctt gtt cta cca ctg; 9f, gtt gtc aag agt gga gat gga c; 
9r, cct gac aca aga cca gtg ag; 10f, cac cca gcg agt atg tca tc; 10r, aaa cat atc tgc agg atg aat g; 11f, tcg agg tcc 
ctg tct tgt g; 11r, aat gac atc tca gaa agc cac; 12f, cca aag gta tca cca aga ac; 12r, tga aat tca aca tca atg atg; 
13f, att ttc tct gca tag ctt tgc; 13r, tcc tga agt tgc att gtt tg; 14f, ctt taa gct tcc ttc tga agc; 14r ctt gct tga gtt cct gtc. 
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pBSKII vector T7, gta ata cga ctc act ata ggg c; T3, aat taa ccc tca cta aag gg; M13 forward, gta aaa 
cga cgg cca gt; M13 reverse, gga aac agc tat gac cat g. 
pGL2 UPS, ctt atg gta ctg taa ctg; DS, gat aga atg gcg ccg ggc c. 
 
2.1.10.3 In vivo transcription assay primers 
Rat AVP f, ccg aca tgg agc tga gac; r, tga gcc tag tga ctg gat tcc c. 
Rat oxytocin f, atc tcg gac tga aca cca acg c; r, ctg tgc aca atc cat atc ggg ac. 
 
2.1.10.4 RFLP primer pairs 
Location Polymorphism Primers Restriction Enzyme 
Rat AVP intron T(+549)C f; TGA GAA CGG GTT AAA CTG GG AciI 
  r; GGG ACA TAC TCC GCT CAG AC  
Rat AVP promoter A(-455)C f; ACA ACT GTC CTT TTT ATT CTT T Eam1104I 
  r; AAT CAT ACT TGA GCA TTT CA  
Rat AVP promoter A(-534)G f; GCA TGT GTC ACA ACT GTC CTT T MaeIII 
  r; TGA GCA TTT CAG CAG CTC TC  
Rat AVP promoter C(-590)T f ; GCA TGT GTC ACA ACT GTC CTT T SfaNI 
  r; TGA GCA TTT CAG CAG CTC TC  
Rat AVP promoter T(-2452)C f; GTG ATT TCA GGT TAG AAC CC HaeIII 
  r; CAC TTT GGC GTC TAC GTG C  
Rat oxytocin exon C(+18)T f ; GCT GTG TCC CTT TTG AGC TC BsmAI 
  r, CTT GGC CTA CTG GCT CTG AC  
Human AVP 3’. G(-558)T f; GCC TCA GGT TCA AGA AGG  MseI 
  r; CCA AGG CAG TGC TCG TGT  
Human AVP promoter C(-229)T f; CTG AAT CCA GAG CGC TGC NlaIII 
  r; GCA TCC TGG TGC ACA CAG  
Mouse AVP exon C(+6)T f; GTT AGC AGC CAC GTT GTC BstNI 
  r; CTC TTG GGC AGT TCT GGA AG  
 
2.1.11 Sequences and accession numbers 
Rat AVP gene (X59496), promoter (AF112362), 3’ region (X01637); Mouse AVP gene 
(M88354), promoter (AL731707); Human AVP gene (X62890), promoter (AL160414);  
Rat CRH gene and promoter (M54987); Rat oxytocin gene (X59496,) promoter (X12792). 
Mouse YY1 mRNA (AB080317); Mouse CBF-A mRNA (D90151); Mouse chromosome 2 
polymorphic regions (C77491, AI747202_153, AI663983_10, AI325259_167, 
AW046744_208, AA410094_61, AI225831_18, AB015595_12, AW541238_50, 
AF091998_162, R7484970, L25602_11, AI385582_268, AL808143, C80276_113, 
AU015228_19, AB012611_76, AL808143_5, AL831753_5, AI118379). 
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2.2 Methods 
2.2.1 DNA Analysis 
2.2.1.1 DNA extraction 
DNA was purified from either 0.5cm tail tips of live rats, or from the spleens of rat autopsies 
using the NucleoSpin Tissue kit (Macherey-Nagel). Extraction from the tail generally gave a 
DNA yield of ~20µg from rats (0.5cm) and mice (0.5-1cm), whereas the spleen (~20mg) gave 
somewhat higher amounts of ~30µg. A further, more cost-efficient, extraction protocol was 
developed to allow the analysis of large numbers of animals during the selectional breeding. 
Tail tissue of mice and rats were digested in 700µl of tail buffer (Tris-HCl pH 8, 0,5M EDTA, 
7M NaCl, 20% SDS) in the presence of 40µg proteinase K at 55°C overnight. 300µl of 
NaCl (7M) was added to the DNA, which was vortexed for 10min and centrifuged at 
14,000rpm in a benchtop centrifuge for 10min. The upper aqueous layer was then added to 
500µl isopropanol, which was mixed and centrifuged at again at 14,000rpm in a benchtop 
centrifuge for 5min to pellet the DNA. The pellet was then washed in 70% ethanol, dried and 
dissolved in TE buffer. DNA was also purified from samples of clotted blood using 
streptokinase. Streptokinase is a proteolytic enzyme, produced by haemolytic streptococci, 
that is capable of dissolving blood clots by converting plasminogen to plasmin. Briefly, a 
small amount (50µl) of clotted blood was incubated at 37°C overnight in the presence of 10U 
streptokinase, after which a spin column tissue extraction protocol (Qiagen) was followed. 
Due to the relatively small size of rats and the presence of fur, collection of blood by 
hypodermic needle is not possible. Furthermore, it is not practical to take tail tips from rats 
over the age of 2 years due to the discomfort it causes. Therefore, a new method was designed 
in this study, circumventing these problems, utilizing faeces from the rats, which contain cells 
from the intestines as the source of DNA. Faeces are generally not a good source of pure 
DNA for the use in PCR procedures due to the presence of contaminating chemicals, which 
inhibit polymerases, and the high concentration of bacteria DNA. A method was devised 
involving the solid-phase chromatography principle of the spin column methods, but using 
streptavidin-coated magnetic poly(vinyl alcohol) (M-PVA) -beads to bind the DNA, allowing 
for more stringent washing steps. Briefly, faeces were taken from cages and DNA extracted 
following the Chemagenic kit instructions, except that the numbers of washes were increased 
by 5-fold, and DNA resuspended in 100µl water. 
This method, surprisingly, resulted in a measurable quantity of DNA (figure 4A), 
though it is expected an overwhelming portion of this emanates from bacteria. However, 
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accepting the possibility of the very low levels of DNA, PCR amplification using 1µl of the 
DNA in a 25µl PCR reaction (39 cycles with a 55°C annealing temperature) still proved 
possible (figure 4B). 
 
 
 
 
Figure 4. DNA extraction and PCR results from rat faeces. (A) Agarose gel loaded with 3µl of spin column 
(tail tip) extracted DNA obtained from tail tip (+ve) and 3µl of faeces extracted DNA with increasing 
amounts of starting material (one wash of faeces with water, five washes, 0.005g, 0.05g and 0.1g). (B) PCR 
amplification reactions for a 550bp product (arrow) using the samples described in figure 4A performed 
in parallel. The first lane contains the spin column extracted DNA, the last lane the –ve control. Both gels, 
of A and B, are representative of three independent experiments. 
 
Naturally, the PCR reactions were less efficient in the faeces extractions than the tail 
tip extractions, both in the quantity of PCR product and the success rate in PCR reactions. It 
also seems that using less starting material does not effect the functioning of the PCR, 
suggesting that the failure of the PCR was not caused by lack of starting material, but perhaps 
by contaminants still present in the DNA extract or an overwhelming concentration of 
bacterial DNA in the final DNA sample.  
However, the finding that this method does result in enough detectible PCR product to 
allow restriction fragment length polymorphism (RFLP) analysis is testament to the use of 
this method as a real option for DNA extraction. Moreover, if DNA is required simply for the 
presence of genotyping one allele then this method represents an alternative to collecting tail 
tips or sacrificing animals solely for this purpose. 
2.2.1.2 PCR 
PCR was conducted on DNA extractions in order to amplify DNA for the use in sequencing, 
single strand conformation polymorphism (SSCP) analysis, cloning and RFLP genotyping. 
Amplification reactions were carried out in a total volume of 25µl in the presence of 50ng of 
DNA, 10x PCR Buffer (with MgCl2), 0.2mM of each dNTP, 0.5µM of each primer and 
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0.25U of Taq (Thermus Aquaticus) DNA polymerase enzyme. For certain analyses outlined in 
this study, such as the in vivo transcription experiments, the DNA polymerase Pfu 
(Pyrococcus furiosus) was used, which is a high fidelity polymerase with a very low rate of 
nucleotide misincorporation. This enzyme also results in the production of blunt ended PCR 
products in contrast to Taq, which produces PCR products with a one base 3'-overhang. 
Annealing temperature and numbers of cycles were optimised for each primer. After an initial 
denaturation step at 94°C for 2min, 30-35 cycles of 1min at 94°C, 1min at an optimised 
annealing temperature, 1min at 72°C were carried out, and a final extension period of 10min 
was performed at 72°C. Optimised annealing temperatures and numbers of cycles for each 
primer pair used in RFLPs are presented in Materials. Primers, used to amplify regions from 
sequences deposited at GeneBank, were designed according to rules laid out by Innis and 
Gelfand (Innis and Gelfand, 1990); primers should be 18-25bp in length, GC content should 
be 40-60%, repetitive stretches of bases should be avoided, no 3’complimentarity between 
primers, if possible two cytosine or guanine residues should be present at the 3’end of each 
primer and the opportunity for internal secondary structure should be kept to a minimum. 
PCR fragments were analysed on agarose gels stained with ethidium bromide (EtBr) to check 
the quantity and quality of amplified product. 
2.2.1.3 SSCP 
Twenty HAB and twenty LAB rats were used to search for polymorphisms in the coding and 
promoter regions of the AVP gene, oxytocin gene, and the CRH gene. Primers were designed 
for SSCP analysis to produce overlapping PCR products of around 300bp long. 3-5µl of PCR 
product, depending on the concentration, were mixed with an equal volume of loading dye 
(10mM NaOH, 20mM EDTA, 95% formamide, 0.025% Bromophenol blue and 0.025% 
Xylene cyanol), denatured at 95°C for 2min and immediately chilled on ice. Then 3-5µl of the 
mixture was loaded on to a non-denaturing 0.5x TBE 8% polyacrylamide gel. Electrophoresis 
was carried out at room temperature in 0.5x TBE buffer using the MiniProtean gel apparatus 
at 80V for 2-3h. After electrophoresis the gels were either stained in EtBr and DNA visualised 
under a UV light, or were silver stained. SSCP reactions were repeated where any suspected 
band pattern differences were evident, and PCR products revealing differences in band 
patterns were sequenced.  
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2.2.1.4 Sequencing 
Plasmid inserts were sequenced using Thermosequenase Cycle sequencing kit in conjunction 
with α-33PdATP. PCR products corresponding to genomic regions were sequenced using the 
Thermosequenase radiolabelled termination cycle sequencing kit and [α-33P]ddNTP. 
Although both protocols are based on the same traditional chain termination sequencing 
method (Sanger, 1977), the first method used for plasmid sequencing involves alkaline 
denaturation of samples, which proved inefficient for the separation of linear DNA fragments 
produced in PCR. Furthermore, the use of [α-33P]ddNTP in the second protocol, ensures the 
radiolabel is incorporated in the 3’ end, allowing longer stretches of DNA sequences to be 
read more cleanly with the occurrence of fewer compressions and BAFLs (Bands across four 
lanes). Primers used for sequencing (refer to section 2.1.10.2) were either complementary to 
inserted sequences or complementary to sequences found in the parent vector backbone. 
Sequencing of plasmids was conducted by firstly denaturing 2-4µg of vector DNA 
(prepared from either maxi-preps or spin columns) in the presence of 1mM NaOH/0.001mM 
EDTA in a final volume of 20:l. The DNA is then precipitated in 3M NaAc (pH 5.2) and 
ethanol, washed in 70% ethanol and annealed with 2pM primer in the presence of sequenase 
buffer. The elongation reaction is performed by adding DTT, 1x label mix, α-33PdATP and 
1.3U T7-Sequenase, which is terminated by the addition of ddNTP(G,A,T,C), and finally, 
formamide loading buffer. This reaction was performed on micro test plates. 
PCR products were cleaned-up prior to sequencing by treating with ExoSAP-IT. 
ExoSAP-IT utilizes two hydrolytic enzymes, Exonuclease I and Shrimp Alkaline Phosphatase, 
to remove unwanted dNTPs and primers from PCR products. Exonuclease I removes residual 
single-stranded primers and any extraneous single-stranded DNA produced in the PCR. 
Shrimp Alkaline Phosphatase removes the remaining dNTPs from the PCR mixture. 
Following this, 100-200ng DNA was included in the Thermosequenase radiolabelled 
termination cycle sequencing reaction, which was performed as described in the 
manufacturers protocol. This reaction was performed in PCR tubes. Sequencing products 
from both reactions were, thereafter, treated the same. The reactions were heated to 75°C for 
2min, to dentature the DNA, and loaded onto an 8% denaturing polyacrylamide gel (see 
Materials). The gels were run in 0.5x TBE at 3,000V and 40-50W for between 1-3h at a 
temperature of 50°C. The gel is then transferred and dried on blotting paper and exposed to 
X-ray film in a cassette for between 12-36h. The film was then developed in an automatic 
developer (Kodak), or developed manually by soaking in developing solution for 1-5min and 
fixing in fixing solution for 2min. 
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2.2.1.5 RFLP analysis 
Polymorphisms detected in genomic DNA from the sequencing reactions described above 
were analysed, using the online DNA analysis program contained in webcutter2 (refer to 
section 2.2.6), to determine if a polymorphism affected a DNA site for a restriction 
endonuclease. Any polymorphisms resulting in differential digestion by a restriction 
endonuclease were used to genotype animals for the presence of the polymorphism concerned. 
This procedure using RFLP is far more cost and labour efficient than sequencing for the 
presence of a genotype in large numbers of animals. Primers are designed spanning the 
restriction site, to give a PCR product of between 300-500bp in length. Ideally, the 
polymorphism is usually located off centre, to allow for electrophoresis separation of both 
digested products; this and the presence of nearby restriction sites determines the positions on 
which the primers are designed. The DNA concentration of PCR products prior to enzyme 
digestion is estimated by agarose gel electrophoresis. Around 1µg DNA is digested in a 
reaction containing reaction buffer (with or without BSA) and between 1 and 5U restriction 
endonuclease. The reaction is then made up to an appropriate volume of between 10 and 20µl 
with distilled water. The digestion reactions are incubated at the optimal temperature required 
by the enzyme for between 8 and 24h. Generally, the whole digestion reaction is mixed with 
1µl loading buffer (see Materials) and loaded on to either an agarose or polyacrylamide gel. 
Agarose gels allow for the efficient separation of large DNA fragments at a relatively low 
resolution of ~20bp – depending on the percentage of agarose. Polyacrylamide gels, on the 
other hand, have a far higher resolution, allowing for the separation of DNA fragments 
differing in size of 5bp. Both types of gel are run at room temperature in the presence of  
1x TBE running buffer and stained in EtBr to allow visualisation of DNA. EtBr is a 
polycyclic fluorescent dye that binds to double-stranded DNA molecules by intercalating a 
planar group between the stacked base pairs of the nucleic acid. EtBr can also bind to 
secondary structure in single-stranded RNA molecules: regions of local base pairing offer the 
stacked base pairs necessary for the dye molecules to intercalate. When excited by ultra violet 
(UV) light (at or near 546nm), the dye-nucleic acid complex exhibits an increased (about 
20-fold) fluorescent yield at an emission wavelength of 590nm. Agarose gels are stained with 
EtBr prior to DNA loading and electrophoresis, and polyacrylamide gels are soaked in EtBr 
after electrophoresis. Markers are also loaded in separate lanes on the DNA gels to allow for 
determination of DNA band sizes. The agarose gels are typically run for between 30min and 
2h at 50 to 80V depending on the size of the electrophoresis chamber used and the percentage 
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agarose present in the gel. The DNA bands are then photographed in the presence of UV light 
using Kodak Polaroid film. 
Rat, mouse or human samples are genotyped at least twice to allow for inefficiencies 
in the digest that may lead to misanalysis. Furthermore, all digests are performed with control 
reactions containing the known polymorphism expected to lead to either absence of, or 
complete, cleavage. All RFLP analyses including the polymorphisms, primer pairs and 
restriction enzymes used in this study are listed in section 2.1.10.4. 
2.2.1.6 Radioactive labelling 
The Forward reaction was used for end labelling dsDNA and annealed oligonucleotides used 
in EMSA experiments, and were performed using fill-in end labelling. The oligonucleotides 
were annealed as described below in the EMSA. 1.5µl of the oligonucleotides were added 
together with 2µl 10x Klenow buffer, 4µl dATG, dGTT, dTTP (5mM), 9-6.5µl H2O, 
2.5-5µl 32P-dCT and 1µl Klenow enzyme. This was incubated at room temperature for 30min, 
after which 4µl dCTP (5mM) was added and the reaction incubated again at room temperature 
for a further 5min. A Biospin column was used to clean up any free label. A working stock of 
20,000cpm/µl was used for all reactions described. 
The Exchange reaction was used for end labelling ssDNA oligonucleotides and was 
performed using the 5’ termini labelling Forward Reaction. The DNA needs to be 
dephosphorylated for this procedure, which is the case for ordered oligonucleotides that are 
supplied dephosphorylated. dsDNA was firstly dephosphorylated by CIAP. This 5’hydroxyl 
terminus, lacking a phosphate group, is then rephosphorylated by transferring the γ-phosphate 
using T4 polynucleotide kinase (PNK). Efficiency depends on the first residue and 
experimental design ensures this was usually a G, which is most efficient, followed by A or T, 
and C, which is the least efficient. The reaction comprises 20pM DNA, 2µl Reaction buffer A, 
5µl (γ32P)ATP, 11µl H2O and 1µl T4 PNK, which was incubated for 1h at 37°C. The reaction 
was terminated by addition of 1µl 0.5M EDTA(pH8.0), after which the unincorporated free 
radionucleotide is removed using a Biospin column. A working stock of 20,000cpm/µl was 
used for all reactions described. 
2.2.2 RNA analysis 
2.2.2.1 RNA extraction 
AVP is expressed in only a small population of the neurons that make up the hypothalamus 
(for review see Burbach et al., 2001). Therefore, in order to obtain AVP mRNA, only the 
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hypothalamic tissue expressing AVP can be used for RNA extraction. Rats were decapitated 
and the brains removed. A 2mm lateral slice is taken containing the hypothalamus, and from 
this the PVN and SON were dissected out under the guidance of the group of Professor 
Landgraf. The PVN/SON samples were kept on ice for up to 10min, until the extraction 
procedure was initiated. The acidic phenol method, developed by Chomczynski 
(Chomczynski and Sacchi, 1987) was used for the extraction procedure. Commercially 
available kits employing spin columns (Qiagen) were tested, though the acidic phenol kit 
proved to be the most efficient for the type and size of material used in this study.   
The frozen brain tissue was crushed with a plastic mortar in a 1.5ml Eppendorf tube. 
To this was added solution D containing β-mecaptoethanol, which breaks down di-sulphide 
bridges, and the potent protein denaturant guanidium thiocyanate which denatures RNases 
present in the sample. The sample was then combined with 2M NaOAc (pH4), acidic phenol 
and chlorophorm/isoamyl and vortexed. This causes the partitioning of proteins, lipids, and 
importantly, DNA into the phenol layer. DNA shows a pH-dependent partitioning while RNA 
does not – when the aqueous phase of phenol is above pH7.5 DNA partitions with RNA into 
the aqueous layer. When low pH4 is used DNA partitions to the phenol layer, leaving only the 
RNA in the aqueous phase. The sample was centrifuged to aid partitioning of the phenol layer, 
and the upper phase removed and added to cold isopropanol to precipitate the RNA. This was 
centrifuged again, and the pellet dissolved in solution D to dissociate any further proteins 
carried with the RNA in the sample. Again the RNA was precipitated with cold isopropanol 
and then washed in 70% ethanol to remove salt. The RNA pellet was further dissolved in 
warm proteinase K buffer and digested with 1µl proteinase K (10mg/ml) at 55°C for 30min to 
enzymatically remove any residual RNases still present in the sample. The sample was then 
mixed with equal volume of phenol/chloroform/isoamyl to denature and remove the 
previously added proteinase K, and the upper layer mixed with 1/10 3M NaOAc (pH5.5) and 
2.5x ethanol to precipitate the RNA which was again washed in 70% ethanol. The final pellet 
was dissolved in between 20-50µl DEPC water. 
Quantity and quality of the RNA samples were determined using spectrophotometry 
(OD260nm) and MOPS/formamide denaturing agarose-gel electrophoresis and EtBr staining 
were performed to check the integrity and size distribution of total RNA. The respective 
ribosomal bands, from all samples used in this study, appeared as sharp bands on the stained 
gel, and the intensity of the 28S ribosomal RNA (rRNA) band was approximately twice that 
of the 18S rRNA band. 
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2.2.2.2 Riboprobe 
To generate the CBF-A riboprobe, used in the in situ-hybridisation experiments, the plasmid 
pBSK-CBF-A, containing the full length CBF-A cDNA cloned into the SmaI site (refer to 
section 2.2.3.2), was digested with BamHI and religated to contain only the 326bp N-terminal 
sequence of the CBF-A cDNA. To generate antisense probe, the plasmid was linearied with 
EcoRV, and for sense probe the plasmid was linearized with XbaI. The template DNA was 
then purified with a phenol/chlorophorm extraction and transcribed and labelled with 35S-UTP 
in a 30µl reaction mixture containing 20U of either T7 (sense probe) or T3 (antisense probe) 
RNA polymerase, 1x reaction buffer, 0.5M DTT, 10mM each of ATP, GTP, and CTP, 
10µM 35S-thio-rUTP (12.5mCi/mM), 1.5 µg of linearized template DNA and 40U of 
recombinant RNasin RNase inhibitor. The reaction was incubated at 37°C for 3h after which 
the reactions were stopped by addition of 2U RNase-free DNase I. Unincorporated 
nucleotides were removed using the RNeasy kit following the clean up protocol.  
2.2.2.3 In situ-hybridisation analysis 
In situ-hybridisation was performed according to a protocol outlined by Cota et al., 2003. 
Slide-mounted frozen brain sections were fixed for 10min in ice-cold  
4% paraformaldehyde/PBS, rinsed in 1x PBS, suspended in 0.1 M triethanolamine at pH 8.0 
and acetylated by addition of 0.25% acetic anhydride over 10min. Both the antisense and the 
control sense probes were applied to the slide-mounted sections in a volume of 
100µl hybridisation buffer/section, containing 4–5×106 cpm of 35S per section. Hybridisation 
buffer consisted of 50% formamide, 20mM Tris-HCl pH8.0, 0.3M NaCl, 5mM EDTA pH8.0, 
10% dextran sulphate, 0.02% Ficoll 400, 0.02% polyvinylpyrrolidone, 0.02% BSA, 
0.5mg/ml tRNA, 0.2mg/ml fragmented herring sperm DNA and 200mM DTT (Marsicano and 
Lutz, 1999). In control experiments slides were pretreated with RNAse A prior to 
hybridisation. All sections were incubated for 20h in a humid environment at 55°C, and then 
rinsed in 2× SSC, washed in a standard series of washes, and dehydrated in a graded series of 
ethanols. The resulting slides were exposed to X-ray film for 8 days. 
The slides were further dipped and the nuclei counterstained in Toluidine Blue. Kodak 
NTB2 was used for dipping. This was heated to 42°C and mixed with an equal volume of 
water. The slides were dipped, in a dark room for 4sec and dried at RT for 30min. They were 
then packed into light-tight black boxes with sufficient desiccant (silica gel capsules) at 4°C 
and exposed for 4 weeks. The slides were developed in Kodak D19 developer for 3min, 
rinsed in water for 30sec and fixed in Kodak fixer for 3min. The slides were then 
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counterstained in 1% tolurodine Blue for 3min and dehydrated in a graded series of ethanols. 
The sections were then embedded in Roti-Histokitt (2 drops) followed by a cover slip. 
2.2.2.4 Allele-specific transcription in vivo 
RNA was extracted from the PVN of the hypothalamus of F1 animals, heterozygous for the 
two AVP promoter alleles, using the acidic phenol method (see above). Oxytocin and AVP 
heterogeneous RNA (hnRNA) was reverse transcribed and amplified using gene-specific 
primers in combination with the OneStep RT-PCR kit from Qiagen. The Qiagen OneStep 
RT-PCR enzyme mix contains enzymes for both reverse transcription and PCR amplification 
in the same tube. Omniscript reverse transcriptase is specially designed for reverse 
transcription of RNA amounts greater than 50ng, and Sensiscript reverse transcriptase is 
optimised for use with very small amounts of RNA (<50ng). This special enzyme 
combination provides highly efficient and sensitive reverse transcription of any RNA quantity 
from 1pg to 2µg. HotStarTaq DNA Polymerase provides hot-start PCR for highly specific 
amplification. During reverse transcription, HotStarTaq DNA Polymerase is completely 
inactive and does not interfere with the reverse-transcriptase reaction. After reverse 
transcription by Omniscript and Sensiscript reverse transcriptases, reactions are heated to 
95°C for 15min to activate HotStarTaq DNA Polymerase and to simultaneously inactivate the 
reverse transcriptases. This hot-start procedure using HotStarTaq DNA Polymerase eliminates 
extension from non-specifically annealed primers and primer–dimers in the first cycle 
ensuring highly specific and reproducible PCR. 
The design of gene-specific primers for the reverse transcription of the oxytocin and 
AVP genes was important. The primers were designed to be 18–30 nucleotides in length with 
a G/C content of 40–60%. The primers were designed with similar Tm values not lower than 
the reverse-transcription reaction temperature (e.g. 50°C). Furthermore, the primers were 
designed to avoid; (i) complementarity’s of two or more bases at the 3' end to reduce primer–
dimer formation, (ii) mismatches between the 3' end of the primer, (iii) runs of 3 or more G or 
C nucleotides at the 3' end, (iv) a 3'- end T, (v) complementary sequences within a primer 
sequence and between the primers of a primer pair. 
It is usually suggested that primers should be designed so that one half of the primer 
hybridises to the 3' end of one exon and the other half to the 5' end of the adjacent exon. 
Primers will anneal to cDNA synthesized from spliced mRNAs, but not to genomic DNA. 
Thus, amplification of contaminating DNA is eliminated. Alternatively, RT-PCR primers 
should be designed to flank a region that contains at least one intron. Products amplified from 
cDNA (no introns) will be smaller than those amplified from genomic DNA (containing 
26 
Materials and Methods 
introns). Size difference in products is used to detect the presence of contaminating DNA. 
However, our study required the analysis of heterogenous prespliced mRNA (hnRNA) and, 
therefore, primers were designed to specifically anneal to sequences in intronic regions. 
Control reactions were used with each RT reaction to test for the presence of contaminating 
DNA in the reagents. Therefore, contaminating DNA in the RT-reaction from the sample was 
checked for by performing deoxyribonuclease I digestion of the RNA sample prior to reverse 
transcription. Briefly, 1µg of RNA was digested in a reaction volume of 10µl containing 
10x reaction buffer with MgCl2 and 1U deoxyribonuclease I and incubated 37°C for 30min. 
The reaction is stopped by the addition of 1µl 25mM EDTA and heating at 65°C for 10min to 
destroy the deoxyribonuclease. 
Primer pairs were designed to anneal to the RNA from oxytocin and the prespliced hnRNA 
from AVP (figure 5). The forward primer for oxytocin (ATC TCG GAC TGA ACA CCA 
ACG C) locates to the 5’ untranslated region 2bp 5’ to the start codon and 20bp 5’ to the 
polymorphism. The gene-specific primer (CTG TGC ACA ATC CAT ATC GGG AC) locates 
to the first intron 28bp 5’ to the intronI/ExonII splice junction. This gives an expected cDNA 
product of 343bp. The forward primer (CCG ACA TGG AGC TGA GAC) and the gene-
specific primer (TGA GCC TAG TGA CTG GAT TCC C) for AVP derived from 
sequences in exon I, 2bp 5’ to the exon I/intron I junction and the first intron. 
 
 
Figure 5. Sequence of oxytocin and AVP gene polymorphisms used in the in vivo transcription assay. 
(A) Oxytocin hnRNA was reverse transcribed using the gene-specific primer (GSP) in intron I, resulting 
in a 354bp cDNA representative of newly synthesised hnRNA. The C(+18)T polymorphism, located in the 
first exon, was further amplified from cDNA using the same GSP in conjunction with a forward primer 
complementary to sequences in the oxytocin RNA 5’ untranslated region to provide a 343bp PCR product 
containing the polymorphism. Sequencing was performed using the forward primer as the sequencing 
primer. (B) AVP hnRNA was reverse transcribed using the gene-specific primer (GSP) in intron I, 
resulting in a 770bp cDNA representative of the hnRNA. The T(+549)C polymorphism, located in the first 
exon, was further amplified from the cDNA using the same GSP in conjunction with a forward primer 
complementary to sequences in exon I of the AVP RNA providing a 600bp PCR product containing the 
polymorphism. Sequencing was performed using the sequencing primer located 59bp upstream of the 
polymorphism. 
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PCR was performed under the following conditions: cDNA synthesis at 50°C for 
30min for the reverse transcription, 94°C 15min to destroy the reverse transcriptase and 
activate the polymerase, amplification for 20 cycles with 94°C 30sec, 55°C 30sec, 68°C for 
30sec. A further 20 cycles of PCR was performed on 1µl of the previous reaction using a 
nested primer and Pfu polymerase (NEB). Products were purified and cloned into the EcoRV 
site of the vector pBSKII (Stratagene). Following transformation into DH5α bacteria DNA 
was isolated from single colonies (Nucleospin miniprep kit, Macherey-Nagel) and sequenced 
to track the allele from which the RNA was transcribed. Every reaction included one negative 
control in every round of RT-PCR that lacked the template RNA in order to detect possible 
contamination of the reaction components. 
2.2.3 Plasmids 
2.2.3.1 Standard and parent plasmids 
pBSKII is a high copy number ColE1-based phagemid with a large and versatile polylinker in 
two orientations to allow for the cloning of a wide variety of products. T3 and T7 promoters 
flanking the polylinker allow for in vitro transcription of RNA. The plasmid contains a gene 
for Ampicillin-resistance in E. coli to allow for selection of transformed bacteria. The plasmid 
further allows for the identification of recombinant clones containing inserts in the polylinker 
located in the β-gal gene, whose activity is destroyed in case inserts are incorporated. 
pGEX-2-Tk vectors allow the construction of GST fusion proteins by inserting a 
cDNA inframe into the multiple cloning site. Expression is under the control of the tac 
promoter, which is induced by the lactose analogue isopropyl-β-d-thiogalactopyranoside 
(IPTG). The vector is also engineered with an internal lacIq gene coding for a repressor 
protein that binds to the operator region of the tac promoter, preventing expression until 
induction by IPTG, thus maintaining tight control over expression of the insert. 
pRK8-PKA contains the catalytic subunit of PKA derived from rat under the control 
of the CMV promoter (Spengler et al., 1993). 
pRK7-FLAG vector was created by cloning the oligonucleotides 
AGCTTCTCGAGATGGACT ATAAGGACGATGACGATAAGG and AGAGCTCTACCT 
GATATTCCTGCTACTGCTATTCCCTAG into the HindIII and BamHI digested pRK7 
vector. These oligonucleotides encode for the short hydrophilic 8 amino acid (aa) peptide 
Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys. This epitope is likely to be located on the surface of a 
fusion protein due to its hydrophilic nature and, therefore, accessible to antibodies. The small 
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size means it has less chance of interfering with the fusion protein’s function and 
transportation. 
pGL2-Basic vector contains the coding region for firefly luciferase, but lacks 
eukaryotic promoter and enhancer sequences, allowing the cloning of putative regulatory 
sequences. Therefore, expression of luciferase activity in cells transfected with this plasmid 
depends on insertion and proper orientation of a functional promoter upstream from the 
luciferase gene. The vector also contains a high copy number prokaryotic origin of replication 
for maintenance in E. coli, and an ampicillin-resistance gene for selection. 
2.2.3.2 cDNA constructs 
pRSKII-CBF-A, which was used for the preparation of the riboprobe, contains CBF-A that 
was released from pSR-CBF-A-N (Kamada et al., 1992) using Tth111I and SacI, after which 
the ends were blunted by T4 DNA polymerase and cloned into the SmaI site of pBSKII.  
2.2.3.3 Expression vectors 
pCMV-YY1 contained the full length YY1 cDNA comprising 16bp of untranslated 
5’ sequence and 28bp untranslated 3’ sequence. This was cloned into the BamH1 site of 
pCMV-NEO-BAM3 under the control of the CMV promoter.  
pRK7-CBF-A expression vector was made by cloning the mouse cDNA for CBF-A 
(a kind gift from Akira Inoue (Osaka, Japan) and Shinji Kamada (La Jolla, USA)) into the 
pRK7 vector downstream the CMV promoter. 
pRK8-PKAc expression vector contains the catalytic subunit of PKA derived from rat 
under the control of the CMV promoter (Spengler et al., 1993). 
2.2.3.4 Recombinant protein constructs 
pGST-2Tk-CBF-A was made by releasing CBF-A from pBSKII, by a partial BamHI and 
EcoRI digest, and inserting into pGEX-2TK digested with BamHI and EcoRI. 
FLAG-CBF-A was obtained by ligating the CBF-A fragment, which was released 
from pBSKII-CBF-A by a partial BamHI digest and EcoRI digest, into the BamHI and EcoRI 
sites of pRK7-FLAG. 
GST-CBF-A deletion constructs were a kind gift from Drs. Leandersson and Aranburu 
(Lund). These constructs contain deletions of either, or both, of the RNA-Binding-Domains 
(RBDs) (Bemark et al., 1998).  
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2.2.3.5 Reporter constructs 
pGL2-AVP proximal vector contains the proximal AVP promoter. Fragments of the rat AVP 
gene were generated by PCR from genomic DNA purified from either a HAB or LAB animal. 
AVP promoter fragments were inserted into the polylinker site of pGL2. A proximal promoter 
fragment of 1146bp containing sequence -860bp (775bp after digestion) to +282bp relative to 
the start codon, was amplified (forward primer, ACA TCC ACT TCC CT CCT GC; reverse 
primer, CGT TCT GGG AAA CCC ATC TA). Pfu polymerase (NEB) was used in a 
50µl PCR reaction (50ng DNA, 2mM MgSO4, 0.2mM each dNTP, 2.5U Taq, 1x High fidelity 
PCR buffer). Amplification of the proximal promoter was performed using 15 cycles of 
94°C 40sec, 58°C 40sec, 72°C 40sec, followed by 20 cycles of 94°C 40sec, 54°C 40sec and 
68°C 2min, ending with 20min of 68°C. The PCR products were purified using Qiagen spin 
columns and the proximal promoter fragment was digested with KpnI and ScaI to give 931bp. 
Following separation by agarose gel electrophoresis, the proximal promoter fragments, from 
the HAB and LAB animals, were cloned into the pBSKII vector digested with KpnI and 
EcoRV. Recombinant plasmids were completely sequenced and inserts were released using 
KpnI and SmaI and then inserted into the pGL2 vector digested with KpnI and SmaI. 
pGL2-AVPdistal vector contained the distal AVP promoter. To include additional 
upstream sequences genomic DNA was amplified (forward primer, GTA CCC CAT CCA 
CAC AGA CC; reverse primer, ATA TAA GAT AAC TGC TTC CTT C) to give a product of 
3119bp harbouring 2797bp upstream from the AVP start codon. This distal promoter was 
amplified using the conditions of an initial 18 cycles 94°C 40sec, 59°C 40sec, 68°C 2min, 
then 12 cycles 94°C 40sec 56°C 40sec 68°C 3min, ending with 20min at 68°C. Both PCR 
products were purified using Qiagen spin columns and the distal promoter was digested by 
KpnI and HincII giving a 2950bp product. Following separation by agarose gel 
electrophoresis, the distal promoter fragments, from the HAB and LAB animals, were cloned 
into the pBSKII vector digested with KpnI and EcoRV. Recombinant plasmids were 
completely sequenced and inserts were released using KpnI and SmaI and then inserted into 
the pGL2 vector digested with KpnI and SmaI. 
pGL2-CArG vectors were developed containing various copies of the CArG elements 
from either the HAB and LAB alleles. These were generated by serially cloning 
oligonucleotides containing the CArG box (LAB sense, ctc tag aga gct ccc act gtC CTT ATT 
AGG aag agg cag ct; LAB antisense, gcc tct tCC TAA TAA GGa cag tgg gag ctc tct aga 
ggt ac; HAB sense, ctc tag aga gct ccc act gtC CTT ATT GGG aag agg cag ct; HAB antisense, 
gcc tct tcC CAA TAA GGa cag tgg gag ctc tct aga ggt ac) into the KpnI and SacI site of 
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either of the following described pGL2 variants (figure 6). The oligonucleotides were 
annealed giving overhanging ends complementary to the digested ends of DNA products 
produced by the restriction enzymes KpnI and SacI. The LAB or HAB sense and antisense 
oligonucleotides (0.2µg) were mixed together, denatured at 85°C for 10min and then allowed 
to slowly cool to 37°C for efficient annealing. The oligonucleotides were then phosphorylated 
in the presence of 2U PNK, 250mM DTT, 50mM ATP and 10x PNK buffer in a reaction 
mixture of 50µl. This was incubated at 37°C for 30min and placed on ice. 
 
 
Figure 6. Sequence of the CArG cassette used for ligation into reporter plasmids. The LAB and HAB 
CArG elements were included with 8bp 5’ and 6bp 3’ of the rat AVP sequence. The 5’ end of the annealed 
oligonucleotides is complementary to the KpnI enzyme site, while the 3’ end contains sequence 
complementary enough to anneal to a SacI digested ‘sticky’ end DNA, without restoring the SacI site. This 
ensures correct orientation of the cassette in the vector. The XbaI site allows identification of recombinant 
clones using an enzyme digest of miniprep DNA, while the SacI site allows for further insertions of 
multiple copies of the cassette. 
 
pGL2-SV40-CArG involves the CArG elements cloned into the pGL2-SV40 vector 
which contains the entire simian virus (SV40) late and early promoter sequence; this 
functions as a highly active transcription initiation element (Benoist and Chambon, 1981). 
The pGL2- SV40 vector was digested with the enzymes KpnI and SacI, and dephosphorylated 
by adding 1U of calf intestinal alkaline phosphatase (CIAP) removing the possibility of the 
small 6bp fragment, lying between the two sites, re-ligating. The vector was then phenol/ 
chloroform purified and precipitated in the presence of Na-Acetate. This digested vector was 
then ligated with the phosphorylated and annealed oligonucleotides in the presence of ATP 
and T4 DNA kinase. This results in the CArG element being placed 375bp upstream of the 
SV40 early and late promoter start codon of the luciferase gene. Successfully ligated 
pGL2-SV40-CArG vector was identified by an XbaI digest on miniprep DNA from 10 
selected clones of each ligation. The presence of an XbaI site in the cloned oligonucleotide 
results in a detectible 445bp fragment due to another XbaI site contained in the parent vector. 
Sequencing data confirmed the presence and integrity of positive clones from the digest 
results (figure 7). 
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Figure 7. Sequences of the CArG ligated pGL2 vector – pGL2-CArG, pGL2-(CArG)2. Sequences were 
read from a sequencing primer located 5’ to the insertion site and luciferase gene. Lane order of the 
nucleotides is G, A, T and C. Further note the HAB and LAB polymorphic CArG sequences. 
 
pGL2-SV40-(CArG)2/ pGL2-SV40-(CArG)3 vectors were obtained by further cloning 
of the CArG elements adjacent to the first copy. This was achieved by digesting the 
pGL2-SV40-CArG vector with KpnI and SacI. This produces one small fragment of 8bp 
containing the XbaI site, which is discarded in the subsequent dephosphorylation and 
phenol/chloroform step. The annealed and phosphorylated oligonucleotides are then ligated 
with this digested vector, as described above. Bearing in mind that the previous XbaI site was 
lost in the previous digestion, inserts were again confirmed by an XbaI digest, where only 
positive clones produce any fragment, which, nonetheless, was 474bp long. pGL2-SV40-
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(CArG)3 containing three copies of the CArG element was further constructed by repeating 
the procedure above starting with a KpnI/SacI digest of pGL2-SV40-(CArG)2 instead of 
pGL2-SV40-CArG.  
pGL2-SV40early vector is derived from the pGL2SV40 vector which contains the 
intact SV40 promoter. The SV40 promoter is composed of two parts; the upstream ‘late’ 
enhancer and the downstream ‘early’ enhancer (figure 8). Since we wished to create a weakly 
active promoter we deleted the late enhancer by an SphI digest, of which two sites are found 
in the early/late promoter and a further site downstream in the vector (see below). 
 
SphI SphI SphIEcoRI
 
 
Figure 8. Schematic diagram of the simian virus (SV40) promoter. The promoter is divided into two 
regions constituting the proximal Early enhancer and the distally located Late enhancer. Three SphI 
restriction sites are contained by the vector, one situated in the late enhancer, the other mapping to the 
late/early enhancer boundary, and a third upstream of the start codon before the SV40 promoter 
sequence begins. An EcoRI sequence also locates close in the vicinity of the third mentioned SphI site. 
 
The larger fragment, containing the early enhancer was purified on an agarose gel and 
the overhanging ends created by the SphI sites were blunted by T4 polynucleotide kinase to 
create sites compatible with other blunt ended restriction fragments such as HincII. This 
fragment was then further digested with EcoRI and then cloned into a pBSKII vector digested 
with HincII and EcoRI. 
pGL2-SV40early-CArG vector consisted of a series of either one, two or three CArG 
elements inserted into the pGL2-SV40early vector. This was performed by cutting out the 
CArG elements from the pGL2-SV40-(CArG)1,2 or 3 by DraIII and XhoI, lying either side of 
the elements and cloning them into the pGL2-SV40early vector digested by DraIII and XhoI. 
All LAB and HAB CArG constructs were verified by XbaI digests, as before. 
The minimal promoter plasmid pGL2-TATA vector contains soley the TATA element 
derived from E1B (Hoffmann et al., 2003).  
pGL2-TATA-(CArG)1, 2 or 3 contained CArG elements cloned in series in front of a 
TATA element. CArG elements were ligated into the pGL2-TATA vector digested with 
DraIII and XhoI, as described above. 
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2.2.4 Cell culture and transfection experiments 
2.2.4.1 Cell cultures 
Saos-2, human osteosarcoma-like cells, (ATTC HTB-85) were established from the primary 
osteogenic sarcoma of an 11-year-old Caucasian female by J. Fogh and G. Trempe in 1977 
(Fogh et al., 1977), and are epithelial in morphology. In this study, they were grown in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% foetal calf serum 
(FCS).  
Lu-165, human small cell lung cancer cell line (a kind gift from Dr. T Terasaki, Tokyo, 
Japan), was established from a 50-year-old small cell lung cancer patient presenting with a 
syndrome of inappropriate anti-diuretic hormone secretion and the cells consequently produce 
a high quantity of anti-diuretic hormone (ADH, 2.8 µg protein) (Terasaki et al., 1994). The 
cells grow as multicellular suspended aggregates and retain their small cell carcinoma 
morphology. In this study, the cells were grown in RPMI1640 with L-Glutamine and 10% 
iron supplemented FCS. The cells grew very slowly and changes in media, including 
Optimum, and DMEM failed to speed up growth. 
Neuro2a is a mouse neuroblastoma cell line established by R.J. Klebe and F.H. Ruddle 
in 1969 (Klebe RJ, 1969) from a spontaneous tumour of a strain A albino mouse (ATCC No. 
CCL-131) and are neuronal in morphology. The cell line does not express AVP but do 
produce large quantities of microtubular protein which is believed to play a role in a 
contractile system which is responsible for axoplasmic flow in nerve cells. They were grown 
in DMEM supplemented with 10% FCS. 
HeLa cells are derived from a cervical epithelial adenocarcinoma of Henrietta Lacks, a 
31 year old woman from Baltimore, USA, who died of cervical cancer in 1951 and 
established by F.W. Scherer (Scherer, 1954) (ATCC No. CCL-2). The cells retain an epithelia 
morphology and in this study were grown in DMEM supplemented with 10% FCS. 
3T3 cell line was established by G. Todaro and H. Green in 1962 (Todaro, 1963) from 
disaggregated Swiss mouse embryos (ATCC No. CCL-92). They consist of fibroblast cells of 
mesodermal origin that make the structural fibres and ground substance of connective tissues. 
They are characterized by an abundant and branched cytoplasm surrounding an elliptical, 
speckled nucleus having one or two nucleoli. These cells were again grown in DMEM 
supplemented with 10% FCS. 
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2.2.4.2 Transfection 
Saos-2 cells were transfected by electroporation. Cells were seeded 12h before transfection. 
They were harvested by trypsinisation and resuspended in Electroporation buffer (EP) 
1x (50mM K2HPO4, 20mM CH3KO2, 20mM KOH) to obtain a concentration of 2x107 
cells/ml. 1x106 cells in 50µl of this was added to a 100µl mixture containing 1µg of AVP-
luciferase vector, 0.2µg pRK7-β-gal expression vector, 4µl MgSO4, 20µl EP5X, 3µg pGEM4 
filling DNA, and water. This was incubated at room temperature for 10min, placed in a 
cuvette and then electroporated using a BTX 600 electroporator (290V, 500µF, 360Ω). After 
pulse delivery the cells were immediately transferred to 24-well culture dishes containing 1ml 
of DMEM+10% FCS and incubated overnight at 37°C 5% CO2. 
Neuro2a cells were transfected using lipofectamine reagent. Cells (2x105) were seeded 
onto 24-well tissue culture dishes in 0.5ml DMEM+10%FCS and grown until 50-80% 
confluence. The medium prior to transfection is removed and the cells rinsed with 200µl of 
DMEM without FCS. For each well 2µl of lipofectamine reagent was mixed with 1µg of 
AVP-luciferase vector and 1µg pRK7-β-gal which was mixed in 50µl of serum free medium 
and incubated for 40min to allow complexes to form, after which a further 150µl of serum 
free DMEM was added. These complexes were added to the rinsed cells and incubated for 5h. 
After this 200µl of DMEM+20%FCS was added, and cells incubated overnight at 37°C. 
Lu-165 cells were transfected using electroporation, as previously described (Coulson 
et al., 1999a). Briefly, 2x105 cells were seeded onto 24-well tissue culture dishes in 0.5ml 
DMEM+10%FCS and grown until 50-80% confluence. The medium prior to transfection was 
removed and the cells rinsed with 200µl of DMEM without FCS. For each well 2µl of 
lipofectamine reagent was mixed with 1µg of AVP-luciferase vector and 1µg pRK7-β-gal 
which was mixed in 50µl of serum free medium and incubated for 40min to allow complexes 
to form, after which a further 150µl of serum free DMEM was added. The reaction was added 
to the rinsed cells and incubated for 5h, after which 200µl of DMEM+20% FCS was added. 
Cells were incubated overnight at 37°C/5% CO2, and luciferase activity measured about 18h 
later. 
2.2.4.3 Luciferase assay 
To measure promoter activity cells were washed twice with PBS and then thoroughly lysed in 
100µl lysis buffer (75mM Tris-HCl, 10mM MgCl2, 1% Triton X-100, 2mM ATP, 1mM DTT). 
Aliquots were measured in a LKB luminometer for 20sec. 
35 
Materials and Methods 
As an internal control of transfection efficiency, the luciferase readings were 
standardised on β-gal activity from a cotransfected β-gal expression vector (pRK7-β-gal) 
(Hoffmann et al., 2003). The β-gal activity in the extracts was measured as described 
previously (Spengler et al., 1993). The luciferase measurements were divided by the β-gal 
values. 
2.2.5 Protein preparation 
2.2.5.1 Nuclear cell extracts 
Cells were transfected with an expression vector for either YY1 or CBF-A, 3 separate 
transfections were pooled together and grown for 24h at 37°C in a 6 well plate. The cells were 
washed with 1x PBS, and were then scrapped into solution in 1ml 1x PBS and centrifuged at 
4,000rpm at RT for 5min. 100µl buffer (10mM Hepes pH7.9, 10mM KCl, 0.1mM EDTA, 
0.1mM EGTA, 1mM DTT, 0.5mM PMSF)  was added and gently mixed, and the cells 
incubated on ice for 15min to swell. To disrupt the cytoplasmic membrane 5µl of 
10% IGEPAL was added for 10min. The sample was then centrifuged and the soluble 
supernatant containing the cytoplasmic extract discarded. The pellet was then resuspended in 
50µl buffer (20mM Hepes pH7.9, 0.4mM NaCl2, 1mM EDTA, 1mM EGTA, 1mM DTT, 
0.5mM PMSF)   containing 1µl protease inhibitor and shaken for 60min at 4°C to disrupt the 
nuclear membrane. This mixture was then centrifuged 14,000rpm, 4°C for 5min in a benchtop 
centrifuge and the aqueous solution containing the nuclear extract was removed. All nuclear 
extracts were either used immediately or stored at -80°C until use. 
2.2.5.2 Recombinant proteins  
Recombinant CBF-A-GST fusion proteins were used for EMSA. Following transformation of 
pGEX-2TK-CBF-A into DH5α bacteria single colonies were grown at 37°C in 50ml 2YT 
(0.16% tryptone, 0.1% yeast extract, 0.1% NaCl) overnight, to which a further 450ml 2YT is 
added and grown for 3h until an OD600 of 0.5-1.0 was reached, after which, they were 
incubated with a final concentration of 1mM IPTG for a further 2h at 30°C. The GST-CBF-A 
protein was purified using glutathione-sepharose beads (Hoffmann et al., 2003). Eluted 
CBF-A was shown to be at least 95% pure as judged by Coomasie blue staining. 
Concentration of CBF-A was determined using Bradford assays and aliquots were stored at -
80°C until usage. The recombinant proteins of the deletion constructs were produced as 
described above and again judged to be at least 95% pure from Coomasie blue staining. 
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For EMSA experiments CBF-A was incubated with 20,000cpm of dsDNA end 
labelled oligonucleotides (LAB CArG sense, gta tcc cca ctg tCC TTA TTA GGa aga ggc aaa; 
LAB CArG antisense, gta ttt gcc tct tCC TAA TAA GGa cag tgg gga; HAB CArG sense, gta 
tcc cca ctg tCC TTA TTG GGa aga ggc aaa; HAB CArG antisense, gta ttt gcc tct tCC CAA 
TAA GGa cag tgg gga). 
2.2.5.3 Protein concentration and purity  
Bradford assays were used to determine the concentration of all proteins used in this study. 
The assay is based on the observation that the absorbance maximum for an acidic solution of 
Coomassie Brilliant Blue G-250 shifts from 465nm to 595nm when binding to protein occurs. 
Both hydrophobic and ionic interactions stabilize the anionic form of the dye, causing a 
visible colour change. The concentrated Assay buffer was first diluted 1:5 and standards were 
prepared containing a range of 20 to 200µg protein (BSA) to a standard volume. The samples 
were diluted (3µl in 200µl water) to an estimated concentration of 20 to 200 µg/ml. 
800µl Bradford assay is added to each sample and protein standard, and the absorbance was 
measured at 590nm. Protein concentration of samples was deduced from the standard curve. 
Coomasie blue staining was then further used to assess the purity and integrity of 
recombinant protein preparations. Protein samples were loaded on to an SDS-PAGE gel (see 
Western blots) with a size marker (refer to section 2.1.1) and run at 150V. The gel was then 
soaked in 0.2% Coomassie blue for 1h and destained in 40% methanol, 50% acetic acid 
solution over night. The gel was then blotted on to paper and dried. All proteins used in the 
study were of at least 95% purity. 
2.2.5.4 EMSA 
Electrophoretic mobility shift assays (EMSA) were used to determine the affinity of a protein 
for a particular DNA sequence. For EMSA experiments CBF-A or YY1 was incubated with 
20,000cpm of double-stranded end labelled (see above) oligonucleotides. Sense and antisense 
oligonucleotides, 30bp long, contained the CArG element and an overhanging GTA for end 
labelling - LAB CArG sense, gta tcc cca ctg tCC TTA TTA GGa aga ggc aaa; LAB CArG 
antisense, gta ttt gcc tct tCC TAA TAA GGa cag tgg gga; HAB CArG sense, gta tcc cca ctg 
tCC TTA TTG GGa aga ggc aaa; HAB CArG antisense, gta ttt gcc tct tCC CAA TAA GGa 
cag tgg gga. The uppercase letters denote the polymorphic CArG element. 
For the YY1 experiments a control oligonucleotide containing a previously reported 
YY1 binding site was used. This binding site was described in the Moloney Murine Leukemia 
Virus (MuLV) promoter, and was integrated into two 29-mer oligonucleotides which were 
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annealed together; MuLV sense, gta tgc ctt gca aaa tgg cgt tac tgc ag; MuLV antisense, gta 
ctg cag taa cgc cat ttt gca agg ca. 
The oligonucleotides were annealed in a 20µl reaction containing 5µg/µl of each of 
the sense and antisense oligonucleotides and 4µl of annealing buffer (1.5M NaCl, 100mM 
TrisHCl). This was heated at 85°C for 10min to ensure DNA separation, and then allowed to 
cool slowly over 3-4h to room temperature to allow for efficient annealing of the sense to the 
antisense oligonucleotide. This mixture was then diluted to 50ng/µl for the labelling reaction 
(see above). A working stock of 20,000cpm/µl labelled oligonucleotide was used for all 
EMSA experiments. ssDNA oligonucleotides were labelled using the forward reaction (see 
above), and again a working stock of 20,000cpm was used. The binding reaction was then 
performed using a specific amount of protein in a volume of 20µl reaction buffer 
(5mM TrisHCl pH7.5, 25mM NaCl, 2.5% glycerol, 0.5mM EDTA, 0.25mM DTT, 
0.5µg dI/dC). This was incubated on ice for 5min and then 20,000cpm of labelled 
oligonucleotide (either single stranded or double stranded) was added and the whole reaction 
was incubated for a further 25min at room temperature. 1µl of loading dye was added and the 
samples were loaded on a 5% polyacrylamide gel (non denaturating). This gel, which was 
pre-run for 30min at 4°C; 150V; 0.5x TBE, was run with the samples at 100V for around 1h 
at 4°C in 0.5x TBE. 
2.2.5.5 Western blots 
Transfected, or non-transfected cells of HeLa, 3T3, Saos-2, Lu-165 and Neuro2a were used 
for Western blots. Cells were seeded 24h before harvesting in 10cm plates. The cells were 
first washed twice with 5 ml 1x PBS. The cells were then scrapped with 0,15 to 0,5 ml T10E1, 
1mM PMSF, 1mM DTT and protease inhibitor cocktail (1/1000). A G21 needle was used to 
break the cells by passing through ~20 times. An aliquot of 50µl was kept at this step for 
measuring protein concentration. To the remaining 450µl were added 150µl of 4x Lammli 
buffer (200mM Tris-HCl pH6.8, 8% SDS, 40% glycerol, 0.4% Bromophenol blue, 
0.1% β-mercaptoethanol). A G21 needle was again used to break the released high molecular 
DNA. A 12% SDS-PAGE, gel was prepared. 20µg of protein is boiled for 5min in an equal 
volume of Lammli buffer to denature the protein. The gel was run on 150V at room 
temperature with a water flow for cooling. The proteins were transferred the to Nitrocellulose 
film in a transfer chamber at 50V for 1-2h RT. The membrane was briefly stained with 
Ponceau red to check if the proteins have transferred from the gel to the membrane. 
Unspecific binding of the antibodies to the membrane was blocked by placing the membrane 
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in Blocking Buffer (10mM Tris, 0.5M NaCl, 0.1% tween, 5% non fat dried milk) which was 
incubated on a shaker at room temperature for 1h. The blocking solution was poured off and 
the membranes incubated with the primary antibody over night at 4°C. Membranes were then 
washed 5-6 times with TBS/0,1 % tween to remove unbound antibody and then incubated for 
1h at RT with the second conjugated antibody. The membranes are washed as before. A 1:1 
mix of the chemiluminescent reagent was prepared and added to the membrane. This was left 
for between 10sec to 5min, after which the membrane was dried slightly and wrapped in saran 
wrap. This is exposed to X-ray film for 30sec to check, adjusting exposure time-dependent on 
the strength of signals. 
2.2.5.6 In vitro DNA unwinding assay 
Between 1ng and 10ng of GST-CBF-A or GST protein were incubated with 20,000cpm of 
end labelled LAB probe for 30min at RT, as described for the EMSA experiments. Varying 
concentrations of S1 nuclease (Amersham) were added to the sample which was then 
incubated at either 4°C or room temperature for between 1min to 1h. The reaction was 
stopped by incubating for 1min at RT with 1µl proteinase K (100µg/ml) to cleave the 
S1 nuclease and the CBF-A binding to the DNA. An equal volume of formamide loading 
buffer (95% formamide, 2mM EDTA, 0.025 % Bromophenol blue and 0.025% Xylene cyanol) 
was added and the whole sample was boiled for 5min to destroy the protein/DNA complexes 
and denature the DNA. The samples were then placed immediately on ice for 1min, then 
heated at 72°C for 2min and separated on either a denaturing 5% polyacrylamide gel and 
exposed to X-ray film. 
2.2.5.7 Antibody analysis 
2.2.5.7.1 Antibodies 
CBF-A anti-N-CBF-A antibody, raised in the rabbit towards the first 75aa of the N-terminal 
part of CBF-A, was a generous gift from Drs. Leandersson and Aranburu (Lund). The anti-N-
CBF-A serum was purified using protein A Sepharose, and has an approximate concentration 
of 1.4 mg/ml dissolved in PBS + 0.1% sodium azide. CBF-A 266, 267 and 269 were a kind 
gift from Dr. Fry (Haifa) and had yet to be tested in Western blots or antibody shift 
experiments. YY1 was commercially acquired (refer to section 2.1.5.1). It was raised against 
an epitope corresponding to amino acids 1-414 representing full length YY1 of human origin. 
It has been previously shown to react with YY1 of mouse, rat and human origin by Western 
blotting, immunoprecipitation, and immunohistochemistry and was further recommended for 
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gel supershift applications. The anti-GST, anti-FLAG and anti-His antibodies were acquired 
commercially (refer to section 2.1.5.2). 
For supershift experiments protein and DNA were initially incubated together, as 
described in EMSA. Various quantities of antibody were then added directly to the mixture 
which was subsequently loaded on to a polyacrylamide gel and electrophoresed, as in the 
EMSA experiments. 
2.2.5.7.2 Immunohistochemistry 
Double immunofluorescence-histochemistry staining was used to visualize CBF-A and 
AVP immunoreactivity simultaneously and was performed by Nicolas Singewald (Innsbruck, 
Austria) to a procedure previously described (Salchner and Singewald, 2002). Briefly, 50µm 
Vibratome sections were preincubated for 30min in immunobuffer containing 5% normal 
donkey serum (Jackson Immunoresearch, West Grove, USA) to block non-specific binding 
sites. After washing in immunobuffer, sections were incubated for 48h at room temperature in 
a polyclonal rabbit antibody to CBF-A (dilution 1:1000) and a polyclonal guinea pig antibody 
to AVP (GHC 8103, Peninsula, Belmont, USA; dilution 1:10,000) in immunobuffer 
containing 5% normal donkey serum. The anti-N-CBF-A antibody, raised in rabbit towards 
the first low conserved 75aa of the N-terminal part of CBF-A, was a generous gift from Drs. 
Leanderson and Aranburu (Lund). After rinsing in immunobuffer, sections were exposed for 
2.5h at room temperature to the species-specific fluorophore-conjugated secondary antibodies 
(Cy2-conjugated donkey anti-rabbit IgG, dilution 1:100; Cy3-conjugated donkey anti-
guineapig IgG, dilution 1:400; Jackson Immunoresearch, West Grove, USA, AMCA-
conjugated donkey anti-guinea pig IgG, dilution 1:100; Jackson Immunoresearch, West Grove, 
USA) diluted in immunobuffer containing 1% normal donkey serum. Following rinsing in 
50mM Tris-HCl (pH 7.4), sections were mounted onto slides and dried overnight. Mounted 
sections were cleared in 100% ethanol and Histoclear (National Diagnostics, Atlanta, USA) 
and coverslipped in Eukitt (Kindler, Freiburg, Germany). Appropriate negative controls were 
performed by omission of the primary antibodies. No staining was observed in the control 
sections. Slides were viewed with a fluorescence microscope equipped with adequate filter 
systems to observe the green Cy2 and red Cy3 fluorescence (figure 38A-D) and to observe the 
red, which was converted from green to facilitate visualization of double labeling, Cy2 and 
blue AMCA fluorescence (figure 38E). 
For semiquantitative immunohistochemistry experiments and correlation analyses, 
5 HAB, 5 NAB and 6 LAB animals were phenotyped on the elevated plus-maze and two days 
later sacrificed for AVP immunohistochemistry. The semiquantification analysis of AVP 
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immunohistochemistry was performed by means of image analysis using optical software 
(Optimas 5.2, Optimas Corporation, Germany). 
2.2.6 Statistical analysis and computer software 
The predicted transcription binding site analyses were performed using the online programs 
TESS (www.cbil.epenn.edu/tess/) (Schug and Overton, 1997) and MatInspector 
(www.genomatix.de) (Quandt et al., 1995). DNA aligns were performed using the DiAlign 
program from Genomatix (www.genomatix.de) (Morgenstern et al., 1996). Analysis of the 
mouse AVP signal peptide was performed using the freely available software SignalP 
(www.cbs.dtu.dk/services/SignalP/) (Nielsen et al., 1997), PredictProtein (www.embl-
heidelberg.de/predictprotein/) (Rost, 1996) and transmembrane helix prediction 
(www.cbs.dtu.dk/services/TMHMM/). Prediction of phosphorylation sites was performed 
using NetPhos 2.0 (www.cbs.dtu.dk/services/NetPhos/) and phosphorylation site prediction 
(www.cbs.dtu.dk/databases/PhosphoBase/predict/predform.php). Intensity of protein bands in 
the EMSA gels were determine using the TotalLab program. Restriction enzyme cut site 
sequences were elucidated through the DNA strider program (Marck, 1988) and the freely 
available Webcutter 2 (www.firstmarket.com/cutter/cut2.html). Primers were designed 
according to previously stated guidelines (Innis and Gelfand, 1990). All statistical analyses 
were performed using the software from Microsoft Excel. Statistical calculations of the 
second F2 analysis of the HAB and LAB rats were performed by Professor Müller-Myhsok 
with the statistical software R.81. All diagrammatic figures were designed through 
CoralDraw 10 (Corel Corporation, Ottawa). 
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3 Results 
The HAB and LAB rat lines have been bi-directionally inbred since 1985 (figure 9A). An 
inbred strain, by definition, is one that has been brother-sister mated for at least 20 generations 
(for review see Beck et al., 2000). Each generation of brother-sister mating increases the 
probability of attaining homozygosity at any given genetic locus, and by 20 generations 
~97.5% of the loci should theoretically be homozygous (Nicholas, 1987). The major value of 
a selective inbreeding strategy emanates from the fact that this approach actively enriches for 
genetic information associated with a particular trait shifting the animal’s phenotype from the 
population mean (Falconer and Mackay, 1996). 
Although it might be assumed that both the HAB and LAB inbred lines are at least 
97-98% homozygous, an initial uncertainty was the extent of intra-line homozygosity i.e. the 
extent to which the lines differ to each other at any given locus. For this reason the study 
began by principally investigating the degree of intra-line homozygosity by conducting a low 
resolution genome screen using simple sequence length polymorphic (SSLP) markers 
(Landgraf and Wigger, 2003). This experiment was based on the analysis of 145 markers 
representing around six locations on each of the rat’s twenty chromosomes, with the 
exception of chromosome 3, where fourteen markers were analysed. Chromosome 3 received 
greater attention due to the finding of line strict differences in the AVP promoter locus on 
chromosome 3, which was at the time of this analysis under study in the candidate gene 
approach (see below). The same DNA samples from the 10 HAB and 10 LAB animals used in 
the candidate approaches were used in this low resolution genome scan. 
Results from figure 9B evidenced seven areas, revealing strict line differences, 
locating to chromosomes 2, 3, 4, 5, 9, 12, 15. It was further obvious that a rather large number 
of SSLPs were informative - sixty-four of the 145 giving a percentage of 44.1%. However, 
while some chromosomes, such as chromosome 3 provided a greater number of informative 
markers, other chromosomes, such as 16 and 17 were completely devoid of informative 
markers. This mosaicism suggests that certain areas of the genome are more heterozygous 
between the lines, than others. 
In relation to the major emphasis of this study, which more specifically concerns the 
AVP locus, it should be noted that chromosome 3, in which the gene localises, revealed a 
number of line-specific differences. It was already evident, from data performed in parallel to 
this experiment, that chromosome 3q21 shows a line-specific difference. However, of concern 
was the size of the region in which the haplotype block, containing the AVP locus, extended. 
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This was of importance to determine, when considering the further association results, in 
being able to discern between a definite number of genes segregating together with the AVP 
locus, and thus, acting as positional candidates. 
 
 
Figure 9. Inbreeding strategy of HAB and LAB rats. (A) Graph highlighting the divergence of the HAB 
and LAB lines in anxiety measured in percentage time spent on the open arm of the EMP (Landgraf and 
Wigger, 2002). (B) Screen of 145 markers across the HAB and LAB genomes (Landgraf and Wigger, 
2003). -= homozygous, x = strict line difference, h = both lines are heterozygous, lH = LAB heterozygous, 
HAB homozygous, Lh = LAB homozygous, HAB heterozygous. 
 
The results presented in figure 9B, revealed chromosome 3 to contain a number of 
strict line differences. The AVP gene, though not physically mapped, localises adjacent to the 
neighbouring oxytocin gene at 683.9 CentiRays (cR) in a radiation hybrid analysis. (Dutil et 
al., 2001). The two furthest homozygous markers spanning the area containing the AVP gene, 
before each region of heterozygosity, lie at ~500cR (D3Rat81) and 840cR (D3Rat63). This is 
compatible with the view that the region presenting with a strict line difference linked to the 
AVP locus, i.e. the area of linkage disequilibrium, is no greater than 340cR, which roughly 
translates to one third of the chromosome. One must also note, however, that the regions for 
which the markers are not informative do not necessarily infer chromosomal regions of 
homozygosity. This simply relates to the fact that markers did not differ at these specific 
alleles, and play no relevance to the fact that regions immediately adjacent to this area may 
show heterozygosity or strict line differences. 
3.1 Candidate gene approach 
A candidate gene approach was followed as part of a pathway analysis, focusing on the two 
ACTH stimulating genes involved in the HPA axis. This approach was also of initial 
importance for firstly, determining a frequency of polymorphisms between the lines in 
association with the previously mentioned genome screen, secondly as a basis for the 
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discovery of markers for future possible QTL analysis and thirdly, to determine if any 
candidate genes might contain possible deleterious mutations underlying the phenotype.  
3.1.1 CRH 
CRH is a 41 amino acid (aa) peptide derived by enzymatic cleavage from a 191aa prepro-
hormone. The gene, localised on chromosome 2q24, encodes a cDNA of 1666 nucleotides 
comprising 2 exons and including 117 nucleotides of 5’ untranslated sequences (Potter et al., 
1991). A TATA and CAAT transcription initiation site were identified 22bp and 60bp 
upstream of the translation initiation site (Thompson et al., 1987) and DNA elements for 
cAMP responsiveness, glucocorticoid receptors and POU homeodomain proteins have been 
described in the region -221 to -278bp (Ramkumar and Adler, 1999). 
The CRH gene and promoter sequence were also subjected to SSCP analysis as part of 
the candidate gene approach. Primers were designed to span the gene in overlapping 300bp 
segments from previously published sequence (M54987) (Thompson et al., 1987), covering 
356bp upstream of the transcriptional initiation site and 222bp 3’ downstream of the stop 
codon (figure 10). 
 
 
Figure 10. Diagrammatic scheme of the rat CRH gene demonstrating promoter, exons (E) and the regions 
investigated by SSCP analysis.  
 
Results of the SSCP analysis lacked alternative band patterns suggesting an absence of 
polymorphisms in the CRH gene and proximal promoter region. 
3.2 AVP 
The AVP gene locates to chromosome 3 in the rat at position 3q35 or 3q41-q42 (figure 13A) 
(Khegai and Ivanov, 1994) encoding a 164aa precursor protein for AVP which includes the 
9aa hormone, its carrier protein, neurophysin II (NPII), and a glycoprotein. The functional 
domains of the protein precursor are coded by 3 exons, the first of which encodes the 
hormone, the second most of the carrier protein, and the third the glycoprotein (figure 11). 
The transcriptional start site leads to a cDNA containing 33 nucleotides of  
5’ untranslated region, and 75 nucleotides of 3’ untranslated region (Ivell and Richter, 1984).  
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Figure 11. Schematic diagram of the rat AVP and oxytocin locus. The two genes locate 11kb apart 
(intergenic region) being transcribed towards each other from opposite strands of the DNA duplex. 
 
3.2.1 AVP levels in the PVN correlate with anxiety-related behaviour 
HAB, LAB and NAB Wistar rats were phenotyped for their behaviour and further subjected 
to immunohistochemistry to determine relative amounts of AVP in the parvocellular and 
magnocellular compartments of the PVN (figure 12A). In both subdivisions AVP peptide 
levels were significantly higher in the HAB animals when compared to either the LAB or 
NAB, which failed to differ (figure 12B). This data convincingly demonstrate that differences 
in AVP mRNA levels translate into peptide levels and confer a basal overexpression of AVP  
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Figure 12. Correlation between AVP immunohistochemistry and anxiety-related behaviour. 
(A) Fluorescence-immunohistochemistry of AVP in rat PVN. The white squares denote the 80-100µm2 
areas of magno- and parvocellular regions of the PVN, which was measured. (B) Percentage of AVP 
fluorescence-immunohistochemistry (relative grey density) performed, in parvocellular and 
magnocellular subdivisions of the PVN, in HAB (n=5) and LAB (n=6) compared to NAB (n=5). 
(C) Immunohistochemistry (relative grey density), in parvocellular and magnocellular subdivisions of the 
PVN, correlates significantly (p<0.001) with anxiety-related behaviour (% time spent on the open arms of 
the elevated plus-maze) in HAB (n=5) (filled diamonds), NAB (n=5) (filled squares) and LAB (n=6) (filled 
circles) rats. 
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in the HAB animals. Furthermore, in both the parvocellular and magnocellular subdivisions 
AVP peptide levels significantly correlate (p<0.001) with anxiety-related behaviour 
(i.e. negatively with % time spent on the open arms of the elevated plus-maze as indicated in 
figure 7C) as measured by the EPM test, the paradigm on which the animals were originally 
selected. This, therefore, suggests that the AVP peptide content in the parvocellular and 
magnocellular neurons relates to HPA axis functioning in these animals. 
This divergence in AVP gene expression between the HAB and LAB/NAB lines 
prompted us to analyse the AVP gene to address the question of whether the differential AVP 
regulation might be the result of a cis-regulatory effect stemming from promoter sequence 
differences between the lines. 
3.2.2 Sequence analysis 
The promoter of the AVP gene was subjected to SSCP analysis in a search for line-specific 
polymorphisms. This experiment evidenced a polymorphic region 341-678bp upstream of the 
start codon; 10 outbred Low Anxiety (LA) animals revealed an alternate pattern of bands 
when compared to 10 outbred High Anxiety (HA) animals (figure 13B). This confirms the 
presence of a strict line difference in this region of the AVP promoter. Further noticeable, in 
lanes 8 and 11 containing the HAB animals, are band patterns representative of both lanes 
suggesting heterozygosity. Considering these animals are the results of HAB and LAB inbred 
line crosses with outbred animals, the presence of the heterozygous sequences in the two 
HAB rats suggests that originally the outbred parents of these offspring contained the LAB 
allele. This is a tentative indication that the LAB allele represents the more common variant. 
 
LA HA  
Figure 13. SSCP analysis of the rat AVP gene. (A) The rat AVP gene is located on chromosome 3 at either 
position 3q35 or 3q41-q42 (Khegai and Ivanov, 1994). (B) The proximal 700bp of the AVP promoter was 
subjected to SSCP analysis. The third PCR product, encompassing the region -341 to -678, revealed 
alternative band patterns specific between the two lines. 
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The polymorphic allele was subsequently sequenced to determine the exact nature of 
the polymorphism(s), and from the results (figure 14) it became evident that a number of 
single nucleotide polymorphisms (SNPs) occur in this region between the HAB and LAB 
animals.  
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Figure 14. Rat AVP promoter (Acc. AF112362). Polymorphisms in the rat are in red capitals and single 
base pair differences or deletions to published sequence but found in both strains are in blue lower case 
characters or marked with a dash in the case of a deletion. Dashed lines under the sequence denote 
homologous bases; the upper line signifies the mouse (Acc. M88354) (Hara et al., 1990), and in the lower 
line the human (Acc. X62890, AL160414) (Bahnsen et al., 1992). Thick bold lines above the DNA sequence 
represent the various transcription factor elements mapping to the vicinity of the polymorphisms. Shaded 
boxes represent previously described AVP promoter elements. 
 
When comparing the LAB and HAB sequences to published sequence of the AVP 
gene (AF112362) (Shapiro et al., 2000), it became apparent that the LAB line was identical to 
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previously published nucleotides in all the SNPs A(-2640)C, A(-2565)T, T(-2453)C,  
C(-1958)A, A(-1276)G, C(-1161)T, A(-594)C, C(-590)T, A(-534)G, A(-455)C (and 
T(+549)C which is not included in figure 14) whilst the HAB line rats contained the divergent 
sequence. It is of importance at this point to retain caution in labelling these polymorphisms 
as mutations until actual frequencies can be confirmed in an outbred population. This would 
determine whether the alleles exist in the outbred population from which they originally 
derived, or if they occurred as spontaneous mutations in the inbred line. A mutation, by 
definition has to occur at a gene frequency of less than 0.1% in an outbred population (Lewin, 
2000;Marez et al., 1997). 
The coding region of the AVP gene was sequenced to determine if any non-
synonymous differences occur leading to an abnormal AVP protein. Intronic regions of the 
AVP gene were also included in this experiment to allow for the possibility of polymorphisms 
spanning exon/intron slicing junctions or the presence of gross deletions/insertions effecting 
RNA splicing or transcriptional regulation (for review see Lewin, 2000). Results of the 
further sequencing confirmed that the coding region of the AVP gene was devoid of any 
polymorphisms, with the exception of a single SNP in intron I, involving the transition of a 
T for a C 549bp downstream from the start codon (figure 15A). The downstream region 3’ to 
the AVP gene was also sequenced, acknowledging the possibility that DNA elements in this 
 
 
Figure 15. Rat AVP promoter polymorphisms. (A) Diagrammatic scheme of the rat distal AVP promoter 
region demonstrating the 2799bp distal promoter harbouring 10 SNPs. The T(+549)C polymorphism, 
located in intron I, was used in the allelic-specific transcription in vivo experiment (see figure 5) 
(B) Sequence of the A(-455)C polymorphism used in RFLP. Primer pairs A(-455)C-forward and reverse 
(refer to section 2.1.10.4) were used to amplify a 327bp DNA product. The restriction enzyme Eam11041 
recognises the sequence CTCTTC and, therefore, only digests the HAB allele containing the  
C polymorphism. (C) Agarose gel of RFLP products digested with Eam11041 for the presence of the  
A(-455)C polymorphism. The HAB allele containing the C nucleotide is digested resulting in two products 
of 203bp and 124bp whilst the LAB allele, containing the A nucleotide, remains uncleaved. 
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region exist which are important for AVP expression (Fields et al., 2003). Here, a further SNP 
was found 245bp 3’ from the termination codon of the AVP gene. 
Analysis of the sequence data using the online program webcutter (refer to section 
2.2.6) allowed for the detection of polymorphisms affecting restriction enzyme sites (figure 
15B). From this information restriction fragment length polymorphism (RFLP) assays were 
developed to genotype, both quickly and efficiently, animals from the HAB and LAB lines 
(figure 15C). 
Genotyping of inbred rats from the HAB and LAB lines revealed a clear line 
difference for three of the SNPs in the promoter (A(-455)C, A(-534)G (figure 16) and 
T(-2455)C), the SNP in the first intron of the AVP gene [T(+549)C] and the C(+18)T 
transition in the first exon of the oxytocin gene, which is described below (refer to section 
2.1.10.4). Therefore, all the polymorphisms segregate together, and the fact that the SNP in 
the oxytocin gene was also linked suggests the whole region segregates in linkage 
disequilibrium. Furthermore, the fact that genotyping revealed the presence of the HAB-
specific allele in all breeding pairs comprising the HAB line suggests that the selective 
inbreeding inadvertently selected for the HAB allele. 
 
 
 
Figure 16. RFLP for A(-534)G in 29 animals representative of all LAB and HAB mating lines. The first 
15 lanes deriving from inbred LAB animals are homozygous for the A allele, while the following 13 lanes, 
from the different mating pairs of the HAB line, are homozygous for the G allele, with the exception of 
two heterozygotes. The end lane contains the negative control PCR. 
 
A number of the AVP SNPs occur in regions sharing homology with the mouse and 
human. DNA alignments reveal the conservation of the A allele from the A(-536)G transition 
in both the mouse and human and further confirm the homology of polymorphisms A(-457)C, 
C(-1163)T, A(-2589)T, A/C Intron I (not shown), and G(-245bp)A in the 3‘ sequence (not 
shown) in the mouse sequence (figure 14). It is of further interest to note the high degree of 
homology in the AVP promoter. The proximal promoter, comprising 1kb upstream of the start 
codon, shows 83% conservation in the mouse and 31% in the human, whilst the distal region 
of 2800bp upstream, still contains 68% conserved sequence in the mouse and 18% in the 
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human. This clearly demonstrates the importance of this area of the promoter, especially 
when considering the high degree of species-conservation in the tissue-specific expression of 
the AVP gene.  
3.2.3 Sequence and genotyping of the adjacent oxytocin gene 
The highly homologous AVP and oxytocin genes are closely linked, tail-to-tail, in the genome, 
being separated by an intergenic region (IGR) of 11kb in the rat (Schmitz et al., 1991), 3kb in 
the mouse (Ratty et al., 1996) and 10kb in the human (Gainer et al., 2001), they are 
transcribed towards each other from opposite strands of the DNA duplex (figure 11).  
Sequencing analysis of the oxytocin gene was performed, firstly to determine if this 
gene might also segregate with the AVP gene. Secondly, it was of interest to clarify if the 
oxytocin gene contained similarly high numbers of SNPs as the AVP gene revealed. Thirdly, 
and importantly, we needed to discover a transcribed polymorphism, revealing line-specific 
segregation, in the HAB and LAB animals for use in in vitro transcription analysis (refer to 
section 3.2.6). 
Sequencing of 2kb of the oxytocin promoter and the 700bp constituting the transcribed 
gene, revealed the presence of four SNPs (figure 17A). One SNP involved the transition of a 
C for a T in the first exon of the oxytocin gene, 18bp downstream of the start codon, whilst 
the other three SNPs involved base pair transitions and transversions 298bp, 734bp and 761bp 
upstream of the start codon in the promoter. Of particular interest was the C(+18)T transition 
in the first exon in codon position 3 encoding a synonymous mutation affecting the amino 
acid leucine at position 6, allowing employment of the in vivo transcription analysis assay. 
Literature and database searches (refer to section 2.2.6) revealed that the three SNPs in the 
promoter were embedded in various transcription factor-binding sites. Of these, only the 
T(-298)C transition effected an element found in mammals, the CACCC (HS40) element, 
which as a major controller of the human alpha-globin gene (Jarman et al., 1991), is unlikely 
to be relevant. Therefore, we conclude that none of the SNPs are suggestive to play a 
regulatory role. 
The C(+18)T transition, lying in Exon I, provided a restriction site for the BsmAI 
restriction enzyme (gtctc), where the sequence containing the C allele, found in the LAB 
animals and consensus sequence (Accession No. X59496) (Schmitz et al., 1991), will be 
cleaved. Therefore, digestion of PCR products (figure 17B) with BsmAI was used to 
genotype animals representative of all the breeding pairs in the HAB and LAB rat lines, to 
establish whether this allele segregated with the AVP promoter alleles. For this analysis the 
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same 29 animals genotyped in the AVP study were again included. These experiments 
showed that the LAB animals were homozygous for the published nucleotide while the HAB 
animals contained the non-conserved T allele (figure 17C), confirming that the oxytocin gene 
is in direct linkage to the AVP gene in each of the two lines. 
 
LAB HAB  
Figure 17. Rat oxytocin polymorphisms. (A) Diagrammatic scheme of the rat oxytocin gene demonstrating 
the 2kb region upstream and 0.7kb region downstream sequenced and the relative positions of the 
polymorphisms T(-761)G, A(-734)C and T(-298)C in the promoter region, and the C(+18)T in the first 
intron. (B) The 245bp PCR product spanning the exonic SNP C(+18)T polymorphism (refer to section 
2.1.10.4). (C) Genotyping of the C(+18)T polymorphism by BsmAI digestion resulted in the detection of 
the C allele by the presence of two digested fragments of 185bp and 60bp.  
 
3.2.4 Association of AVP gene and anxiety in EPM test 
To address the question of an eventual contribution of the HAB-specific AVP allele to the 
anxious/depressive-like phenotype, a small scale, preliminary association study was 
performed. Sixty-six HAB/LAB F2 generation rats, the result of a cross-breeding between 
HAB and LAB lines, and 27 HAB/outbred F2 generation rats, resultant from a cross between 
a HAB rat and an outbred animal, were genotyped for both the Ksp632I and MaeIII 
polymorphisms and tested on the EPM test to measure their levels of anxiety-related 
behaviour. 
When correlating the EPM test behaviour with AVP genotypes some associations 
were seen (figure 18). The latency to the first arm entry appeared to highlight a trend evident 
of a dosage effect of the AVP allele in association with anxiety-related behaviour; animals 
containing the HAB-derived AVP allele presented with longer durations to the initial entry 
into the open arm. This trend was evident in both the HAB/LAB and HAB/outbred crosses 
(figure 18A,C). Moreover, when latency to first open arm entry was compared amongst the 
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male group of the HAB/LAB cross, the correlation between behaviour and genotypes become 
significant between the homozygous HAB and LAB allele groups (p<0.05) (figure 18B). 
 
HAB H/L LAB HAB H/L LAB HAB H/Out Out  
Figure 18. Preliminary association study of HAB/LAB-derived AVP promoter alleles and latency to first 
arm entry on the EPM test. (A) Latency to first arm entry in HAB/LAB F2 animals (16 homozygous for 
the HAB-specific polymorphisms, 26 heterozygous and 24 homozygous for the LAB sequence). 
(B) Latency to first arm entry in HAB/LAB F2 males (13 homozygous for the HAB allele, 15 heterozygous 
and 9 homozygous for the LAB allele cross). (C) Latency to first arm entry in HAB/outbred (Out) F2 
animals involved 10 homozygous animals for the HAB allele (17 animals homozygous for the Out (LAB) 
allele and 15 heterozygous). *, Significantly different (p<0.05). 
 
Although the latency to first arm entry appears to suggest a trend other EPM test 
measurements performed in these animals did not associate as one might expect if the AVP 
allele was the single major determining factor in anxiety. The reasons for the lack of a clear 
significant association could depend on a number of reasons; firstly, the relatively small 
number of animals used in this study might have proved limiting to the statistical power. 
Secondly, the HAB/LAB mating or the HAB cross mating strategy might have somehow 
effected the behaviours of the animals i.e. if both animals represent clear isolated populations 
showing a distinct genetic makeup - in which the phenotype under study no longer presents as 
a continuum of variation - then a cross between these two genomes might result in a distinctly 
altered phenotype. Thirdly, the role of the AVP gene in controlling anxiety-related behaviour 
might, to some extent, depend on the contribution of other genetic loci, such as modifier loci, 
which would be separated from the AVP locus in this crossbreeding strategy. Fourthly, and 
not least, it appears feasible that the innate behaviour of the HAB line might result from a 
number of genes working in concert. 
The issue of this association and the importance in quantifying the exact contribution 
of the AVP allele to anxiety was, therefore, readdressed in a larger study incorporating a 
greater number of animals and employing a more extensive battery of behavioural tests. The 
experiment was performed by mating HAB and LAB parents and crossing the F1 offspring to 
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give 228 male animals, which were subjected in the behavioural analyses. These animals were 
kept in group cages of between 3 and 5 and were behaviourally phenotyped on the EPM and 
FS tests from the age of 6 weeks. Subsequent to the phenotyping, tail DNA was taken and the 
animals genotyped for the AVP SNPs.  
Evident from the results was a complete lack of association between any of the 
phenotypic markers and the AVP allele. However, upon closer inspection it became clear that 
some cages associated with far higher or lower levels of anxiety and depression-related 
behaviour than others (figure 19A). Furthermore, when taking into consideration the 
differences in home cage behaviour, and standardising for this, patterns began to emerge. This 
became particularly apparent for the latency to float index in the FS test in which a clear 
promoter allele dosage effect occured in which the HAB allele associated with a shorter 
latency to floating (figure 19B). Multiple regression analyses can be used to test whether, 
based on linear combinations of interval, dichotomous, or dummy independent variables, that 
a set of independent variables explains a proportion of the variance in a dependent variable at 
a significant level. When performing a Multiple Rank based Regression analysis on the data 
in figure 19B, a highly significant correlation emerged whereby the HAB allele associated 
with the shorter times to float, and the LAB homozygotes presenting with the longest 
durations (p<0.005) (all multiple regression analyses were performed by Dr. Müller-Myhsok 
(Munich)). 
 
 
Figure 19. Large-scale association study on 228 F2 animals resultant from a cross between a HAB and 
LAB. (A) Graph of the average latency to float (seconds) in the FS test in each cage of multiply housed 
animals (B) Graph of latency to float between the HAB, heterozygote and LAB animals when home cage 
behaviour is standardized. 
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The fact that the AVP allele did not associate with any further behavioural correlates, 
such as the EPM test, does raise some doubt as to the actual influence of the AVP gene on all 
aspects of the HAB behaviour, especially when considering that it was in the EPM test, and 
not the FS test, that these animals were originally selected. However, the observation that 
behavioural indices can fragment under F2 generation breeding has previously been reported 
(Henderson et al., 2004). And considering that the FS test has been well documented as a 
strong predictor for HPA axis dysregulation (Solberg et al., 2003) serves to suggest that this 
behavioural facet might have been the most robust marker of the HAB phenotype, aiding its 
survival during the F2 mating strategy.  
3.2.5 Genotyping HAB AVP allele in an outbred population 
The possibility of whether the LAB animals represent the common wild type allele, and HAB 
animals a less frequent allele needed to be investigated. To clarify this issue we tested for the 
presence of four SNPs spanning the first intron to the distal promoter of the AVP gene 
[T(+549)C, A(-455)C, A(-534)G, T(-2455)C] by RFLP analysis in 100 outbred Wistar rats, 
purchased from Charles River (Sulzfeld, Germany), as exemplified in figure 20A. Firstly, the 
four SNPs spanning the gene segregated together, reaffirming our original conclusion that the 
SNPs represent one allele and are in complete linkage. Secondly, the fact that all four 
polymorphisms were indeed present in the outbred animals confirms that non of these SNPs  
 
 
Figure 20. RFLP analysis for the HAB-specific AVP allele in an outbred rat population. (A) RFLP results 
of two polymorphisms, A(-455)C digested with Eam11041 and A(-534)G digested with MaeIII, in the AVP 
promoter which were screened in 100 animals. The -ve PCR controls, containing no DNA are included 
with two +ve controls for digestion efficiency of LAB (L) and HAB (H) DNA. Three animals (H1, H2, H3) 
were heterozygotes, whilst the remaining 97 were homozygotes (Ho). (B) EPM test data of the % time 
spent on the open arms in 100 outbred rats demonstrating those animals showing low (LA) and high (HA) 
anxiety-related behaviour. The three animals heterozygous for the HAB-specific polymorphisms (denoted 
by arrows) spent less than the mean time of 13.6± 1.5% on the open arm instead spending an average of 
7.8%. 
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represent mutations which occurred during the inbreeding. This which would be highly 
unlikely anyway accepting that the approximate mutation frequency of any given base in the 
genome per generation is less than 1x10-9 (Lewin, 2000); this would require the passage of a 
far greater number of generations in the HAB and LAB lines since their divergence. Thirdly, 
the fact that, of the 100 animals examined, three were found to be heterozygous indicates an 
allelic frequency of 1.5% for the HAB allele in the outbred population. 
Overall, the results of the outbred genotypes are compatible with the view that 
bi-directional inbreeding selected for the HAB allele, which in turn, might critically 
contribute to increased anxiety in this line. This was further supported by the fact that indeed, 
all three heterozygous rats showed a 2-fold higher anxiety-related behaviour on the EPM test 
than the population mean (7.2% average for SNP containing animals vs. 13.6% ± 1.5% 
average time spent on the open arm of the EPM for NA animals, figure 20B). 
To pursue further the issue of AVP in relation to anxiety and depression, and to gain 
insight into the molecular mechanism underlying the behaviour in our rat lines, we decided to 
focus our further investigations on AVP as a candidate gene for HPA dysregulation and the 
associated phenotype in the HAB rat line. 
3.2.6 In vivo transcription analysis 
The above findings raised the question of whether the observed differences between HAB and 
LAB alleles could confer the differential transcriptional activities, evident in the previously 
described in situ-hybridisation studies (Wigger et al., 2004). This issue became of particular 
importance when considering that the oxytocin locus, located 10kb centromeric to the AVP 
locus, revealed additional SNPs. Previously published in situ-hybridisation analysis of AVP 
and oxytocin gene expression in the PVN of HAB and LAB animals evidenced clear 
differences only in case of the AVP gene, with AVP mRNA levels being about 2-fold higher 
expressed in HAB compared to LAB animals (figure 1B). In agreement, in silico analysis 
failed to evidence an eventual regulatory role for SNPs present in the oxytocin gene. The two 
closely linked AVP and oxytocin genes form part of a locus that is subject to precise 
differential cell-specific and physiological regulation, where the peptide products, both of 
which are expressed in hypothalamic neurones, function in the maintenance of distinct 
physiological systems, which in turn, respond to distinct regulatory cues. This was the rational 
behind taking the oxytocin gene as a control in testing for AVP overexpression in the PVN; 
we postulated that only SNPs in the AVP gene fulfil a regulatory role in conferring higher 
gene expression, in contrast to the non-differentially regulated oxytocin gene. 
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To obtain further experimental evidence for this concept we aimed to study the 
transcriptional activity of HAB and LAB alleles in vivo. We queried whether AVP 
overexpression in the PVN may be due to regulation in cis, caused by the polymorphisms in 
the regulatory region of the AVP gene or, alternatively, due to regulation in trans resulting 
from different cellular environments in the PVN of the HAB and LAB respectively 
(figure 21A). 
To discern between these possibilities we devised a strategy that envisaged both 
promoter alleles within the same cellular environment, allowing for the standardisation of 
variations, in both, non-cell autonomous, i.e. synaptic input, and cell autonomous, i.e. cellular 
composition, traits between the HAB and LAB line animals. This is the case for a 
heterozygote animal derived from crossing homozygous HAB and LAB lines. As 
schematically shown in figure 21B, the representation of polymorphisms transcribed by the 
coding part of the gene is a result of the strength of the respective promoter allele, which in 
turn is critically dependent on the presence of regulatory polymorphisms in the promoter. 
Therefore, by extracting RNA from the PVN of a heterozygote animal and cloning the 
reverse-transcribed specific cDNA it is possible to determine the frequency of plasmid clones 
containing either transcribed polymorphism.  
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TF TF
Cis
Trans
 
Figure 21. In vivo transcription analysis outline. (A) Scheme of cis and trans gene regulation. Cis- 
regulation refers to the promoter element working in cis, independent of cellular composition, to control 
expression levels. Trans regulation, alternatively, describes the process of where a promoter is entirely 
controlled by activities of cellular transcription factors (TF) independent of any sequence differences in 
the promoter of the gene in question. Therefore, a similar increase in gene expression might be caused, for 
instance, by either a stronger binding of TF to the promoter, or a higher level and/or higher activity of 
intercellular TF. (B) Scheme of the allele-specific transcription method. A heterozygote animal contains a 
promoter allele from both the HAB and LAB lines expressed in the same PVN neurons. A transcribed 
polymorphism localised on the same allele as a putative regulatory polymorphism in the promoter, can be 
used to track the promoter allele from which the mRNA was transcribed. RNA extracted from the PVN is 
used in RT-PCR and subcloning. Sequencing of the resulting products yields a precise measure of the 
efficiency by which either allele was transcribed in vivo. 
 
This method allows one to track precisely which RNA species is more prevalent  
in vivo and, consequently, which promoter is more transcriptionally active. 
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The PVN of two male F1 heterozygote rats were used for AVP and oxytocin studies 
and a further two female heterozygotes were used for AVP expression. In addition, the SON 
of four more heterozygotes were included for AVP expression as a second control as in situ-
hybridisation and immunohistochemistry data suggest that AVP overexpression does not 
occur in this population of neurons. Over one hundred, randomly picked, plasmid clones 
harbouring the respective cDNA from each animal were sequenced to determine the allelic 
origin (figure 22A). The frequencies of the allelic cDNAs are included in figure 22B. 
 
 
Figure 22. In vivo transcription analysis of AVP and oxytocin. (A) Autoradiogram of allele-specific 
transcript sequence demonstrating the CT-tracking. (B) Table of results from the in vivo expression 
analysis for AVP and oxytocin. (C) Allelic transcription rate for AVP and oxytocin in the PVN and SON. 
Values are given in percentage of 100 clones sequenced. In situ-hybridisation data of the AVP and 
oxytocin mRNA are also included. **, Significantly different (p<0.005).  
 
The allelic transcription rate for AVP in the PVN in each experiment evidenced a 
60:40 ratio in favour of the HAB allele. When the results were combined in a Student’s t-test 
a significantly (p<0.005) distinct difference between the two lines was obtained with the HAB 
AVP promoter revealing a 50% increase in activity over the LAB promoter allele (figure 22C). 
Included in figure 22 are the in situ-hybridisation data from the HAB and LAB PVN tissues 
further demonstrating this higher level of AVP mRNA in the HAB animal, which correlates 
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well with the higher activity of the AVP promoter. In contrast, the allele-specific transcription 
rate for oxytocin in the PVN revealed a 50-50% ratio, in agreement with the in situ- 
hybridisation data demonstrating a lack of difference between the HAB and LAB lines. 
Furthermore, no significant differences between the LAB and HAB alleles resulted from the 
SON studies confirming the previously published finding of AVP overexpression being 
specific only to the PVN and not the SON. 
Concluding, the differences in the expression of AVP in vivo are, largely, due to 
differences in the cis-regulation of the AVP promoter allele, which further prompted us to 
study exactly which SNP(s) could be key to this differential expression.  
3.2.7 Transcription factor element analysis 
Having established that the HAB-specific allele confers higher transcriptional activity in vivo 
we further asked whether any of the SNPs in the promoter region exerts a regulatory role 
underlying the enhanced expression of AVP mRNA and secretion (Keck et al., 2002). We 
addressed this issue by first analysing each SNP in order to identify those which were 
embedded in putative DNA binding sites by scanning transcription factor databases (refer to 
section 2.2.6). We were particularly interested in cis-regulatory sequences important to 
expression, such as protein binding sites. Secondly, we asked whether the nucleotide 
differences between the HAB and LAB allele might affect the function of such DNA binding 
sites, altering the binding or activity of candidate proteins. Thirdly, we correlated these 
findings with a detailed survey of the literature regarding the expression of regulatory factors 
in the PVN. Questioning the relevance of any candidate protein to AVP expression in vivo, it 
is obviously imperative that the protein is expressed in the same cells as AVP. Based on these 
criteria, the particular SNPs highlighted in table 1 appeared to be of potential interest. 
 
Table 1. SNPs embedded in putative consensus DNA-binding sites. Additionally, only those DNA binding 
sites are listed where the respective transcription factor (TF) is known to be expressed in the PVN. 
SNP AVP sequence  TF Element Expression Reference 
A/G -1276
 
A/C -596, 
C/T -592 
gtccttattAggaagagg  
 
ccccAtgaCgccagcca 
YY1  
CBF-A 
CREB, 
CREM, 
ATF-2 
CCWTNTTNNNW 
CC(A/T)6GG 
TGACGMYMR 
Brain  
PVN  
Ubiquitous 
Ubiquitous 
Ubiquitous 
Shrivastava and Calame, 1994 
Treisman, 1987 
Angel et al., 1987 
Masquilier and Sassone-Corsi, 1992 
Hai and Curran, 1991 
 
Of further consideration in evaluating the possible importance of any candidate regulatory 
protein was the relevance of the prospective transcription factor in regulation of the HPA-axis 
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and behaviour. For this, literature searches were used to evaluate if a candidate transcription 
factor regulates genes involved in anxiety and if the transcription factor, or gene, responds to 
changes in neurotransmission or drug treatment. 
3.2.8 C(-592)T and cAMP responsive element 
The polymorphism involving the transition of a C to a T, 590bp upstream of the AVP start 
codon, located in an imperfect cAMP responsive element (CRE) site (Angel et al., 
1987;Masquilier and Sassone-Corsi, 1992) (table 2). This sequence, though not conforming at 
one position (position 6) to the palindromic structure usually found in such elements, might 
further be disrupted by the HAB sequence polymorphism at position 4 adjacent to the 
symmetry axis. 
 
Table 2. Comparison of the consensus cAMP responsive element (CRE) with the LAB and HAB SNP 
590bp upstream of the start codon of the AVP gene. The CRE comprises two palindromic half sites of the 
TGAC sequence. The LAB allele contains one mismatch to this consensus, whilst the HAB allele differs at 
a further nucleotide. 
Nucleotide position 1234 5678  
consensus seq. 
LAB seq. 
HAB seq. 
TGAC GTCA 
ccaTGAC-GCCAgcc 
cccTGAT-GCCAgcc 
 
With respect to the putative CRE, present in the LAB animal, our in vitro studies 
failed to evidence any difference in basal or in cAMP-dependent AVP promoter activity 
related to this SNP (refer to section 3.2.11.1). This finding was not unexpected since the AVP 
promoter contains at least two additional CREs, at positions -220bp and -116bp (Iwasaki et al., 
1997), which suggests that this putative distal CRE site does not contribute to CRE-dependent 
expression of the AVP promoter. In further support of this view a recent genome-wide survey 
suggested that functional CREs preferentially locate more proximal to the transcriptional 
initiation site (Conkright et al., 2003).  
3.2.9 A(-1276)G and YY1 
The A to a G transition 1276bp upstream from the AVP start codon is predicted to disrupt a 
CArG element in the HAB promoter (figure 23A). This theory was supported by the view of 
Richard Treisman (London), the leading expert in the field of CArG elements, who suggested 
that such a change in the HAB would effect DNA binding of SRF by 5-10 fold (personal 
communication).  
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The CArG element is characterised by the sequence of two Cs followed by a motif of 
six Ts or As and two Gs i.e. C, A repeat G (Minty and Kedes, 1986) (figure 23B). This 
cis- regulatory element, also known as a serum response element (SRE), is bound by serum 
response factor (SRF) (Treisman, 1987) and CArG binding factor A (CBF-A) (Kamada and 
Miwa, 1992). The consensus site for YY1 (Shrivastava and Calame, 1994) also matches the 
 
 
Figure 23. Nucleotide sequence of LAB and HAB CArG boxes in the AVP promoter at the A(-1276)G 
polymorphism. (A) Sequence of the SNP located 1276bp from the start codon consisting of an adenine ‘A’ 
in the LAB sequence substituted for a guanine ‘G’ in the HAB. (B) Table demonstrating comparison of 
the YY1 consensus sequence with the YY1 binding site in the MuLV promoter, the LAB sequence and the 
HAB sequence at the A(-1276)G polymorphism. W = A or T. 
 
sequence for the LAB allele, and disruption of the usually A/T rich sequence by the 
substitution of a G in the HAB allele could effect YY1 binding, a scenario found in the YY1 
consensus polyA tract of the motor neuron gene (SMN1) (Martin et al., 2002). However, 
opinion on the authenticity of this sequence as a YY1 element varied among experts in the 
field of YY1 research; Dr. Ed Seto (Tampa) was confident that this sequence was not a YY1 
site, whilst Dr. Wayne Vedeckis (New Orleans) and Dr. Amy Lee (Los Angeles) both 
suggested that it was possible, and certainly worth testing with an electrophoretic mobility 
shift assay (EMSA) (personal communications). Moreover, other molecular biology groups 
specialising on the AVP promoter, namely the group of Dr. Judy Coulson (Liverpool), were 
also working on YY1 as a TF in AVP expression (personal communication). Furthermore, 
YY1 has been extensively reported to bind to CArG elements competing with other 
transcription factors to mediate repression (Ellis et al., 2002;Galvagni et al., 1998;Itoh et al., 
2001;L'Honore et al., 2003;Martin et al., 1997;Vincent et al., 1993). 
3.2.9.1 EMSA experiments  
YY1, a 414aa protein with a molecular weight of 44kDa, is a member of the GLI-Krüppel 
family containing four of the C2H2 type zinc finger domains (figure 24A) involved in 
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repression and activation of DNA elements (Hariharan et al., 1991). According to its 
ambiguous transcriptional activities, which are influenced not only by the nature of the DNA 
element but also by the cellular background, the name ying-yang, i.e. YY, has been coined. 
YY1 shows an expression pattern involving a wide variety of tissues including the 
hypothalamus (Hurd et al., 1999). YY1 interacts and competes with a number of transcription 
factors, which further modulate repressing and activating activities in a wide variety of genes. 
Previous reported YY1 binding site disruptions have been described for spinal musculature 
atrophy at a polyA sequence in the SMN1 promoter (Martin et al., 2002), and in cystic 
fibrosis where the CFTR promoter polymorphism T(-102T)A leads to differential expression 
disrupting a YY1 site at a CArG box (Romey et al., 2000). 
Due to the uncertainty of whether this sequence might serve as a binding site for YY1, 
electrophoretic mobility shift assay (EMSA) experiments were conducted using nuclear 
extracts from Saos-2 cells transfected with the YY1 expression vector pCMV-YY1, and 
comparing the binding of the YY1 protein to the AVP promoter element with a known YY1 
binding site (figure 24B) derived from the Moloney murine leukemia virus (MuLV) gene. The 
long terminal repeat of MuLV gene contains the upstream conserved region (UCR), 
CGCCATTTT, which has been well documented to bind to YY1 mediating negative 
regulation (Flanagan et al., 1992). 
 
 
Figure 24. YY1 protein and binding element. (A) Schematic structure of the YY1 protein. The 
transactivation domain is contained in the acidic N-terminus whilst the DNA-binding domain maps to the 
C-terminal zinc-fingers. H; histidine, G; glycine, K; lysine, Zn; zinc-fingers. (B) Sequence alignments of 
the YY1 consensus sequence with the YY1 binding site in the MuLV promoter, the LAB sequence and the 
HAB sequence at the -1276bp polymorphism. W = A or T. 
 
The results of the EMSA experiments in figure 25 substantiates previous evidence for 
YY1 binding, as expected, to the MuLV element with high specificity. This further confirms 
that the mouse YY1 protein, when produced in human osteosarcoma cells, retains the ability 
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to bind its consensus DNA. The mouse and human YY1 proteins are 98.8% homologous 
(Hariharan et al., 1991). The specificity of the protein/DNA structure was further confirmed 
in an antibody shift assay, where the protein/DNA complex was retarded (‘shifted’) during gel 
electrophoresis upon addition of YY1 antibody (figure 25A). The YY1 antibody, though 
raised against full length protein of human origin is also specific for mouse and rat (refer to 
section 2.1.5.1). Moreover, nuclear extracts from mock-transfected Saos-2 cells failed to form 
a complex with this YY1 site further attaining to the authenticity of the observed complexes 
(data not shown). 
The ability of the putative DNA element in the AVP promoter to function as a YY1 
binding site was then tested. Equal amounts of HAB, LAB and MuLV oligonucleotides were 
mixed with equal volumes of YY1 protein in order to determine the specificity of the AVP 
elements by comparing these AVP elements to a highly specific YY1 binding site. As evident 
in figure 25B, YY1 from non-transfected nuclear extracts of HeLa, Saos-2 and 3T3 cells 
binds the MuLV sequence up to 20-fold more than either the LAB or HAB elements. 
 
 
Figure 25. EMSA experiments using YY1. (A) Consensus MuLV binding site oligonucleotide incubated 
with 1:g nuclear extracts of YY1 transfected Saos-2 cells. In the absence of antibody YY1 binds as one 
single, high intensity, band (thin arrow). Addition of the YY1 antibody causes an almost complete 
supershift of this band (thick arrow), attesting to specificity of this band as YY1 bound DNA. (B) EMSA 
experiment comparing the MuLV element with the HAB and LAB AVP elements for binding of YY1. 5µg 
nuclear extracts of HeLa (H) cells, Saos-2 (S) cells and 3T3 (3) cells with (*), or without transfected YY1 
expression vector, were incubated with the elements. A protein/DNA band clearly forms in the MuLV 
probe (thick arrow). Furthermore, YY1 can be seen to bind with similar efficiency to the LAB and HAB 
elements in the transfected cells, but at 20-fold less efficiency (thin arrow). (C) Western blot of 5µg of 
nuclear extracts from Saos-2, HeLa and 3T3 cells incubated with YY1 antibody. An abundance of native 
YY1 protein is evident in HeLa cells and, to a lesser degree, in both the Saos-2 and 3T3 cells. Results of all 
gels are representative of at least three independent experiments. 
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This suggests that the AVP element functions as a very weak YY1 binding site which 
does not, however, discriminate between HAB- and LAB-derived oligonucleotide probes.  
3.2.9.2 YY1 and AVP promoter expression 
Having established that YY1 weakly binds to the AVP promoter, it remained to be clarified 
whether YY1 regulates AVP expression in vitro, and if this might discriminate between the 
promoter alleles. Cotransfection experiments were conducted with either the HAB or LAB 
distal and proximal AVP promoter sequences cloned upstream of the firefly (Photinus pyralis) 
luciferase reporter gene and a β-galactosidase (β-gal) expression vector, used to standardise 
luciferse rates on transfection efficiency. 
These experiments evidenced no significant expression differences when comparing 
the distal and proximal AVP promoter alleles (which are presented later in figure 33). 
However, it remained to be determined if these cell lines actually contain native YY1 protein. 
To test this, Western blots of non-transfected nuclear extracts were incubated with a YY1 
antibody, and from the results it became evident that Saos-2 cells, HeLa cells and 3T3 cells all 
contain YY1 protein (figure 25C). The highest concentrations of YY1 were found in HeLa 
cells followed by Saos-2 and 3T3 cells, which contained a quarter of the amount. Therefore, 
the lack of line-specific luciferase expression differences in the promoter constructs 
transfected in the Saos-2 cells suggests that YY1 is actually not differentially regulating the 
LAB and HAB promoters. 
However, the regulatory role of YY1 in AVP expression still needed to be determined 
because in addition to the weak polymorphic YY1 element at -1276bp, two further YY1 
consensus binding sites exist in the AVP promoter, present only in the distal construct and 
absent from the proximal one (figure 26A). Therefore, the HAB and LAB distal and proximal 
promoter constructs were cotransfected with a YY1 expression vector, with the idea that 
differences in AVP-luciferase expression between the distal and proximal promoter constructs 
reflects the presence or absence of these YY1 sites. The expression experiments revealed that 
YY1 negatively regulated the AVP promoter (figure 26B). A gradual dose-dependant 
decrease in expression upon increased cotransfection of the YY1 expression vector occurred 
at 0.1µg, producing a 20% decrease of expression in both the distal and proximal promoter 
constructs. The pGL2 vector alone containing no AVP promoter construct was not repressed 
by increasing concentrations of YY1 (data not shown). However, it became evident that there 
was no significant difference, between the proximal and the distal promoter constructs, 
strongly suggesting that the predicted YY1 elements are not functional. 
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Possible regulatory differences between the LAB and HAB AVP promoters by YY1 
was still further explored because YY1 appeared to slightly repress the LAB constructs when 
compared with the HAB. Therefore, we conducted triple transfection experiments with the 
pRK8-PKAc-rat expression vector containing the catalytic subunit of cAMP-dependent 
protein kinase A (PKA) (Spengler et al., 1993) in addition to the YY1 expression and AVP 
reporter vectors. Protein kinases regulate a myriad genes involved in cellular processes during 
growth and development and form an integral part of the machinery activated in response to 
stress. The idea of the triple transfection was of two-fold; firstly to achieve a higher activated 
expression status of the promoter, in which a repressing factor might have a greater effect and 
secondly, to explore previous studies suggesting that YY1 can be activated by 
phosphorylation (Becker et al., 1994;Patten et al., 2000), indeed, the protein appears to 
contain a number of putative phosphorylation sites when analysed with phosphorylation site 
predicting programs (refer to section 2.2.6). Interestingly, when YY1 and PKA were 
cotransfected together with the promoter constructs of the AVP-luciferase vector, 
 
 
Figure 26. Activity of distal and proximal promoter AVP promoter constructs. (A) Schematic diagram 
demonstrating the rat AVP constructs used in the expression analysis. The distal promoter construct 
contains all 10 polymorphisms in the promoter, while the proximal construct contains only the four closest 
polymorphisms to the start codon (A/C -594, C/T -590, A/G -534, A/C -455). The filled and empty circles 
represent consensus and the weak polymorphic consensus YY1 binding sites respectively. (B) Luciferase 
expression of distal (empty circles) and proximal promoter (empty squares) AVP-luciferase constructs in 
Saos-2 cells cotransfected with YY1 in a dose dependant manner. (C) Gene expression of the distal and 
proximal LAB (empty circles) and HAB (filled circles) promoter AVP-luciferase vectors co-expressed with 
a fixed amount of 0.01mg PKA in Saos-2 cells cotransfected with YY1 in a dose dependant manner. 
Results of B and C are means of three independent experiments ± SD. 
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YY1 caused a more pronounced decrease in expression in the distal construct than the 
proximal, with about a 75% reduction in expression (figure 26C). This, therefore, suggests 
that YY1 might preferentially repress induced AVP promoter activity – such as under PKA – 
due to binding to the distal consensus YY1 elements. 
3.2.10 A(-1276)G and CArG box binding factor A (CBF-A) 
CArG box binding factor A (CBF-A) is a ubiquitously expressed transcription factor specific 
found in the mouse and the rat. The CBF-A gene encodes a 1,573 nucleotide mRNA giving 
rise to a 285aa protein which is alternatively spliced at exon 7 resulting in a variant 47aa 
shorter (Dean et al., 2002). Both isoforms are found in the nucleus of cells whilst the spliced 
form further locates to the cytoplasm (Dean et al., 2002). CBF-A is also subject to 
posttranslational modifications leading to various phosphorlylated forms including two 
phosphorylation sites at amino acid positions 90-97 and 259-274 according to matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) predictions. 
(Umar et al., 2003). The close homologues of CBF-A in the human, AUF1 (Dean et al., 2002) 
and hnRNPA/B (Cvekl et al., 1995), are subject to many forms of posttranslational 
modification involving sumoylation (Vassileva and Matunis, 2004) - the conserved 
sumoylation sequence is found in CBF-A at lysine 207 within the consensus sumoylation 
target sequence ØKXE, Ø being a hydrophobic residue and X any residue (Verger et al., 2003) 
- methylation (Wada et al., 2002), and ubiquitination (Laroia and Schneider, 2002). Indeed, 
CBF-A closely resembles members of the hnRNA binding proteins (hnRNP) and ssDNA 
binding proteins (ssDBP) families containing the highly homologous two imperfect repeats 
located in the central portion of the protein which form the RNA and DNA binding domains 
(RBD) (Weisman-Shomer et al., 2002) (figure 27A). The hydrophilic carboxy-terminus of the 
protein shares similarities to sequences involved in nuclear cytoplasmic shuttling of JKTBP 
(Kawamura et al., 2002), which perhaps relates to the dual role of CBF-A as both a 
transcription factor and mRNA binding protein.  
Owing to the co-expression of CBF-A with AVP in the PVN (see below), and its 
differential expression in vivo and in vitro under drug administration and its importance in 
controlling genes involved in behaviour (see Discussion), we carried out further experiments 
to determine, in detail, if CBF-A binds to the CArG box, and if CBF-A differentiates between 
the CArG boxes from HAB and LAB alleles. 
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3.2.10.1 CBF-A binds to the AVP CArG element 
Preliminary EMSA studies were performed with nuclear extracts of cells transfected with the 
CBF-A expression vector to determine if binding of CBF-A to the CArG element occurred. 
Results in figure 27B clearly evidenced that CBF-A bound to the CArG elements in a dose-
dependent manner. Although whole cell extracts showed additional bands, as seen in the gel 
(figure 27B), these did not change in their intensities upon CBF-A cotransfection. Importantly, 
the antibody shift assays, in figures 27E+F, using recombinant CBF-A attests to the 
specificity of CArG box binding. 
 The EMSA experiment with nuclear extracts lacked the resolution to measure 
precisely CBF-A binding between LAB and HAB elements, due the presence of unrelated 
protein-DNA bands in the gel. Therefore, purified recombinant CBF-A was tested in EMSA. 
For this a mouse full-length CBF-A cDNA was expressed in E.coli as a GST-fusion protein. 
CBF-A was purified using glutathione-sepharose beads (see Methods) and judged to be 
95% pure from Coomasie blue stained gels (figure 27C). The specificity of the recombinant 
protein was further verified using a GST antibody in immunoblots (figure 27D). The single 
band visualised demonstrates that intact full length CBF-A-GST fusion protein was purified.  
Following incubation of GST-CBF-A with the CArG element two distinct protein-
DNA complexes were observed under non-denaturing polyacrylamide gel electrophoresis 
(figure 27E). This was interesting as only one band associating to CBF-A was evident in the 
nuclear extract. Addition of increasing amounts of the GST antibody to the incubation 
reaction caused a supershift of both the major low mobility and the minor higher mobility 
complexes. In contrast, preincubation with control IgG or BSA failed to elicit a supershift 
attesting to the specificity of the observed DNA-protein complexes (data not shown). The 
formation of two complexes with GST-CBF-A fusion protein, a stronger with lower mobility 
and a weaker with somewhat higher mobility, has previously been reported and suggested to 
be a function of the GST part of the recombinant GST-CBF-A fusion protein (Bemark et al., 
1998). This would explain the lack of similar bands in nuclear extract obtained from Saos-2 
cells transfected with non-tagged CBF-A. In support of this new His-CBF-A and 
FLAG-CBF-A fusion proteins bound the CArG element as a single major DNA-protein 
complex, which was completely shifted by the respective antibodies, whereas this was not the 
case for additional weaker higher and lower mobility complexes, which appear thus unrelated 
to CBF-A. 
Overall, the EMSA results demonstrate that CBF-A, produced in either eukaryote or 
prokaryote cells, binds with the same specificity to the AVP CArG element. Since eventual 
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posttranscriptional modifications in eukaryotic systems appeared of no importance to CBF-A 
DNA-binding in vitro, bacterially produced CBF-A protein was used in the following studies. 
 
RNA/DNA binding domain
1 2 3
 
Figure 27. CBF-A binds to the AVP CArG element. (A) Schematic diagram of the structure of CBF-A. 
The two inverted repeats between 75 and 234aa form the RNA and DNA binding domain (RBD). 
(B) EMSA using nuclear extracts of Saos-2 cells transfected with increasing amounts of the PRK7-CBF-A 
expression vector and incubated with the double stranded CArG element from the LAB (L) and HAB (H) 
lines. A number of unspecific bands are evident, however, increasing concentrations of CBF-A result in 
the appearance of a specific band (arrow), which binds to the CArG element. Furthermore, the specific 
band appears to bind to the LAB allele with higher specificity. (C) Purified GST-CBF-A protein (arrow) 
migrates at a weight of about 60kDa and appears to be at least 95% pure, as judged by Coomasie blue 
staining. (D) An immunoblot using a GST antibody attests to the specificity and purification of the GST 
tag and antibody when comparing GST purified protein (lanes 1 and 2) with unpurified E.coli protein 
extract. (E) Recombinant GST-CBF-A binds specifically to the CArG element from the AVP promoter of 
the LAB line forming two complexes in an EMSA. The major low mobility and minor higher mobility 
complexes (thin arrows) are both supershifted with increasing concentrations of GST antibody (thick 
arrow). (F) Recombinant FLAG-CBF-A and His-CBF-A bind to the CArG element as a single major 
complex (thin arrow) and each is supershifted with increasing concentrations of FLAG and His antibody 
(thick arrows). Results of B-F are representative of at least three independent experiments. 
 
The CBF-A antibody was tested for its affinity to bind the CBF-A fusion proteins, 
firstly as a control for the validity of the CBF-A part of the fusion protein, and secondly to 
test for the specificity of the CBF-A-specific antibody for further use in Western blots and 
immunohistochemistry. As evident in figure 28A, the antibody was unable to completely shift 
either the GST or the His tagged protein in the same way that the GST, His or CBF-A 
antibodies did. 
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The inability of the antibody to elicit a complete shift of the recombinant-protein/DNA 
complexes might be caused by the N-terminus being inaccessible to the N-terminal-specific 
N-CBF-A antibody, which has been previously reported (Bemark et al., 1998). However, this 
low specificity might also be the result of the tagged domain of the fusion proteins interfering 
with the binding site of the antibody to the CBF-A protein. The third possibility might be that 
the antibody is simply inefficient, and to address this question further experiments were 
performed using an immunoblot with E.coli produced GST- and His-labelled CBF-A 
incubated with the CBF-A antibody. This procedure allows more efficient binding of the 
antibody to the membrane-bound protein, and subsequently, a more direct measure to test the 
relative efficiencies of each of the antibodies. The result in figure 28B demonstrate that  
N-CBF-A clearly recognises the recombinant proteins, binding to both GST and His-CBF-A. 
 
 
 
Figure 28. (A) Antibody shift analysis of recombinant GST- and His-CBF-A using increasing amounts of 
N-CBF-A antibody. The N-CBF-A antibody causes some shift of the GST-CBF-A resulting in two shifted 
bands (arrows) as well as a slight shift of His-CBF-A. (B) Immunoblot of GST- (thick arrow) and His-
CBF-A protein (thin arrow) with the N-CBF-A antibody. The two gels are representative of at least three 
independent experiments. 
 
3.2.10.2 CBF-A binds differentially to LAB and HAB polymorphisms 
We next investigated whether CBF-A discriminates between binding to the HAB and LAB 
CArG elements in EMSA. Interestingly we observed, for different concentrations of CBF-A, 
a strikingly stronger binding of CBF-A to the CArG box derived from the LAB allele when 
compared to the HAB allele (figure 29A). We obtained similar results in three independent 
experiments making differences in the probe preparations – such as separation of labelled 
from unlabelled probe – an unlikely source for this differential CBF-A binding.  
To substantiate our findings we carried out a competition assay in which identical 
concentrations of labelled LAB oligonucleotide were incubated with increasing 
concentrations of either unlabelled LAB or HAB oligonucleotide. In this experiment the LAB 
oligonucleotide was clearly more efficient than the HAB oligonucleotide to compete for 
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CBF-A binding as evidenced by the rapidly decreasing radioactive DNA-protein complex 
(figure 29B). 
In conclusion, CBF-A binds to the CArG element of the AVP promoter with high 
affinity and specificity and, importantly, the SNP A(-1276)G in the AVP promoter greatly 
reduces the binding of CBF-A by a degree of 4-5 fold. 
 
 
Figure 29. EMSA of CBF-A with HAB and LAB CArG boxes. (A) Increasing concentrations of 
GST-CBF-A were tested with double stranded CArG elements derived from either the HAB (H) or LAB 
(L) alleles. CBF-A clearly has a higher affinity for the LAB CArG box than for the HAB CArG sequence. 
(B) A fixed amount of labelled LAB CArG box was competed with increasing concentrations of either 
unlabelled LAB or HAB CArG elements. The unlabelled LAB oligonucleotide competes more efficiently 
than the unlabelled HAB oligonucleotide for CBF-A binding demonstrating that the CArG element from 
the LAB animal binds CBF-A more efficiently. Gels are representative of three independent experiments. 
 
3.2.10.3 CBF-A binds ssDNA of the CArG element 
In the EMSA experiments so far we used double-stranded DNA (dsDNS) as the probe, 
however, CBF-A has also been reported to bind to single-stranded DNA (ssDNA) with an 
even higher affinity (Kamada and Miwa, 1992) which might be important to its function in 
RNA metabolism and additionally to its function in transcriptional regulation (see below). To 
address this topic, and to obtain further insight into the consequences of CBF-A binding to the 
CArG-box element of the AVP promoter, we competed the LAB probe with increasing 
concentrations of dsDNA self-oligonucleotide or, alternatively, with increasing concentrations 
of ssDNA sense or antisense self-oligonucleotide. As demonstrated in figure 30A, the ssDNA 
probes were clearly more efficient for CBF-A binding in this assay than the dsDNA probe. Of 
further interest was the finding that, CBF-A bound to the antisense probe with higher affinity 
than the sense probe, revealing a further level of specificity in the recognition of the CArG 
element. This finding was corroborated by an EMSA experiment in figure 30B where the 
antisense probe clearly shows a greater specificity for CBF-A than the sense strand. 
 
69 
Results 
 
Figure 30. CBF-A binds to single stranded CArG element. (A) A fixed amount of labelled dsDNA LAB 
oligonucleotide is competed with increasing concentrations of unlabeled dsDNA of LAB CArG element 
(dsLAB), ssDNA of sense strand (sense) and ssDNA of the antisense strand (antisense) of the CArG 
element for GST-CBF-A binding. The ssDNA probes compete more efficiently for CBF-A DNA binding 
than the dsDNA element. Additionally, CBF-A DNA binding to the dsDNA CArG box is preferentially 
competed with the antisense ssDNA of the CArG element. Thick arrows denote probe bound by protein, 
and thin arrows free probe. (B) EMSA experiment using GST-CBF-A protein incubated with single 
stranded antisense and sense DNA of the LAB-specific CArG element. The ssDNA probes bind CBF-A 
forming a major high molecular weight band (thick arrow) and a minor band (medium arrow), similarly 
to the dsDNA probe. Thin arrow denotes protein trapped in wells of the gel. The results of A and B are 
representative of at least three independent experiments. 
 
3.2.10.4 CBF-A causes local unwinding of dsDNA CArG element 
In view of this high affinity of CBF-A for ssDNA, we examined further the possibility that 
CBF-A could induce or stabilize single-stranded regions within the AVP promoter CArG 
element. To test this hypothesis we devised an experiment utilising the specificity of 
S1 nuclease to preferentially digest ssDNA (figure 31A). CBF-A protein is firstly incubated 
with the dsDNA CArG element, after which S1 nuclease is added, which will cleave any 
ssDNA regions, induced by CBF-A binding, rapidly into mononucleotides. Therefore, in case 
CBF-A  
 
 
Figure 31. CBF-A causes DNA strand separation. (A) Scheme of the S1 nuclease assay for the detection of 
dsDNA melting. CBF-A binding to dsDNA is predicted to cause local strand separation and to confer 
increased sensitivity to S1 nuclease that cleaves the DNA into mononucleotides. (B) S1 nuclease assay for 
differing concentrations of CBF-A and GST with LAB CArG element. GST alone causes no cleavage of 
the dsDNA probe (thick arrow), whereas, increasing amounts of CBF-A cause dsDNA cleavage into 
mononucleotides (thin arrow). The results in B are representative of five independent experiments. 
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supports the formation of any ssDNA regions in the dsDNA CArG probe S1 nuclease 
cleavage will be enhanced, as evidenced by the appearance of mononucleotides at the expense 
of dsDNA. Different concentrations of CBF-A were supplemented with GST protein alone to 
keep total protein concentrations in each reaction constant. The results of the experiments in 
figure 26B clearly demonstrate an increase of S1 nuclease mediated degradation correlating 
with concentration of CBF-A and not GST. This data, therefore, suggests that CBF-A 
enhances melting of the dsDNA CArG box. 
3.2.10.5 CBF-A RBD domains are important for unwinding 
We further aimed to test to which extent this DNA melting is dependent on DNA binding of 
CBF-A by the RNA-Binding-Domains (RBD). For these experiments we used a series of 
CBF-A deletion constructs lacking either or both of the RBDs (figure 32A). Previous work 
has shown that the amino terminus and carboxy-terminal regions of the CBF-A protein have 
little or no effect on DNA binding, which in contrast critically depends to equal parts on both 
the central RBDs (Bemark et al., 1998).  
The deletion constructs were expressed as GST-fusion proteins in E.coli and purified 
using glutathione-sepharose beads as previously described. All deletion constructs were 
judged to be, at least, 95% pure from Ponceau stained gels (figure 32B). To adjust the 
concentrations of the recombinant proteins, immunoblots were carried out with the 
GST-antibody (figure 32C). 
EMSA experiments using similar adjusted amounts of the recombinant CBF-A 
deletion proteins support, in general, these findings in demonstrating that the presence of both 
of the RBD domains of CBF-A are crucial for the dsDNA binding. Specifically, however, our 
results reveal the second amino-terminal RBD of CBF-A appears to be of more importance in 
dsDNA binding (figure 32D). The deletion of the N-terminus results in a slight reduction in 
binding, and, moreover, the appearance of only one major band. The ∆RBD1 and ∆RBD2 
proteins also produced only one band, migrating at the same molecular weight as the 
∆N-terminus. This difference in the importance of the RBDs in DNA binding, in contrast to 
the previous work of Bemark (Bemark et al., 1998), might reflect the nature of the probes 
used as the previous study involved an A-T rich region (AATTTACTTC) of the SP6 promoter, 
in contrast to the CArG element (CCTTATTAGG) used here. The deletion proteins were 
further tested with ssDNA to gain more insight into the mechanism of DNA binding, if either 
the sense or antisense specificity is crucial for binding-specifically to the LAB CArG element 
than to the HAB, and if one of the RBDs might be of particular importance in sequence 
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recognition of the ssDNA element. Therefore, EMSA experiments were conducted incubating 
the various CBF-A proteins with either the sense or antisense ssDNA elements from the LAB 
and HAB CArG elements. The results in figure 32E prove that the sequence of the LAB 
antisense CArG strand provides the highest specificity-binding site for full length CBF-A. 
Deletion of the N-terminus, although resulting in somewhat less binding, does not alter the 
specificity of the protein for the LAB antisense strand, in comparison to the deletion of RBD2 
which results in a more variable binding between the four ssDNA sequences. 
 
 
Figure 32. RNA binding domain (RBD) deletion mutants and CArG element binding. (A) Scheme of RNA 
binding domain (RBD) deletion mutants. The two RBDs, labelled RBD 1 and RBD 2, localize to the 
central part of CBF-A and are flanked by an acidic amino-terminal and a basic carboxy-terminal region. 
(B) A Ponceau stained gel of purified GST-CBF-A deletion constructs suggested the protein preparations 
to be of, at least, 95% purity. (C) An immunoblot verified the authenticity of the purified proteins 
concerning the size and reactivity with the GST antibody. GST protein alone migrates at a size of 25kDa, 
whilst the GST-CBF-A ∆ 1 & 2 migrates at a slightly higher weight of 33kDa. The two proteins lacking 
either RBD 1 or 2 both run at 40kDa, while the ∆N-Terminus runs at 52kDa. The full length protein, as 
stated previously, migrates at a weight of 60kDa. (D) EMSA of RBD deletion mutants. The RBD motifs 
are crucial for dsDNA binding as evidenced by full-length CBF-A DNA binding compared to the ∆RBD 
1,2 protein. Moreover the presence of the N-terminus RBD 1 is more important for DNA binding than the 
COOH-terminal RBD 2. (E) EMSA experiment comparing the HAB and LAB sense (Hs and Ls) and 
antisense ssDNA (Has and Las) for binding with the various CBF-A deletion constructs. The thick arrow 
indicates the free unlabelled probe while the thin arrow indicates the CBF-A/protein complex. 
(F) S1 nuclease assay of CBF-A RBD deletion mutants. The thick arrow indicates the dsDNA and the thin 
arrow denotes the degraded mononucleotides. The presence of either of the RBD motifs leads to S1 
nuclease sensitivity. Moreover, the ∆RBD 1,2 protein which was unable to bind DNA conferred no such S1 
nuclease mediated digestion. The autoradiograms of D-F are representative of at least three independent 
experiments. 
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The results of the S1 nuclease assay when conducted using the CBF-A deletion 
proteins, revealed that DNA binding strictly correlates with S1 nuclease sensitivity since the 
CBF-A protein containing a deletion of both RBDs is unable to enhance S1 mediated DNA 
digestion (figure 32F). The recombinant CBF-A proteins containing either of the RBD 
domains, however, both increased S1 nuclease sensitivity suggesting that despite reduced 
DNA-binding in the absence of the N-terminal RBD, the proteins were still able to efficiently 
promote S1 nuclease sensitivity. 
3.2.11 Reporter assays 
3.2.11.1 AVP promoter expression in cell culture transfection experiments  
Reporter gene assays were used to delineate which regions of the AVP promoter were 
important for the differential expression seen in the allele-specific transcription in vivo, and if 
above differences in CBF-A binding translate into different transcriptional activities.  
Reporter plasmids containing the proximal and distal AVP promoter sequences of the 
HAB and LAB rats were transfected into, the osteosarcoma cell line, Saos-2. Results were 
standardised against a cotransfected expression vector for β-galactosidase (β-gal). Firstly, it 
became evident after repeating this experiment a considerable number of times that the AVP 
gene promoters revealed no differences in expression between either alleles from the HAB 
and LAB lines (figure 33A). Secondly, this experiment confirmed that the construct 
containing the distal promoter exhibits a third of the activity of the proximal promoter. 
Therefore, the proximal promoter construct is considerably more active than the distal 
construct. This finding has been previously reported (Iwasaki et al., 1997), and suggests that 
the region lying between the constructs, 2.8kb-0.9kb upstream from the start codon, contains 
regulatory elements important for repression of the AVP gene. 
The mouse neuronal cell line Neuro2a was transfected with the AVP promoter 
constructs, as described above. It was queried that a cell line more relevant to the rat AVP 
promoter, i.e. from a more closely related species, and consisting of neuronal cells, might 
contain specific factors which could highlight any differences between the polymorphic 
promoters. Again, however the cell lines produced no significant differences between the 
HAB and LAB sequences (figure 33B). 
Finally, the AVP-expressing small cell lung cancer cell line (SCLC), Lu-165, was also 
transfected. It was argued that a cell line specifically expressing AVP might contain further 
factors, absent in the previous cell lines, important for the AVP-specific expression of this 
promoter construct, and these factors might finally highlight a differential expression effect 
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between the LAB and HAB sequences. The Lu-165 cells, however, grew very slowly, and it 
became evident that a large number of cells needed to be transfected, which took many 
months to collect. Owing to the limiting factor of cell quantity, transfection efficiencies were 
low. In addition, the AVP promoter constructs revealed minimal levels of expression, on the 
borderline of detection (figure 33C), in contrast to the pGL2 vector, lacking the AVP 
promoter sequences, which showed a 4-fold increase of expression. Overall, no significant 
differences in expression levels arose between either the distal, proximal, HAB or LAB AVP 
promoter constructs in the Lu-165 cells. 
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Figure 33. AVP promoter gene assays for HAB and LAB proximal and distal AVP promoter activity. (A) 
Saos-2 cells (B) Neuro2a cells (C) Lu-165 cells. ± SD. * p<0.05, ** p<0.005. All results were taken from 
three individual experiments. 
 
3.2.11.2 PKA and AVP promoter expression 
The previous luciferase expression experiments suggest that either the cells lines investigated 
lack the specific transcription factor important for enhanced AVP gene activity in HAB 
animals, which might be expressed only in the PVN, or that other factors in the cell lines, 
such as SRF in the Saos-2 and HeLa cells, might even mask the effect of the regulatory SNPs 
on AVP promoter expression under these experimental conditions.  
Therefore, we considered that any possible differences between the HAB and LAB 
alleles might become unmasked under promoter activation. For this reason we co-expressed 
the proximal and distal LAB AVP promoter constructs with the pRK8-PKAc-rat expression 
vector. Results revealed, as expected and previously published (Iwasaki et al., 1997), that 
PKA induced activation of the AVP promoter dose-dependently (figure 34). It was further 
evident from these results that the distal promoter construct was more potently activated to 
give expression levels 2-3 fold higher than the proximal construct; the reverse as to what was 
seen in the non-stimulated transfections (figure 33A). This, therefore, suggests that a number 
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of DNA elements activated by the PKA pathway, such as AP1, AP2, CREB etc. (for review 
see Tasken and Aandahl, 2004) locate to the promoter region between the distal and proximal 
constructs. However, when comparing the LAB and HAB constructs under PKA stimulation 
no significant differences emerged (data not shown). 
 
 
Figure 34. AVP promoter activity is activated by PKA. PKA-induced activation of LAB distal promoter 
construct in relation to the proximal promoter construct. Squares represent the distal promoter, circles 
the proximal. Values are expressed as the percentage increase of basal standardised luciferase values. 
Results are means of three independent experiments ± SD. 
 
Results of the PKA activation experiments failed to assign a functional role to any of 
the polymorphisms, not least the CArG element located in the distal promoter. Therefore, we 
next tested the presence of a single particular transcription factor in relation to the single 
polymorphism in the CArG element by overexpressing CBF-A. 
3.2.11.3 Transcription control of AVP promoter by CBF-A 
Cotransfecting an expression vector for CBF-A with the AVP-luciferase constructs 
revealed that increasing concentrations of CBF-A repressed promoter activity in both the 
Lu-165 (figure 35) and Saos-2 (data not shown) cell lines. 
 
 
Figure 35. CBF-A differentially repressed LAB and HAB promoter activity. HAB (filled circles) and LAB 
(empty cicles) distal promoters were cotransfected with an expression vector for CBF-A in Lu-165 cells. 
Both the HAB and the LAB promoter constructs are repressed with increasing concentrations of CBF-A. 
Importantly the LAB promoter, though not significantly different, is more efficiently repressed to a higher 
degree. Results are means of three independent experiments ± SD. 
75 
Results 
 
Although non of the values reached statistical significance, dose-dependent differences 
were consistently measured in CBF-A mediated repression between the HAB and LAB 
constructs with the HAB AVP sequence being less prone to repression than the LAB 
construct at similar CBF-A concentrations. 
3.2.11.4 AVP CArG element expression in cell culture transfection experiments  
To clarify if this differential repression of the HAB and LAB constructs might be mediated by 
CBF-A through the polymorphic CArG element at position -1276 we created promoter 
constructs carrying only the CArG element, flanked by 8bp up- and downstream of the 
neighbouring AVP sequence, in front of a TATA element. Firstly, we wanted to determine if 
the CArG sequence behaves as a regulatory element in such a less complex system, secondly 
if the polymorphism might influence this function and, thirdly, if CBF-A confers 
transcriptional regulation through this element. The CArG element has been well documented 
as a potent activating sequence (Greco et al., 2002;Scott et al., 2002), with SRF being one of 
the major transcription factors to bind (Treisman, 1987). Expressing the LAB CArG element 
in osteosarcoma cells, which contain SRF (Bebien et al., 2003), indeed showed the element to 
function as a potent enhancer (figure 36A). Moreover, insertion of additional copies of the 
CArG element in the promoter increased the activity by double and triple the expression, in 
accordance with previous studies (Greco et al., 2002;Scott et al., 2002). When comparing the 
HAB and the LAB CArG elements, however, we observed that the LAB sequence conferred 
twice the activity of the HAB, demonstrating that the polymorphism affects the function of 
the CArG element (figure 36A). CBF-A has been reported to confer both repression (Kamada 
and Miwa, 1992) and activation (Mikheev et al., 2000) at the CArG element. Therefore, we 
next aimed to determine the role of CBF-A in relation to AVP promoter expression. When 
Saos-2 cells were cotransfected with a constant amount of an expression vector for CBF-A 
and the minimal CArG promoter plasmids, we measured that CBF-A repressed promoter 
activity, and this repression was closely related to the number of CArG elements present 
(figure 36B). 
Next, we cotransfected increasing amounts of CBF-A with the minimal promoter 
construct encoding three copies of either the LAB or HAB line derived CArG boxes. We 
observed, at the highest doses of CBF-A, a striking 4-fold repression of the LAB line derived 
CArG box when compared to the HAB (figure 36C).  
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Figure 36. Minimal CArG element reporter constructs are differentially expressed. Constructs containing 
CArG elements derived from either the LAB or HAB AVP promoter were expressed in Saos-2 cells. 
(A) One, two or three copies of the CArG element from the LAB animal (black bars) conferred a potent 
transactivation, when compared to an empty TATA vector (shaded bar), which is impaired in the 
presence of A(-1276)G polymorphism derived from the HAB line (empty bars). (B) Constructs containing 
the CArG element of the LAB AVP promoter cloned in series, and cotransfected with a constant 0.1µg of 
CBF-A expression vector (shaded bars), were repressed by CBF-A. The most pronounced repression was 
evident when three copies of the CArG element were cotransfected with CBF-A. (C) CBF-A dose-
dependent repression of the CArG element. Minimal reporter constructs containing 3 copies of either the 
HAB (filled circles) or LAB (empty circles) CArG elements were cotransfected with increasing amounts of 
an expression vector for CBF-A in Lu-165 cells. The CArG element from the LAB line is strongly 
repressed when compared to the HAB element. ± SD. * p<0.05, ** p<0.005. All results were taken from 
three individual experiments. 
 
The pGL2.TATA vector alone, containing no CArG elements in the entire plasmid 
sequence, was not repressed by increasing concentrations of CBF-A (data not shown) 
demonstrating that CBF-A dependent repression required the presence of the CArG box 
element. Together, these findings support the view that the A(-1276)G transition in the CArG 
element impairs CBF-A binding to the minimal HAB reporter construct which in turn relates 
to a weakened repression of the intact HAB AVP promoter by CBF-A. 
3.2.12 CBF-A expression in the PVN 
Collectively, our results so far support a role for CBF-A in repression of the AVP gene 
promoter in vitro and suggest a similar function for CBF-A in vivo. Therefore, we next 
addressed the issue of CBF-A expression in relation to AVP containing neurons in the PVN. 
A previous study reported that CBF-A messenger RNA is intensely expressed in the PVN of 
the hypothalamus (Rushlow et al., 1999). However, this finding needed further characterising 
which neurons of the PVN specifically express CBF-A, and in particular, if CBF-A is co-
expressed with AVP in the parvocellular compartment. 
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3.2.12.1 Immunohistochemistry 
A preliminary study conducted using mice brains supported the presence of CBF-A in the 
PVN. This experiment was performed with the N-CBF-A antibody on 3 separate mice 
(figure 37). Immunohistochemistry data show that CBF-A locates to a number of brain 
regions such as the hippocampus, dendrate gyrus, habenula, thalamus and amygdala. More 
importantly in this context was the high expression of CBF-A in the PVN, observed in both 
the parvocellular and magnocellular sections where, approximately, 80% of the neurons in 
this region were CBF-A immunopositive. 
 
 
Figure 37. Immunohistochemistry of CBF-A expression in mouse hippocampus, hypothalamus and PVN. 
CBF-A shows neuron-specific labelling intensely localising to the PVN. CA1/2/3; field of hippocampus, DV; 
dorsal 3rd ventrical, Fl; flocculus, DG; dentate gyrus, LPMR; lateral posterior thalamic nucleus, 
mediorostral part, LV; lateral ventricel, MH; Medial habenular nucleus, PaLM; paraventricular 
hypothalamic nucleus, lateral magnocellular part, PaMM; paraventricular hypothalamic nucleus, medial 
magnocellular part, PaMP; paraventricular hypothalamic nucleus, medial parvicellular part, 
Pe; periventricular hypothalamic nucleus, SCN; suprachiasmatic nucleus, V; ventricle. 
 
3.2.12.2 Double immunohistochemistry 
To determine if CBF-A localised to the specific parvocellular AVP-producing neurons of the 
PVN double fluorescence-immunohistochemistry was performed for AVP and CBF-A. These 
double fluorescence-immunohistochemistry experiments for CBF-A and AVP expression in 
the PVN of the hypothalamus evidenced an intensive colocalisation of AVP and CBF-A in 
both the magnocellular and parvocellular regions (figure 38). 
 Interestingly, CBF-A locates to the lateral magnocellular subdivision of the PVN 
containing the magnocellular neurons, as well as the parvocellular neurons that make up the 
more medial parvocellular subdivision. Furthermore, it should be noticed that CBF-A also 
localises in the magnocellular neurons that make up the entire SON of the hypothalamus, as 
well as the SCN. It is within only the parvocellular PVN, where CRH is also synthesised, that 
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Figure 38. Double fluorescence-immunohistochemistry for CBF-A and AVP in rat hypothalamic neurons. 
(A) CBF-A and AVP expression broadly overlaps at the hypothalamic and cellular levels. Fluoro-
immunohistochemistry for CBF-A (upper left) and AVP (lower left) expression in rat PVN. Merge of 
CBF-A and AVP fluoro-immunohistochemistry (right). Scale bar = 200µm. (B) CBF-A localises with the 
AVP expressing neurons of the SON. Fluoro-immunohistochemistry for CBF-A (upper left) and AVP 
(lower left) expression in rat SON. Merge of CBF-A and AVP fluoro-immunohistochemistry (right). 
(C) Cellular colocalisation of CBF-A and AVP. Fluoro-immunohistochemistry of CBF-A (upper left) and 
AVP (lower left) in neurons of the rat PVN. Merge of CBF-A and AVP fluoro-immunohistochemistry 
(right). Scale bar = 25µm. 
 
AVP gene expression is suppressed by adrenal glucocorticoids as part of the negative-
feedback loop and, therefore, regulated by stress as part of the HPA axis (Sawchenko, 1987). 
The magnocellular neuron-produced AVP, in both the PVN and SON, on the other hand, has 
a crucial role in osmoregulation, being released into the blood circulation upon physiological 
demand, such as a consequence of dehydration (Burbach et al., 1984;Sherman et al., 1988). 
These neurons are in contrast again to the dorsal-medial region of the SCN, the circadian 
generator of the mammalian brain (Weaver, 1998), where diurnal cues modulate AVP gene 
expression in these cells (Tominaga et al., 1992). Nerve signals here, from the SCN, cause the 
PVN to release pulses of CRH roughly once per hour, resulting in HPA axis activation and 
cortisol release. There are also direct links between the SCN and the adrenal gland itself 
(bypassing the HPA axis) through sympathetic nerve fibres, causing the adrenal gland to 
become more sensitive to ACTH stimulation during the morning, further adding to the 
circadian pattern of cortisol release throughout the day (Sage et al., 2002). 
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The HAB and LAB rats differ in AVP content in only the PVN- magnocellular and 
parvocellular neurons - whilst SON and SCN AVP content are unchanged. The fact that 
CBF-A is present in those cells showing no AVP expression differences then suggests that 
another level of control, either pre- or post-translational, involving the CBF-A factor might be 
at work. This is a line of thought currently being followed up in drug response and CBF-A 
expression in the PVN of the HAB rats. 
3.2.12.3 In situ-hybridisation 
To exclude line-specific differences in CBF-A expression between the LAB and HAB - which 
would bias the importance of binding to the polymorphic CBF-A element - five non-stressed 
HAB and 5 non-stressed LAB animals were subjected to in situ-hybridisation with a 
riboprobe specific for CBF-A. Furthermore, 5 stressed HAB and LAB rats were included as a 
preliminary study in determining to which extent CBF-A might be altered under stressed 
states. The animals were exposured to the open arm of the EPM, the same stressor previously 
used to highlight the HAB and LAB AVP differences in rat PVN sections. Our in situ-
hybridisation data revealed that no differences in CBF-A expression existed in the PVN 
between the HAB and LAB animals under basal or stressed conditions (figure 39). This 
finding rules out the possibility that differing levels of CBF-A between lines could underlie 
 
 
Figure 39. In situ-hybridisation and immunohistochemistry confirm similar CBF-A expression in the PVN 
between the HAB and LAB lines. (A) In situ-hybridisation for CBF-A in the rat brain (B) In situ-
hybridisation for CBF-A in the PVN of five LAB and five HAB animals reveal similar CBF-A expression 
between the LAB and HAB lines under either basal or stressed conditions. (C) Immunohistochemistry for 
CBF-A in the PVN of five LAB and five HAB animals again reveal no significant differences in CBF-A 
expression between the lines.  
 
the increased AVP expression present in the HAB AVP neurons. This result was further 
supported by immunohistochemistry stains for N-CBF-A (figure 39B). The trend for higher 
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levels of CBF-A in the PVN after stress exposure, however, seemed evident in both the HAB 
and LAB animals (figure 39A), compatible with the idea that CBF-A is responsive to stress.  
3.2.13 Model for the polymorphic CArG element leading to differential AVP 
expression 
Our data for rat AVP and CBF-A are summarised in the following model describing the 
differential regulation of the two AVP promoters by CBF-A (figure 40). 
 
 
Figure 40. Model for derepression at the AVP promoter by the A(-1276)G polymorphism. The A(-1276)G 
polymorphism impairs binding of the transcriptional repressor CBF-A resulting in overexpression of AVP 
in magno- and parvocellular neurons of the PVN under non-stressed basal conditions.  
 
SNP [A(-1276)G] conferred reduced binding of the transcriptional repressor CBF-A in 
the HAB allele, the consequent differential regulation of the AVP promoter resulting in an 
overexpression of AVP in vitro and in vivo. Furthermore, CBF-A is highly co-expressed in 
AVP-containing neurons of the PVN supporting an important role for regulation of AVP gene 
expression in vivo. The in vivo transcription analysis data lead us to conclude that the 
promoter region of the AVP gene plays a causal role in the differential AVP expression 
between the HAB and the LAB rats. In vitro analysis revealed an increased binding of CBF-A 
to the LAB-specific CArG sequence consequently resulting in “super” repression in the LAB-
specific minimal construct sequence. This, we hypothesise, leads to the observed ~1.7-fold 
overexpression of AVP peptide in the parvocellular and magnocellular neurons of the PVN 
under non-stressed basal conditions. Taken together, our results demonstrate a role for an 
AVP gene polymorphism and CBF-A in elevated AVP expression in the PVN of HAB rats 
likely to contribute to their behavioural and neuroendocrine phenotype (Murgatroyd et al., 
2004). 
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3.3 Genetic analysis of HAB and LAB mice lines 
Ongoing studies in the laboratory of Professor Landgraf focus on HAB and LAB mice, 
developed from 1999 onwards by selective breeding for their response in the EPM test. The 
practicality of a QTL analyses was investigated by assessing a limited set of published 
markers. Alternatively, considering the absence of sufficient CD1-specific markers, 
outbreeding the HAB mice to another mouse strain, for which sufficient published markers 
exist, is required. In this case, marker analysis of different mouse strains serves to identify 
those most genetically divergent and, therefore, most informative in an outbreeding strategy. 
To address this question, sequencing analyses were conducted to determine to which extent 
SNPs from CD1 are informative for an intraline versus an interline cross. 
3.3.1 Marker analysis of mouse chromosome 2 
Polymorphic markers on chromosome 2 were selected from the Mouse Genome Database 
(MGD) to cover the complete length of chromosome 2. Fourteen of these regions were 
amplified and sequenced and compared to sequences of eight other common inbred and 
outbred mouse strains; Spre, DBA/2J, CAST/Ei, C3H/HeJ, BALB/cByJ, A/J, 129s1/SumJ and 
c57bl/6J. Each region, contained up to 15 SNPs, all of which were genotyped in two LAB and 
two HAB mice (figure 41). 
 
 
Figure 41. SNP screen of chromosome 2 in mice strains. (A) Table of the percentage of polymorphisms 
found at each of the 14 loci that are conserved in the CD1 mice. Also included are the chromosome 
locations of each locus in centimorgans (Cm). The data, demonstrate that the SPRET mouse strain is the 
most genetically removed from CD1, whilst 129s1/SvimJ is the most closely related at all loci. 
(B) The mouse AVP gene is located on chromosome 2 at location 73.2cM. 
 
The data demonstrate that the CD1 mouse strain is genetically distinct from all of the 
other mice strains analysed and share no strain-specific polymorphisms. Furthermore, an SNP 
at the fifth locus lying at 33.1cM, revealed a line difference where the HAB animals contained 
an A and the LAB animals a T. Considering that the AVP locus also contains line differences 
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in SNPs (see below) one can speculate that a gene segment of, at least, 33.1cM to 73.2cM is 
differentially inherited between the HAB and LAB lines; this signifies half of chromosome 2. 
3.3.2 AVP 
The 5.5kb region of the mouse AVP gene, encompassing the three exons, two introns and 
3kb of promoter, was entirely sequenced to determine if any HAB or LAB line-specific 
polymorphisms existed in this locus. The mouse AVP gene is situated on chromosome 2 at 
73.2cM (Marini et al., 1993) (figure 41B) encoding a 168aa prepro-AVP protein highly 
homologous to the rat (figure 43). 
Sequencing of the AVP gene resulted in numerous nucleotide line-differences. 
However, it quickly became evident that sequences between the HAB and LAB mice differed 
to those in the rat lines in a number of ways (figure 42). Firstly, the LAB and HAB mice 
contain AVP alleles divergent from each other and, in addition, from the published sequence 
(accession M88354) (Hara et al., 1990). Secondly, the alleles contain single nucleotide 
deletions. Thirdly, the LAB allele contains a sequence gap in the promoter comprising 12bp. 
Fourthly, both alleles show SNPs in the coding sequence. Together, these data support the 
idea that these sequences represent distinct alleles that diverged from a common sequence, 
perhaps some time ago. Lastly, the LAB allele contains an SNP resulting in a non-
synonymous mutation in the signal peptide of the AVP protein. 
 
 
Figure 42. Scheme of the promoter, introns and exons (E) of the mouse AVP gene subjected to sequence 
analysis. Included are the LAB- and HAB-specific polymorphisms. 
 
The HAB allele contains three SNPs in the 5.5kb of the AVP locus sequenced. One of 
the SNPs, the C to T transition [C(+1450)T]in exon 2, lies in the coding region of the AVP 
gene coding for a same-sense mutation at amino acid position 91 (serine) in the neurophysin 
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part of the prepro-AVP protein. The other two SNPs involve deletions of As, the first 504bp 
upstream of the transcriptional start site A(-504)∆, and the second further 5’ at position 
1672bp upstream A(-1672)∆. The A(-504)∆ polymorphism seemed to effect no protein 
binding sites and matched no other DNA regulatory elements according to transcription 
element search programs (refer to section 2.2.6). The other polymorphism deleted specifically 
in the HAB line, again represented an A deletion, A(-1672)∆. This deletion occurs in the 
spacer region of an imperfect palindromic element (TGACCTgatcAGGTCA) previously 
shown to bind nuclear receptor heterodimers and particularly the T3R-beta homodimers as 
evidenced from DNase I footprinting (Kurokawa et al., 1993). This could, therefore, suggest 
that the HAB allele lacks this element, which might function in controlling the AVP gene 
through nuclear receptor binding, although this remains to be experimentally tested. 
The LAB allele also reveals a number of sequence differences to either the HAB allele 
and published sequence. These involved four SNPs, one single nucleotide deletion and a 12bp 
deletion. Two of the SNPs located in the translated sequence, one causing a synonymous 
mutation [A(+1354)G], and the other a non-synonymous mutation [C(+40)T]. The 
A(+1354)G transition occupied position 3 of the codon encoding Proline at amino acid 
position 59 in the neurophysin part of the AVP protein. The C(+40)T transition, importantly, 
lays in codon position 2 exchanging the third amino acid, Alanine, to a Valine during 
translation (figure 43). 
The position of the third Alanine amino acid, located in the signal peptide, is 
evolutionary conserved in the rat (it is not conserved in the human) supporting the idea that 
this amino acid plays an important role in the functioning of the AVP precursor. AVP is 
synthesised by neurons of the hypothalamus as a pre-pro-hormone. Pro-AVP is generated by 
cleavage of the signal peptide from pre-pro-AVP during cotranslational translocation and is 
released into the lumen of the endoplasmic reticulum. It is subsequently transported within 
neurosecretory vesicles to the axon terminal in the neurohypophysis via the regulated 
secretory pathway yielding AVP, neurophysin II (NPII) and glycoprotein (for review see 
Burbach et al., 2001). Signal peptides are, therefore, important in targeting the protein for 
secretion, taking part in an array of protein–protein and protein–lipid interactions. Signal 
peptides are 22-23aa long and have a common structure: a short, positively charged amino-
terminal region (n-region), a central hydrophobic region (h-region), and a more polar 
carboxy-terminal region (c-region) containing the site that is cleaved by the signal peptidase 
(figure 44A) (for review see von Heijne, 1998). 
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SignalPAVP Neurophysin Glycoprotein
LAB gtc
HAB gcc
Val
Ala
Exon I Exon II Exon III
MLARMLNTTLSACFLSLLAFSSACYFQNCPRGGKRAISDMELRQCLPCGPGGKGRCFGPSICCADELGCFVGTAEALRCQEENYLPSPCQSGQKPCGSGGRCAAVGICCSDESCVAEPECHDG--FFRLTRAREPSNATQLDGPARALLLRLVQLAGTRESVDSAKPRVY
MLAMMLNTTLSACFLSLLALTSACYFQNCPRGGKRATSDMELRQCLPCGPGGKGRCFGPSICCADELGCFLGTAEALRCQEENYLPSPCQSGQKPCGSGGRCAAAGICCSDESCVAEPECREG--FFRLTRAREQSNATQLDGPARELLLRLVQLAGTQESVDSAKPRVY
    MPDTMLPACFLGLLAFSSACYFQNCPRGGKRAMSDLELRQCLPCGPGGKGRCFGPSICCADELGCFVGTAEALRCQEENYLPSPCQSGQKACGSGGRCAAFGVCCNDESCVTEPECREG--FHRRARASDRSNATQLDGPAGALLLRLVQLAGAPEPFEPAQPDAY
    MPDATLPACFLGLLALTSACYFQNCPKGGKRAMSDLELRQCLPCGPGGKGRCFGPSICCGDELGCFVGTAEALRCQEENYLPSPCQSGQKPCGSGGRCAAAGICCNDESCVTEPECREGASFLRRARASDRSNATLLDGPSGALLLRLVQLAGAPEPAEPAQPGVY
    MPDATLPACFLSLLAFTSACYFQNCPRGGKRAMSDLELRQCLPCGPGGKGRCFGPSICCGDELGCFVGTAEALRCQEENYLPSPCQSGQKPCGSGGRCAAAGICCNDESCVTEPECREGVGFPRRVRANDRSNATLLDGPSGALLLRLVQLAGAPEPAEPAQPGVY
    MACPSLACCLLGLLALTSACYIQNCPLGGKRAVLDLDMRKCLPCGPGGKGRCFGPSICCADELGCFVGTAEALRCQEENYLPSPCQSGQKPCGSGGRCAATGICCSPDGCRTDPACDPESAFSER  
Figure 43. The arginine vasopressin-neurophysin II (AVP-NPII) gene consists of three exons. The first 
exon encodes the signal peptide, AVP and NH2-terminal region of neurophysin II (NPII); the second exon 
accounts for the central region of NPII and the third exon gives rise to the COOH-terminal region of NPII 
and glycoprotein. The polymorphism in the LAB animal causes an amino acid change in position 3 of the 
signal peptide resulting in an Alanine, which is also conserved in the rat, being substituted by a Valine. 
Protein alignments include the AVP protein sequences of the mouse, rat, human, pig, cow and mouse 
oxytocin.  
 
As the signal peptide emerges from the ribosome, it is first recognized by a 
ribonucleoprotein complex, the signal recognition particle (SRP), at the highly variable 
h-region (Nagai et al., 2003). The signal peptide is then inserted in a lipid-exposed location at 
the ER translocon, at this point the signal peptide spans the membrane with its carboxy-
terminal end facing the ER lumen. Although still associated with the translocon, it is also 
exposed to membrane lipids and its h-region has a helical conformation. The signal peptidase 
then skims the lumen surface of the membrane, looking for suitably exposed signal-peptide 
cleavage sites where the h-region serves to position the c-region near the lipid headgroups, 
within reach of the signal peptidase. This may also explain why signal peptidase does not 
cleave trans-membrane helices in integral membrane proteins, or signal peptides with 
artificially lengthened h-regions (Nilsson et al., 1994) or helix-breaking proline residues 
(Ryan and Edwards, 1995). Such helices generally extend across the lipid head-group region, 
so they do not present the required extended conformation, and naturally have to be 
hydrophobic in nature. Indeed, the degree of hydrophobicity of this region of the signal 
sequence is a major determinant of translocation efficiency (Bird et al., 1990;Ryan et al., 
1993). Therefore, it is of some interest to note that the inactive hydrophobic amino acids 
A and V (also including Glycine (G), Leucine (L) and Isoleucine (I)) differ in their 
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hydrophobicity, where the LAB Valine is more hydrophobic than the Alanine amino acid 
present in the HAB (relative hydrophobicity V= 4.2, A= 1.8) (Kyte and Doolittle, 1982) 
(figure 44B). 
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Figure 44. Signal peptides and aliphatic amino acids. (A) Schematic diagram of a signal peptide 
illustrating the conserved amino acid regions. (B) Comparing hydrophobicity of amino acids demonstrates 
that Valine is more hydrophobic than Alanine. 
 
Using protein structure prediction programs of PROF (Rost and Sander, 1993) and 
PHD (Profile fed neural network systems from Heidelberg) (Rost et al., 1996) it became 
further evident that the A to V amino acid substitution would alter the helical h-region of the 
signal peptide, the LAB structure predicting a longer helical region extending further towards 
the n-region (figure 45). However, overall the difference in hydrophobicity at this position 
results in the HAB, wildtype, signal peptide containing a higher percentage of helical 
structure and a greater solvent accessibility. 
One might speculate from this that the predicted helical h-domain in the LAB, for 
assigning the transmembrane helix, is altered to an extent that the peptide would situate 
differently across the ER lipid membrane compared to the wildtype prepro-AVP, with more 
amino acids in the LAB signal peptide locating outside the membrane. This alteration of the 
h-region might further effect interaction with the SRP system resulting in less efficient AVP 
peptide processing. 
Further evidence for the role of this signal peptide difference in the impairment of 
AVP release was provided in the behaviour of the animals in which fluid intake and serum 
osmolarity was measured in relation to the DI hypothesis provided above. Firstly, the animals 
from the LAB line all show a robust 2-3-fold increase in water drinking than the HAB line. 
Secondly, the LAB animals when deprived of water, show a massive increase in osmolarity 
and die of dehydration after 2 days when compared to control animals. Thirdly, the LAB 
animals show a reduction in neuronal density in the PVN, which becomes further evident as 
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Figure 45. Comparison of the secondary structures of the LAB and HAB AVP signal peptides using the 
PHD (Profile network prediction Heidelberg) and PROF secondary structure prediction programs. 
PHD sec; predicted secondary structure H=helix, E=extended (sheet), blank=other (loop). Rel sec; 
reliability index for PHDsec prediction (0=low to 9=high). SUB-sec; subset of the PHDsec prediction, for 
all residues with an expected average accuracy > 82%. P 3 acc; PHD predicted relative solvent 
accessibility (acc) in 3 states: b = 0-9%, i = 9-36%, e = 36-100%. Rel acc; reliability index for PHDacc 
prediction (0=low to 9=high) SUB acc; subset of the PHDacc prediction, for all residues with an expected 
average correlation > 0.69. PHD acc; PHD predicted relative solvent accessibility (acc) in 10 states.  
PHDhtm; PHD predicted membrane helix: M=helical transmembrane region, blank=non-membrane, 
PHD = Profile network prediction Heidelberg. Rel htm; reliability index for PHDhtm prediction (0=low to 
9=high). SUB htm; subset of the PHDhtm prediction, for all residues with an expected average accuracy 
> 98%. N: is non-membrane region. PHDrhtm; refined PHD prediction: M=helical transmembrane 
region, blank=non-membrane. PiMohtm; PHD prediction of membrane topology: T=helical 
transmembrane region, i=inside of membrane, o=outside of membrane. PT htm; 'probability' for 
assigning transmembrane helix. The tables demonstrate the predicted secondary structure using the PHD 
and PROF programs and the predicted solvent accessibility composition (core/surface) ratio of the two 
proteins; e=residues exposed with more than 16% of their surface, b=all other residues. 
 
the animals age (Kessler et al., unpublished data). It is well known that progressive 
degeneration of AVP-producing cells might accelerate the pathogenesis of diabetes insipidus 
(DI) (for review see Maghnie, 2001). These three findings certainly support the diagnosis of 
DI. 
Electrolyte abnormalities in DI are caused by the loss of urinary free water, which 
produces hyperosmolar dehydration, leading to hypernatremia, hyperchloremia, and prerenal 
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azotaemia caused by diminished blood volume (for review see Verbalis, 2003). Azotaemia is 
characterised by a high level of urea or other nitrogen containing compounds in the blood 
caused by the inability of the kidney to excrete these compounds. Therefore, it is also of 
interest that an enhanced expression of the enzyme, glyoxalase I (GLO1), occurs in the LAB 
animals (Kroemer et al., unpublished data). GLOI is part of the glyoxalase system present in 
the cytosol of cells catalysing the condensation of methylglyoxal and reduced glutathione to 
form S-lactoyl-glutathione; GLO2 converts the latter substance to D-lactic acid and reduced 
glutathione (for review see Thornalley, 2003). Remarkably, GLO1 deficiency leads to 
azotaemia (Miyata et al., 2001) highlighting the importance in the regulation of this enzyme 
in regard to osmolarity control. 
Aside from the signal peptide mutation, the LAB allele contains a further number of 
polymorphisms in 2.5kb of the promoter sequence (table 3). The C(-1425)T transition results 
in a sequence containing a T allele in the HAB line forming a z-box element characterised by 
the consensus of ggaccct. This binds the little known transcription factor NF-Zz in 
lymphocytes (Tsang et al., 1990). Both alleles of the A(-2409)∆ form binding sites for 
different factors. The HAB allele containing the A forms a binding site for the 
sex-determining factor gene product (Trimmer et al., 1998), as well as matching an artificial 
sequence TGTGGT, which binds the acute myeloid leukaemia I (AML1) gene product in 
EMSA experiments (Meyers et al., 1993). The deletion of the A in the LAB line forms an N-
box sequence (cttgtg) which has been shown by DNaseI footprinting to bind the bHLH factor 
HES1 (Ishibashi et al., 1994) conferring transcriptional inhibition. This allele further results in  
 
Table 3. Polymorphisms in the mouse AVP promoter embedded in protein-binding DNA elements. 
Included are the relative transcription factors binding to the respective DNA elements and if they are 
specifically expressed in the hypothalamus. 
Polymorphism Allele Element  Sequence Transcription 
Factor 
Expression in 
hypothalamus 
Reference 
C(-1425)T T z-box ggaccct RFX and NF-Y Yes, ? Tsang et al., 1990 
A(-2409) ∆ A CD3γ gene 
enhancer 
aacaag sex determining 
factor 
Yes Trimmer et al., 1998 
 A  tgtggt AML1 ? Meyers et al., 1993 
 ∆ N-box cttgtg HES1 Brain Ishibashi et al., 1994 
 ∆ thymidine 
kinase promoter 
cccncnnnct Yi ? Dou et al., 1991 
T(2524)C C B-element agccag NF-1 Brain Takiguchi and Mori, 1991 
∆-2183-2194 +  ccagagctacag HNF1A, NF-1 Brain, brain Courtois et al., 1987; 
Takiguchi and Mori, 1991 
 ∆ F-element tggctgg  no Uzan et al., 1991 
 
88 
Results 
a sequence identical to an element in the mouse thymidine kinase promoter which, by DNaseI 
footprinting and EMSA, has been shown to bind inducible proteins (Dou et al., 1991). 
A transition further 5’ involving T(2524)C results in the formation of a B-element (agcccg) in 
the case of the HAB-specific C allele. This element, found in the rat type arginase promoter, 
binds the NF-1 controlling factor, evidenced by DNaseI footprinting (Takiguchi and Mori, 
1991) 
Of most interest in the LAB promoter was the 12bp deletion found between 
nucleotides -2183 to –2194, which was not present in either the HAB or published sequence. 
This sequence, ccagagctacag, does not match any mobile genetic elements (for review see 
Bennet et al., 2004), or neighbouring sequence – evident of a duplication or inversion - and 
one must conclude that it arose via a spontaneous deletion in a founder individual. The HAB 
allele and published sequence, with the extra 12bp, contains the consensus sequence for 
HNF1A (Courtois et al., 1987) and another NF-1 site (Takiguchi and Mori, 1991). The LAB 
allele deletion, on the other hand, results in a consensus F-element (tggctgg) which, by 
DNaseI analysis, binds transcription factors and controls the platelet glycoprotein IIb gene 
(Uzan et al., 1991). 
3.4 Human AVP gene as a candidate gene for anxiety 
The human AVP gene is located on chromosome 20 at position 20p1 (Rao et al., 1992) 
(figure 46A). The promoter and the 3’ downstream region of the human AVP gene were 
sequenced to elucidate polymorphisms that might be of use in an association study in order to 
test whether the role of AVP as a culpability gene in rat and mice, in addition, extends to 
anxiety and depressive disorders in human patients. This was, naturally, the ultimate goal of 
these animal experiments. 
3.4.1 Sequence analysis 
The DNA from 15 humans was subjected to sequencing in regions of 1kb upstream of the 
AVP gene and 1kb downstream revealing a number of polymorphisms (figure 46B). These 
areas were chosen as it was believed that polymorphisms may be more prevalent in the non-
transcribed than in the transcribed region, and it was assumed that a polymorphism upstream 
and downstream enables a more powerful statistical analysis in an association study. 
Furthermore, this study has focused on AVP promoter polymorphisms in the rat and mouse 
and, therefore, it was of interest to analyse the homologous region in the human.  
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Figure 46. The human AVP gene and location of polymorphisms. (A) The AVP gene is located on 
chromosome 20 at position 20p1. (B) Schematic diagram of the human AVP locus highlighting the 
locations of SNPs discovered in the vicinity. 
 
3.4.2 C(-229)T promoter SNP 
The C(-229)T transition lies close to the TATA box of the human AVP gene. The 
polymorphism actually affects a number of very interesting putative protein binding sites. 
Firstly, the C allele results in the consensus sequence of an Sp1 binding site (Gustafson and 
Kedes, 1989), and furthermore would also be predicted to bind the histone H4 gene-specific 
transcription factor H4TF-1 (Stauffer et al., 1998). Both factors bind to the consensus 
sequence of GGGGGAGGGG, as evidenced by EMSA, methylation interface and DNaseI 
footprinting. Sp1 is an important transcription factor controlling a large number of genes in a 
variety of cell types (for review see Li et al., 2004). Moreover, the rat AVP gene has 
previously been reported to bind and be regulated by Sp1 at a GC-rich region in position -
170bp (Grace et al., 1999) which is homologous to the human AVP promoter GC-rich region 
containing the C(-229)T polymorphism (figures 14 and 47A).  
The C(-229)T polymorphism, therefore, represented a good candidate polymorphism 
for the regulation of AVP, as well as providing a marker for the AVP gene itself to be used in 
an association study. To test the feasibility of this marker in a patient-control association 
study 100 human DNA samples were analysed using an RFLP based approach (refer to 
section 2.1.10.4) (figure 47B). We calculated a gene frequency for this polymorphism of 
75% T allele and 25% C allele. The common nature of the alleles, in addition to possible 
functional effects caused by disruption of an Sp1 element makes this SNP a good candidate 
for further association and functional genomic studies. 
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HUMAN cccctcccccatgatcccc
RAT ------- --- - -- -
MOUSE ------- --- - -- -
A B
C
D
 
Figure 47. Human AVP polymorphisms. (A) Homology between the human, rat and mouse at the 
promoter GC rich region. Note that the C polymorphism, lying 229bp upstream from the start codon in 
the Sp1 element, is further conserved in both the rat and mouse. (B) Analysis of the C(-229)T 
polymorphism with the NlaIII RFLP in human controls and patients with affective disorders. The 
T polymorphism results in only two digested products of 252bp and 64bp, whereas the C polymorphism 
results in an extra digestion product leaving sizes of 221bp, 64bp and 31bp. The 64bp and 31bp fragments 
are not visible on the gel. (C) Schematic diagram of the 5’ and 3’ human AVP polymorphisms. (D) RFLP 
analysis of the G(-558)T polymorphism lying 3’ of the AVP gene. Incubation with the MseI enzyme results 
in cleavage of the 435bp product into 223 and 212bp products only in the presence of the t allele.  
 
3.4.3 G(-558)T downstream SNP 
Sequencing of the region downstream of the human AVP gene revealed a number of SNPs 
(figure 46). As previously described, polymorphisms in the 3’ region of the human AVP gene 
were required for inclusion in a prospective association study. The G(-558)T polymorphism, 
embedded in a MseI restriction site sequence, provided a suitable SNP for RFLP analysis 
(figure 47D) (refer to section 2.1.10.4). This second SNP downstream of the AVP gene was 
included for two reasons. Firstly to determine if the AVP gene represents a real candidate 
locus, in which a meta-analysis of the 5’ C(-229)T transition combined with the 3’ G(-558)T 
transversion (figure 47C) should provide greater statistical power and, secondly, to test the 
hypothesis that the 3’ region of the AVP gene contains major control elements for AVP 
tissue-specific expression.  
As evident from figure 47C, the G(-558)T transversion also makes an ideal SNP to 
study in association studies from its ease in RFLP studies using the MseI restriction enzyme 
and its relatively common alleles frequencies of 55% G and 45% T allele when tested in the 
same 100 human samples. 
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It would, therefore be of interest to test these two polymorphisms in a case/control 
study and to further calculate to which extent the two polymorphisms are in linkage to each 
other. This is of importance in testing for disequilibrium, and subsequent relevance of these 
polymorphisms in an association study. However, this experiment is beyond the scope of this 
study. 
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4 Discussion 
4.1 HAB rat 
Previous work demonstrated a critical role of AVP gene overexpression in a HAB/LAB 
animal model of trait anxiety and comorbid depression, which was established by 
bi-directional breeding (for review see Wigger et al., 2004). This approach enriches for 
genetic information associated with a particular trait, which shifts the animals phenotype from 
the population mean (Falconer and Mackay, 1996). In an extension of this work we identified 
here a A(-1276)G transition within the AVP which plays a causal role in the differential AVP 
expression where this particular SNP results in a decrease in binding of the CBF-A leading to 
less efficient transcriptional repression of the AVP gene. This would, therefore, result in the 
observed overexpression of AVP in the magno- and parvocellular neurons of the PVN under 
non-stressed basal conditions. HAB animals have been well documented to show increased 
AVP mRNA expression, as well as elevated release of the neuropeptide in the PVN, which 
correlates with a hyperactive HPA axis. We now present direct evidence for line-specific 
differences in the sequence of the AVP promoter playing a direct role in this differential AVP 
expression. In the heterozygous rat PVN, the HAB AVP promoter shows a 50% increased 
activity compared to the LAB sequence, which lacks all of the HAB-specific SNPs. Evidently, 
this difference will enlarge under the homozygous condition present in the HAB animal and, 
in turn, correlates well with the differences seen in the AVP messenger RNA studies. The fact 
that the allele-specific transcription rate was measured in vivo, circumvents the limitations 
associated with the analysis of cell-specific genes in cultures and adds further relevance to 
these findings. Genotyping the promoter SNPs in outbred Wistar rats resulted in the finding 
that the HAB-specific allele occurs with a frequency of 1.5%, compatible with the common-
disease–common variant hypothesis (Lohmueller et al., 2003), and supports the idea that trait 
selection leads to homozygosity at loci conferring trait anxiety/depression. Moreover, we 
observed that the LAB-specific AVP allele was identical to published sequences from outbred 
rats in accordance with normal levels of hypothalamic AVP gene expression (figure 40). 
Hence, LAB and HAB lines represent distinct disease entities, with AVP behaving as a 
vulnerability gene solely in the latter. The line-, neuropeptide- and site-specificity of AVP 
overexpression in the PVN of HAB animals is underlined by the findings that 
(i) the expression of oxytocin, the structurally and functionally related neuropeptide, did not 
differ between the lines, and (ii) AVP expression in the SON, in contrast to the PVN, did not 
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differ between the lines. Further studies are necessary to identify the mechanism(s) 
responsible for this nucleus-specificity (see below). 
We further provide preliminary evidence for the polymorphic AVP locus associating 
with anxiety. We observed that F2 animals from a HAB/LAB or HAB/outbred cross 
containing the HAB-specific polymorphic promoter sequence tended to present with longer 
durations until the initial exploratory entry onto the open arm of the EPM, reflecting a higher 
innate anxiety. The small number of animals involved in this preliminary study, we speculate, 
was the limiting factor underlying the reduced statistical power evident in these results. 
However, these results led us to repeat this experiment using a greater number of animals, 
which was performed in the autumn of 2003 with 238 male F2 animals. We observed that the 
latency to float in the FS test associated with the AVP allele. However, this association 
depended on a home cage effect, which might reflect the effects of group housing. Although, 
cages with higher numbers of animals were not on average more or less anxious (data not 
shown), the chance that group-housing could affect the AVP polymorphism in relation to the 
HPA axis is a real possibility. Indeed a study on nociceptin/orphanin FQ knockout mice, 
revealed the presence of increased anxiety only when the animals were group-housed 
(Ouagazzal et al., 2003). Furthermore, the anxiety in these gene knockout, group-housed, 
animals correlated with increased levels of basal and post-stressed plasma CORT, suggestive 
of an elevated HPA axis underlying genetic-environmental interactions. It is well accepted 
that environmental stressors, such as group housing has a role in the effect of behaviour 
(Hilakivi et al., 1989;Karolewicz and Paul, 2001;Rodgers and Cole, 1993;van Loo et al., 
2001). Considering that the FS test is a robust predictive marker of HPA axis dysregulation 
(Will et al., 2003), it is feasible that this polymorphism might represent a real association 
which, however, responds to environmental effects; a situation well known in the clinic. 
Therefore, we plan to conduct this experiment again using singularly housed rats to 
corroborate the present results. 
Of the 10 SNPs found in the distal promoter of the AVP gene, only two mapped to 
known consensus DNA binding sites. The C(-592)T transition embedded an imperfect 
putative CRE site, which locates further upstream to the TATA element than the optimal 
distance CREs usually require (Conkright et al., 2003) and seems, therefore, not to fulfil a 
regulatory role in agreement with previous studies. In fact, we observed no differences in the 
proximal promoters, which led us to conclude that both the SNP and the CRE element might 
play only a negligible role in expression. The CArG element, however, appears an attractive 
candidate, regarding differential regulation of the AVP gene. CArG boxes form the core of 
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the serum response element (SRE), which is bound by the transcription factor SRF (Treisman, 
1987), and SREs have been characterised in the promoter regions of a number of Immediate-
Early-Genes (IEGs) such as c-fos (Gilman et al., 1986), FosB (Lazo et al., 1992), zif268 
(Changelian et al., 1989), cyr61 (Kim et al., 2003), nurr77 (Williams and Lau, 1993) and 
pip92 (Latinkic and Lau, 1994). IEG expression in the brain responds to a variety of stimuli 
including growth factors, stress, mechanical injury, seizures and ischemia, as well as 
numerous chemical agents and receptor agonists and antagonists (for review see Herdegen 
and Leah, 1998). Importantly, CBF-A binds equally well to the CArG element hereby 
possibly attenuating gene expression and has, therefore, been suggested to be involved in the 
refractory period observed for c-fos induction upon repeated stimulation (Rushlow et al., 
1999). Interestingly, c-fos, as well as a number of the IEG genes, are expressed in the same 
tissues as AVP and are both strongly upregulated in response to stress (for review see Pirnik 
et al., 2004) - AVP expression occurs in step with IEG responses, contrasting to the rapid 
induction of CRH, which is in parallel to that of CREB phosphorylation, but preceding 
induction of c-fos (Kovacs and Sawchenko, 1996). This might suggest that these IEG genes 
and the AVP gene could share similar regulatory elements. We indeed provide evidence that 
the CArG element, which also controls c-fos, repressed the AVP promoter in vitro when 
CBF-A protein levels were increased in Saos-2 cells. SRF also binds the CArG box (Treisman, 
1987) and is highly expressed in a large number of brain areas such as the forebrain, cortex, 
striatum, amygdala and hippocampus, and in some scattered neurons in the medulla and 
spinal cord, as well as peripheral non-neuronal tissue (Norman et al., 1988). Interestingly, 
SRF, though moderately expressed in the hypothalamus, (Herdegen et al., 1997;Stringer et al., 
2002), is distinctly absent in the PVN (Blume et al., 1998, which was further supported by 
personal communication from Annegret Blume (Kiel)). Conversely, CBF-A reveals an intense 
expression in the PVN in this study, in addition to being widely expressed in many other areas 
of the brain including the olfactory bulb, hippocampus, cerebellum and hindbrain and 
additional tissues such as the spleen, lung and thymus (Rushlow et al., 1999). In the PVN, 
therefore, CBF-A seems to act independently of SRF possibly as a constitutive repressor or 
alternatively competing with an, as yet unknown, PVN-specific activating transcription factor 
operating at the CArG box. It should also be further noted that our immunohistochemistry 
experiments also revealed CBF-A expression in the SON (figure 38C). This raises the issue of 
why AVP expression does not differ in this nucleus despite the presence of CBF-A, and lead 
us to propose that a further level of control, perhaps involving posttranslational modification 
of CBF-A, is at work in the SON of the hypothalamus. Indeed, different alternatively spliced 
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isoforms of CBF-A exist, in addition to post-translational modifications involving either 
differential phosphorylation or glycosylation (Bemark et al., 1998), all of which can be 
regulated in response to certain cellular signals (Umar et al., 2003;Cok et al., 2004). This 
might explain the differential activity of CBF-A irrelevant of its similar 
expression/concentration in the PVN and SON, as measured by in situ-hybridization and 
immunohistochemistry (data not shown). 
We explored the possible mechanism by which CBF-A mediates repression. Key to 
these experiments was our observation that CBF-A preferentially binds ssDNA. Therefore, 
the high affinity binding of CBF-A to the specific ssDNA appears to be the driving force for 
local DNA strand separation at this element. CBF-A is closely related to members of the 
heteronuclear RNA binding proteins (hnRNP) and ssDNA binding proteins (ssDBF) 
containing the characteristic conserved RNA binding domains (RBD) allowing interaction 
with RNA (Weisman-Shomer et al., 2002). However, its additional role in DNA-binding and 
transcriptional regulation has also been increasingly recognised and well documented 
(Kamada and Miwa, 1992). Members of the hnRNP and ssDBF protein families, which bind 
ssDNA, have been thoroughly investigated as being implicated in transcriptional regulation of 
a wide variety of genes, including growth related genes such as thymidine kinase (Hsieh et al., 
1998), EGF receptor (Chen et al., 1993) and Growth hormone receptor (Schwartzbauer et al., 
1998), and IEGs such as Egr (Taira and Baraban, 1997), c-Myc (Michelotti et al., 1996b), 
c-fos (Sadakata et al., 2000) and Src (Ritchie et al., 2003) at a diverse range of elements in 
promoter regions such as CT rich regions (Michelotti et al., 1996b), hormone response 
elements (Chen et al., 1998;Chen et al., 2003), CREs (Sadakata et al., 2000) and repeat 
regions. Specifically, hnRNP K (Michelotti et al., 1996a), FUSE binding protein (Michelotti 
et al., 1996b), Msy-1 (Schwartzbauer et al., 1998) ERDBP-1 (Chen et al., 1993), puralpha 
(Sadakata et al., 2000), and cold shock domain proteins (Coles et al., 2002) have been 
demonstrated to induce or stabilize single-stranded regions. These alterations in DNA 
conformation and topology may underlie gene expression by affecting the DNA binding 
activities of transactivating factors operating through cis-regulatory elements located within 
or next to these structures. This would provide an efficient mechanism for the regulation of 
genes showing very low basal activity which can be induced by up to 100-fold very quickly in 
response to a stimulus, i.e. c-fos. A number of these hnRNP and ssDBF proteins are 
differentially regulated under various signals. It could, therefore, be envisaged that these 
ssDNA binding proteins keep the gene promoter in a repressed conformation which may be 
relieved by specific signals allowing activating factors to bind. This mechanism could then 
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apply to CBF-A pointing to a role in regulating repression of the AVP gene by governing the 
binding of dsDNA-dependent activators in the PVN to the CArG element or adjacent 
sequences. 
It is well established that the ssDBF protein families have preferences for A/T rich 
regions, which appears evident in this study when substituting a G for an A. The 
stoichiometry of the DNA helix differs considerably dependent on sequence. Studies on the 
A/T composition of CArG elements have highlighted the importance of the precise sequence 
order on the nucleotides to DNA topology. On average more local bending occurs at T-A 
steps (8.21°), which display a positive role bending towards the major groove, than at an A-T 
step (5.71°) that displays a negative role bending slightly towards the minor groove of the 
DNA helix. Sequences of A-tracts containing at least four consecutive As or Ts are relatively 
straight and rigid, while addition of an A-T causes the sequence to become more bent 
displaying more variable deformations of minor groove, width, cup twist and buckle (for 
review see Mack et al., 2001). This explains why proteins usually choose pyrimidine-purine 
steps as the locus for bending and involve A/T tracts near that locus, and this might further 
explain the preference for ssDNA binding proteins for this site. In view of this, the A/T rich 
regions of the CArG elements might be crucial to the binding of ssDNA binding proteins. 
AVP overexpression and over release at the PVN level is likely to contribute to the 
anxious and depressive-like phenotype of HAB rats. Accordingly, periferal administration of 
the V1-receptor antagonist d(CH2)5Tyr(Me)AVP induced a shift towards reduced depression 
and anxiety-related behaviour. Similar antidepressant effects were triggered by paroxetine, 
probably via normalisation of AVP expression (Wigger et al., 2004). In addition to its 
behavioural effects, paroxetine, as well as the peripherally administered V1 receptor 
antagonist, have been shown to normalise the pathological outcome of the DEX/CRH test in 
the HAB animals (Keck et al., 2002;Keck et al., 2003). In this context it is of interest to note 
the growing literature linking AVP expression to affective disorders (see below and for 
review see Scott and Dinan, 2002;Millan, 2003). Thus, our finding that the SNP in position 
1276 of the AVP gene promoter underlies AVP overexpression in the PVN of HAB rats, 
makes this SNP a potential target for further studies aimed at improving diagnostic and 
therapeutic tools. Interestingly, CBF-A may represent a “drugable” target. Cells treated with 
nerve growth factor cause upregulation of CBF-A which correlates with downregulation of 
c-fos and zif268 attesting to the important role CBF-A plays in response to neuronal signals 
(Rushlow et al., 1999). In addition, the dopamine D1 agonist SKF-82958 effects CBF-A and 
resulting c-fos expression (Rushlow et al., 2000). Furthermore, acute injections of the 
97 
Discussion 
neuroleptic fluphenazine or clozapine also cause an upregulation of CBF-A increase in the 
brain (Rushlow, 1997). These findings provide tentative evidence that CBF-A might be 
regulated by, or play some role in the efficacy to, certain psychiatric drugs. 
Condensing, we provide a mechanism underlying the overexpression of genes 
involved in an altered anxiety-like phenotype of a rat model. Furthermore, elucidating this 
mechanism provides the opportunity to study candidate proteins important in this pathway. In 
turn, these proteins, such as CBF-A, then represent putative drug targets for controlling the 
expression of genes, such as AVP, presumed to underlie the phenotype. 
4.2 HAB mouse 
It remains unclear whether the behaviour of the HAB mice pertains to the HPA axis, and 
whether this model correlates with the HAB rat line. AVP levels in the PVN do significantly 
differ to non-anxiety bred animals, though whether this AVP increase is causal or 
inconsequential remains to be tested in vivo. Moreover, the hypothesis that the SNPs residing 
in the AVP promoter might lead to the similar effects we discovered in the HAB rat line, 
concerning gene regulation, remains tempting and mandatory to be studied. 
4.3 LAB mouse 
Familial neurohypophyseal DI is an autosomal dominant disorder caused by a deficiency of 
AVP. Symptoms of DI, such as polyuria, polydipsia, and thirst, usually manifest several 
months or years after birth. A limited number of autopsy studies have reported a paucity of 
AVP-producing neurons in the hypothalamus of patients with DI, leading to the hypothesis 
that progressive degeneration of AVP-producing cells might be involved in the pathogenesis 
of the disease (for review see Maghnie, 2003). The AVP precursor (prepro-AVP) is 
synthesized in magnocellular and parvocellular neurons of the hypothalamus and is converted 
to pro-AVP by the removal of the signal peptide and the addition of carbohydrate side chains 
within the ER. After trafficking to the ER, precursors are further glycosylated and packaged 
into dense core granules. Subsequent proteolytic processing during axonal transport to the 
posterior pituitary results in the generation of AVP, neurophysin II, and glycoprotein, all of 
which are stored within neurosecretory vesicles in the nerve terminals and released into the 
blood in response to osmotic stimuli. AVP then binds to the V2-type receptors in the kidney 
and controls serum osmolarity by reducing renal water excretion. 
In patients with DI, 48 distinct mutations have been found in the AVP gene encoding 
the AVP precursor (GenBank accession number M11166) (for review see Christensen et al., 
2004). Most of the mutations occur within the signal peptide and the NPII domain. Among 
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the signal peptide mutations, a substitution of threonine for alanine at the –1 position, A(–1)T, 
has been reported in several different ethnic groups (Ito et al., 1993;Krishnamani et al., 
1993;McLeod et al., 1993;Kawakami et al., 1998). For the most part, genotype-phenotype 
correlations are not apparent, and most mutations lead to a similar clinical presentation, 
although there is some variation even within the same family. An exception, however, is the 
aforementioned A(–1)T signal peptide mutation, which is frequently associated with delayed-
onset or milder DI (for review see Hansen, 1997). These signal peptide mutations have been 
suspected to interfere with cleavage of the signal peptide and consequently inhibiting release 
of the functional 9aa AVP peptide. It remains to be determined if the polymorphism in the 
LAB mice in this study might also be subjected to a similar mechanism, although, to date, no 
such mutations in this part of the AVP gene have been reported. This can be tested for by 
expressing both the prepro-AVP constructs in AVP-expressing cell lines and measuring for 
AVP secretion into the medium. Further studies might also be followed up to investigate the 
role of the peptides in cell degeneration studies. It should also further be noticed that partial 
DI in human patients has received little attention, and the existence of individuals presenting 
with less severe mutations in this AVP gene and showing less evident DI symptoms is fully 
feasible. This idea is shared with experts in the field, notably David Jentsch (Los Angeles) 
(personal correspondence). 
The relevance of DI to psychiatric research might be questioned at this point. 
Nevertheless, one has to appreciate the role of AVP, and in specific, the PVN neurons in 
regulation of the HPA axis. Of the vasopressinergic neurons, the magoncellular cells might 
secrete far greater levels of AVP than the parvocellular neurons, in response to osmotic 
challenges, but degeneration of these neurons might well accompany the parvocellular 
neurons, which processes AVP in an identical mechanism. One further has to appreciate, that 
this event, as well as disturbing AVP expression, would also disrupt the further co-expression 
of CRH from a large number of these parvocellular AVP/CRH co-expressing neurons. As 
described in the introduction, there is evidence that high levels of AVP expression in the PVN 
present with the development of affective disorders. It is further well documented that high 
numbers of CRH expressing neurons in this region also result in depressive behaviour. These 
results in itself provide evidence of tentative a relationship between vasopressinergic and 
CRH-expressing neuron density in affective disorders, where low AVP/CRH-containing 
neuron density, on the contrary, may result in an individual being less prone to developing 
HPA-axis dysregulation. 
99 
Summary 
5 Summary 
Two inbred rat lines have been developed that show either high (HAB) or low (LAB) anxiety-
related behavior. The behavioral phenotype correlates with arginine vasopressin (AVP) 
expression at the level of the hypothalamic paraventricular nucleus (PVN), but not supraoptic 
nucleus, with HAB animals overexpressing the neuropeptide in both magnocellular and 
parvocellular subdivisions of the PVN. 
This study aimed to investigate the molecular cause of the AVP overexpression in the 
PVN of the HAB animals. Sequencing of the AVP locus resulted in the detection of a number 
of single nucleotide polymorphisms (SNPs) in the promoter differing between the HAB and 
LAB animals. Two of the SNPs were embedded in cis-regulatory elements. Genotyping 
further revealed that the HAB-specific allele of the AVP gene promoter occurs in 1.5% of 
outbred Wistar rats. An assay was developed to address the question of differential allele-
specific transcription rates between the LAB and HAB alleles using cross-mated HAB/LAB 
F1 animals. Results from the experiment revealed the HAB AVP promoter to be more 
transcriptionally active in vivo. EMSA assays confirmed that one specific SNP [A(-1276)G] 
conferred reduced binding of the transcriptional repressor CArG binding factor A (CBF-A) in 
the HAB allele. Reporter gene assays supported the view that the A(-1276)G transition in the 
CArG element impairs CBF-A repression in the HAB allele, which in turn relates to a 
weakened repression of the intact HAB AVP promoter by CBF-A. Furthermore, CBF-A is 
highly co-expressed in AVP-containing neurons of the PVN supporting an important role for 
regulation of AVP gene expression in vivo. Taken together, these results demonstrate a role 
for an AVP gene polymorphism and CBF-A in elevated AVP expression in the PVN of HAB 
rats likely to contribute to their behavioral and neuroendocrine phenotype. 
Phenotypic variation among organisms is central to evolutionary adaptations 
underlying natural and artificial selection, and also determines individual susceptibility to 
common diseases including cardiovascular, metabolic and age related and psychiatric diseases. 
Most phenotypic diversity in natural populations is characterised by differences in degree 
rather than in kind. In accordance with this view, HAB rats lacked changes in the coding part 
of the vasopressin gene, but instead were homozygous for the polymorphic promoter region. 
Therefore, the HAB specific AVP promoter represents a natural model for AVP 
overexpression and highlights, in turn, cognate molecular pathways which potentially fuel the 
resulting pathologies. Specifically, our finding that the SNP in position 1276 of the AVP gene 
promoter underlies AVP overexpression in the PVN of HAB rats, makes this SNP a potential 
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target for further studies aimed at improving therapeutic tools. Finally, further studies are 
necessary to understand to which degree and in concert with which vulnerability loci 
vasopressin overexpression underlies the complex neuroendocrine and behavioural stigmata 
in the HAB line. Certainly, such studies will yield important insights into gene-gene 
interactions between susceptibility genes and shed light on additional pathways suitable for 
therapeutic interventions. In conclusion, this present work exemplifies that selective 
inbreeding for behavioural traits and combined phenotypic and molecular analysis of 
candidate genes is an important step and tool to address these issues. 
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6 Abbreviations 
6.1 Standard 
aa  Amino acids     A  Adenine 
Amps   Ampere      Bp  Base pair 
C  Cytosine      cDNA   Complementary DNA 
cR  CentiRays     Ci   Curie 
cm,mm   Centimeter, Millimeter   cpm   Counts per Minute 
DNA   Deoxyribonucleic acid    EMSA  Electrophoretic mobility shift assay 
G  Guanine      g  Gram 
h, min, sec  Hour, Minute, Second    kb   Kilobase 
kDa   Kilodalton     l   Litre 
µ  Micro      m  Milli 
min  Minute(s)     Mb  Megabase 
M  Molar      mRNA   Messenger-RNA 
n   Nano      OD   Optical density 
PCR   Polymerase chain reaction   RNA   Ribonucleic acid   
rRNA  Ribosomal RNA    RT   Room temperature   
RT-PCR   Reverse transcription-PCR   sec(s)  Second(s)    
T  Thymine     Tm  Melting temerature   
U  Uracil     Vol   Volume  
W  Watt     Zn  Zinc   
  
   
6.2 Buffers and substances 
Ac             Acetate     AMCA       7-amino-4-methylcoumarin-3-acetic acid 
Amps        Ammoniumperoxodisuphate   ATP           Adenosine TriPhosphate 
BSA           Bovine serum albumin    Cy2            Cyanine (spectrum green) 
Cy3           Indocarbocyanine (texas red)   ddH2O   Distilled water 
DEPC        Iethylpyrocarbonate     DH5α          Escherichia coli 
DMEM      Dulbecco’s Modified Eagle Medium  DMSO   Dimethylsulphoxide  
DdNTP      Dideoxyribonucleoside triphosphate   dNTP   Deoxyribonucleoside triphosphate 
DTT         Dithiothreitol     EDTA   Ethylendiamintetraacetate 
EGTA  [ethylenebis(oxonitrilo)]tetra-acetate  EtBr           Ethidium Bromide    
EtOH   Ethanol     FCS            Foetal calf serum    
HEPES  N-2-Hydroxyethylpiperazin-N´-2´-Ethansulfate  IPTG          Isopropyl-β-d-thiogalactopyranoside 
M-PVA  Magnetic poly(vinyl alcohol)   MetOH   Methanol    
MOPS  3(N-Morpholine)propane-sulfonic acid  32P   Phosphor-Isotope 32  
33P  Phosphor-isotope 33    PAGE  Polyacrylamide gel electrophoresis  
PBS  Phosphate buffered saline   PMSF    Phenylmethylsulfonylfluoride  
PNK           Polynucleotide kinase   SDS   Sodium dodecyl sulphate  
SSC          Sodium chloride sodium citric acid  tRNA  Transfer RNA 
TE   Tris Ethylenediaminetetraacetic acid  TAE           Tris acetic acid 
TBE            Tris boric acid    TEMED   N,N,N’,N’-Tetramethyl-ethylenediamine 
Tris  Tris-(hydroxymethyl)-aminomethane  X-Gal    5-bromo-4-chloro-3-indoyl-ß-D- 
galactosidase 
6.3 Non standard 
ACTH Corticotropin     AML-1 Acute myeloid leukaemia gene 
AP1 Activating protein 1      APOE Apolipoprotein E 
Arg Arginine       Arnt2 Aryl hydrocarbon receptor nuclear translocator 2 
ATG Start codon sequence      AVP Arginine Vasopressin 
AVP1aR Arginine Vasopressin 1a receptor   BAFLs Band across four lanes  
B-element Nopaline synthase promoter (bacteria)    β-gal β-galactosidase 
bHLH Basic helix-loop-helix protein family   BmalI Arnt-like protein1, brain and muscle 
BRCA1 Breast cancer 1 gene     CAAT  Sequence involved in trans-activating 
cAMP Cyclic AMP adenosine (3',5'-phosphate)    CArG  C, A/T repeat (6), G 
CAT Chloramphenicol acetyltransferase   CBF-A CArG binding factor-A   
c-domain Cleavage domain (signal peptide)   c-fos Murine osteosarcoma viral oncogene homolog 
CFTR Cystic fibrosis transmembrane conductance regulator  CLOCK Circadian locomotor output cycle kaput 
CNS  Central Nervous system    COMP Cartilage oligomeric matrix protein 
ColE1 Colicinogenic factor E1 bacterial plasmid   CORT Cortisol/Corticosterone 
CRE cAMP responsive element     CREB cAMP responsive element binding protein 
CRH Corticotropin releasing hormone    CSF Cerebral spinal fluid     
Cyr61 Cysteine-rich, angiogenic inducer, 61   d(CH2)5Tyr(Me)AVP         AVP V1 receptor antagonist 
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DEX Dexamethasone      DI Diabetes Insipidus     
dsDNA Doule stranded DNA     E-box Enhancer element     
E.coli Escherichia coli     EGF Epidermal growth factor   
Egr1 Early growth response factor 1    EMSA Electrophoretic mobility shift assay   
EPM Elevated plus maze     ER Endoplasmic reticulum    
ERDBP-1 EGF responsive DNA-binding protein   EST  Expressed sequence tag   
FBE-A Drosophila yolk protein fat body enhancer element  F-element Promoter of Drosophila LINE element   
FLAG DYKDDDDK     FosB FBJ murine osteosarcoma viral oncogen homolog B      
FS Forced swim     FUSE Polykaryocytosis inducer gene   
GAD Generalised anxiety disorder    GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GLO1/2 Glyoxalase ½     GR Glucocorticoid receptor   
GRE Glucocorticoid receptor DNA binding element  GST  Glutathione-S-transferase    
H4TF-1 Histone H4 gene-specific transcription factor   HA High-anxiety-related-behaviour (non-anxiety bred) 
HAB High-anxiety-related-behaviour (anxiety bred)  h-domain Hydrophobic domain (signal peptide)  
HES1 Hairy/enhancer of split (drosophila homologue)  HiNF-A Histone 4 nuclear factor A   
His Histone      HNF1a Hepatocyte nuclear factor 1a   
hnRNA Heteronuclear RNA     hnRNP Heteronuclear RNA binding protein  
HPA Hypothalamic-pituitary-adrenocortical axis    HS40  Alpha-globin gene element   
IEGs Immediate-early response genes     IGR Intergenic region (AVP and oxytocin)  
IHC Immunohistochemistry    IL Interleukin    
IRF3 Interferon regulatory factor 3    ISH In situ-hybridisation    
JKTBP AU-rich element RNA binding factor   LA Low-anxiety-related-behaviour (non-anxiety bred) 
LAB Low-anxiety-related-behaviour (anxiety bred)  Lyf1 Ikaros, zinc finger protein   
MaoA Monoamine oxidase A    MBP Myelin basic protein    
Mertk Mer tyrosine kinase protooncogene   MSY-1 Mouse Y-box protein-1   
MuLV Moloney murine leukemia virus    Myc Avian myelocytomatosis viral oncogene homolog 
NAB Non-anxiety bred     N-box Neuregulin element    
n-domain Amino-terminal region (signal peptide)   NF-1 Neurofibromatosis type 1   
NF-Zz IFN-gamma inducibile element    NGFI-B nerve growth factor I-B    
NPII Neurophysin II     NRF Nuclear respiratory factor   
Nur1/77 Orphan receptor family nuclear proteins   Pax3 Paired box gene 3    
P-box Element in phenylpropanoid biosynthetic genes  PCR Polymerase chain reaction   
PDE5 Phosphodiesterase 5     Pea3 ETS transcription factor   
Pip92 Proline-rich induced protein 92    PKA cAMP-protein dependent kinase   
Pou Pou-domain transcription factor    POZ Zinc finger protein 278   
Pro Proline      PTSD Posttraumatic stress disorder   
Puralpha PUR element binding protein    PVN  Paraventricular nucleus    
QTL Quantitative trait locus    R121919 CRH 1 receptor antagonist   
RAP1 Ras-related protein     Ras GTPase activating protein   
RBD RNA binding domain     RFLP Restriction fragment length polymorphism  
SCLC Small cell lung cancer    SCN Suprachiasmatic nucleus   
SimI  Single-minded, drosophila, homolog 1   Smad3 Mothers against deapentaplegic (drosophila) 
Sm22 Smooth muscle protein 22    SMN1 Survival of motor neuron 1 gene   
SNP Single nucleotide polymorphism    Snrpb Small nuclear ribonucleoprotein polypeptide B 
SON  Supraoptic nucleus     SP6 Salmonella bacteriophage   
Sp1 Transcription factor Sp1    Src Avian sarcoma viral oncogene homolog  
SRE Serum response element    SRF Serum response factor    
SRP Signal peptide recognition protein   SSCP  Single stranded conformation polymorphism 
ssDBF Single-stranded DNA binding proteins   ssDNA Single stranded DNA    
SSLP Sequence length polymorphism    SSRI Selective serotonin re-uptake inhibitor  
T3R Thyroid hormone receptor    TATA Sequence involved in trans-activating   
TCF11 Nuclear factor reythroid 2-like 1    TF Transcription factor    
Thing1 bHLH factor Hand     TS Tail suspension    
UCR Upstream conserved region    UTR Untranslated region    
Val Valine      W A/T nucleotide    
Y-box Inverted CCAAT box     YY1 Yin Yang 1 protein 
zif268 Zinc-finger transcription factor 268 
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